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Background: The risk of developing long-term complications of type 1 diabetes (T1D) is related to
glycaemic control and is reduced by the use of intensive insulin treatment regimens: multiple daily injections
(MDI) (≥ 4) and continuous subcutaneous insulin infusion (CSII). Despite a lack of evidence that the more
expensive treatment with CSII is superior to MDI, both treatments are used widely within the NHS.
Objectives: (1) To compare glycaemic control during treatment with CSII and MDI and (2) to determine
safety and cost-effectiveness of the treatment, and quality of life (QoL) of the patients.
Design: A pragmatic, open-label randomised controlled trial with an internal pilot and 12-month
follow-up with 1 : 1 web-based block randomisation stratified by age and centre.
Setting: Fifteen diabetes clinics in hospitals in England and Wales.
Participants: Patients aged 7 months to 15 years.
Interventions: Continuous subsutaneous insulin infusion or MDI initiated within 14 days of diagnosis
of T1D.
Data sources: Data were collected at baseline and at 3, 6, 9 and 12 months using paper forms and were
entered centrally. Data from glucometers and CSII were downloaded. The Health Utilities Index Mark 2 was
completed at each visit and the Pediatric Quality of Life Inventory (PedsQL, diabetes module) was completed
at 6 and 12 months. Costs were estimated from hospital patient administration system data.
Outcomes: The primary outcome was glycosylated haemoglobin (HbA1c) concentration at 12 months.
The secondary outcomes were (1) HbA1c concentrations of < 48 mmol/mol, (2) severe hypoglycaemia,
(3) diabetic ketoacidosis (DKA), (4) T1D- or treatment-related adverse events (AEs), (5) change in body
mass index and height standard deviation score, (6) insulin requirements, (7) QoL and (8) partial remission
rate. The economic outcome was the incremental cost per quality-adjusted life-year (QALY) gained.
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Results: A total of 293 participants, with a median age of 9.8 years (minimum 0.7 years, maximum 16 years),
were randomised (CSII, n= 149; MDI, n= 144) between May 2011 and January 2015. Primary outcome data
were available for 97% of participants (CSII, n= 143; MDI, n= 142). At 12 months, age-adjusted least mean
squares HbA1c concentrations were comparable between groups: CSII, 60.9 mmol/mol [95% confidence interval
(CI) 58.5 to 63.3 mmol/mol]; MDI, 58.5 mmol/mol (95% CI 56.1 to 60.9 mmol/mol); and the difference of
CSII –MDI, 2.4 mmol/mol (95% CI –0.4 to 5.3 mmol/mol). For HbA1c concentrations of < 48mmol/mol (CSII,
22/143 participants; MDI, 29/142 participants), the relative risk was 0.75 (95% CI 0.46 to 1.25), and for partial
remission rates (CSII, 21/86 participants; MDI, 21/64), the relative risk was 0.74 (95% CI 0.45 to 1.24). The
incidences of severe hypoglycaemia (CSII, 6/144; MDI, 2/149 participants) and DKA (CSII, 2/144 participants;
MDI, 0/149 participants) were low. In total, 68 AEs (14 serious) were reported during CSII treatment and 25 AEs
(eight serious) were reported during MDI treatment. Growth outcomes did not differ. The reported insulin use
was higher with CSII (mean difference 0.1 unit/kg/day, 95% CI 0.0 to 0.2 unit/kg/day; p= 0.01). QoL was
slightly higher for those randomised to CSII. From a NHS perspective, CSII was more expensive than MDI mean
total cost (£1863, 95% CI £1620 to £2137) with no additional QALY gains (–0.006 QALYs, 95% CI –0.031 to
0.018 QALYs).
Limitations: Generalisability beyond 12 months is uncertain.
Conclusions: No clinical benefit of CSII over MDI was identified. CSII is not a cost-effective treatment in
patients representative of the study population.
Future work: Longer-term follow-up is required to determine if clinical outcomes diverge after 1 year.
A qualitative exploration of patient and professional experiences of MDI and CSII should be considered.
Trial registration: Current Controlled Trials ISRCTN29255275 and EudraCT 2010-023792-25.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 22, No. 42.
See the NIHR Journals Library website for further project information. The cost of insulin pumps and
consumables supplied by F. Hoffman-La Roche AG (Basel, Switzerland) for the purpose of the study were
subject to a 25% discount on standard NHS costs.
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Plain English summary
People with type 1 diabetes cannot make insulin, a hormone that controls blood sugar levels. This typeof diabetes is treated with insulin. Insulin can be given by injections at mealtimes, with additional
injections in the evening and/or morning. Alternatively, insulin may be given by pumps that give a small
amount of insulin continuously by a fine plastic tube and needle that goes under the skin.
Pump treatment costs more than treatment with injections. If pumps treat this type of diabetes better
during childhood, then patients may not need as much medical care as adults. If there is no difference
between injections and pumps, money may be better spent in other diabetes services.
We compared these two methods of treatment in 293 newly diagnosed children aged 7 months to
15 years. Half of the patients were treated with insulin pumps and half with injections. The method of
insulin delivery was decided randomly; neither the doctor nor patient could choose which they received.
We measured how good each method was at controlling blood sugar levels, growth and weight gain,
doses of insulin needed, side effects and quality of life (QoL) reported by parents and children. After
1 year, we compared these measurements. On average, children treated with continuous subcutaneous
insulin infusion (CSII) had poorer blood glucose control, used more insulin and had more adverse effects
than children who had multiple daily injections, but these results were not statistically significant. However,
parents of children on CSII reported a small, but statistically significant, increase in QoL, but this was not
observed in the child-reported QoL. In this study, pump treatment cost £1863 per patient per year more
than injections. The results of our study are not necessarily true for children after the first year of diabetes.
Further research is needed in children who have had diabetes for longer.
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Scientific summary
Background
Type 1 diabetes (T1D) is one of the most common chronic diseases of childhood, affecting > 26,000
children and young people in the UK. The daily treatment burden of T1D is high, requiring the
administration of subcutaneous insulin in doses calculated according to carbohydrate intake, energy
expenditure and blood glucose readings. In the longer term, complications of T1D may result in blindness,
renal failure, premature heart disease, stroke and amputation.
The risk of long-term complications of T1D is related to glycaemic control and is lower in patients treated
with intensive insulin treatment regimens: multiple daily injections (MDI) (≥ 4 injections) or continuous
subcutaneous insulin infusion (CSII). Despite a lack of evidence that the more expensive treatment with
CSII is superior to MDI, both treatments are used widely within the NHS.
The current treatment costs for children and young people with T1D range from £52M to £70M per
annum, but this could increase by 50% if all patients used CSII. Previous economic evaluations indicate
CSII to be cost-effective in paediatrics, but these were reliant on data from small trials, which were rated as
being at risk of bias, and the application of extensive modelling.
Objectives
Internal pilot study
Internal pilot objectives targeted recruitment and generalisability.
Primary objective
l To acquire an understanding of the acceptability of randomisation to MDI or CSII at diagnosis of T1D in
children and young people.
Secondary objectives
l To define the characteristics of patients who consent and those who decline to participate.
l To generate data to confirm the standard deviation (SD) used in the sample size calculation of the
full study.
Full study
The following objectives were addressed during the first year following the diagnosis of T1D.
Primary objective
l To measure glycaemic control, assessed by glycosylated haemoglobin (HbA1c) concentration 12 months
after diagnosis of T1D in participants receiving CSII compared with those receiving MDI.
Secondary objectives
To compare the following outcomes in children and adolescents receiving CSII with those receiving MDI:
l percentage of participants in each group with HbA1c concentrations of < 7.5%
l incidence of severe hypoglycaemia
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l incidence of diabetic ketoacidosis (DKA)
l change in height standard deviation score (SDS)
l change in body mass index (BMI) SDS
l insulin requirements (unit/kg/day)
l Pediatric Quality of Life Inventory (PedsQL) score
l cost-effectiveness based on the incremental cost per quality-adjusted life-year (QALY) gained.
Methods
Participants
Participants were recruited from 15 children’s diabetes services in England and Wales with experience of
treating ≥ 10 patients with CSII. Patients were eligible to participate in the study if they met the following
inclusion criteria:
l The patient has newly diagnosed T1D.
l The patient is aged 7 months to 15 years.
l The parent/legal representative of the patient is willing to give consent for the study.
l The parent/legal representative of the patient is able to comply with the treatment regimen and
study visits.
Participants with the following characteristics were excluded from the trial:
l previous treatment for T1D
l haemoglobinopathy
l co-existing pathology conditions likely to affect glycaemic control
l psychological or psychiatric disorders
l receipt of medication likely to affect glycaemic control
l allergy to a component of insulin aspart or insulin glargine
l sibling with existing T1D
l known thyroid condition in a non-euthyroid state
l known coeliac disease and inability to maintain a gluten-free diet.
Study procedures
Informed, written consent and, when appropriate, assent was obtained from parents/guardians and
patients. Patients were randomised with 1 : 1 web-based block randomisation stratified by centre and age
(7 months to < 5 years, 5 years to < 12 years and ≥ 12 years) to treatment with CSII or MDI. Owing to the
nature of the interventions, blinding was not possible.
Screening logs were completed at each centre for all newly diagnosed T1D patients. Data were collected
on age, sex, ethnicity and deprivation score. The reasons why patients were ineligible, why eligible patients
were not approached to participate and why those who were approached declined to participate were
recorded along with the dates and times when patients were approached about the SubCutaneous Insulin:
Pumps or Injections? (SCIPI) study, when trial information was provided and when consent discussions
took place.
The following data, when measured routinely, were collected at baseline:
l biochemical parameters at diagnosis: blood pH, blood glucose, HbA1c concentration and thyroid
function tests
l immunology studies: anti-islet cell and anti-glutamic acid decarboxylase antibodies, tissue
transglutaminase or other antibody tests for coeliac disease
l growth: height and weight.
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Randomised treatment started within 14 days of diagnosis of T1D. Starting insulin doses were calculated
according to weight and age, and titrated against blood glucose readings in accordance with local protocols.
To support this process, clinical practice guidelines and written patient information were shared from the
lead centre for use by recruiting centres at their discretion.
Study visits coincided with clinic appointments at 3, 6, 9 and 12 months. At each visit, the following data
were collected:
l HbA1c concentrations
l adverse events
l height and weight
l insulin usage from general practitioner (GP) prescriptions, glucometer and insulin pump downloads
(CSII) and patient-kept records (MDI).
The diabetes module of PedsQL was completed at 6 and 12 months.
The primary outcome was HbA1c concentrations at 12 months. The secondary outcomes were (1) HbA1c
concentrations of < 48mmol/mol, (2) severe hypoglycaemia, (3) DKA, (4) T1D- and treatment-related
adverse events (AEs), (5) change in BMI and height SDS, (6) insulin requirements, (7) quality of life (QoL) and
(8) partial remission rates. The economic outcome was the incremental cost per QALY gained.
Sample size
To achieve 80% power, a sample size of 143 participants in each group was required to detect a
difference in means of 0.50, with common SD of 1.50, using a two-group t-test with a 0.05 two-sided
significance level. An adjustment was made for 10% loss to follow-up, giving a total of 316 participants
(158 per group).
Statistical analysis
Primary analysis used the intention-to-treat (ITT) principle. A 0.05 level of statistical significance and 95%
confidence intervals (CIs) are used throughout. The statistical analysis plan was developed prior to analysis
and is available as a separate document [URL: www.journalslibrary.nihr.ac.uk/programmes/hta/081439/#
(accessed 26 July 2018)]. All analyses were conducted using SAS® software (version 9.2; SAS Institute Inc.,
Cary, NC, USA). SAS and all other SAS Institute Inc. product or service names are registered trademarks or
trademarks of SAS Institute Inc. in the USA and other countries. ® indicates USA registration.
When available, HbA1c measurements from samples analysed centrally were used in preference to samples
analysed locally. The primary outcome used least squares regression adjusted for age category and centre
as a random effect. Binary outcomes are presented as relative risks. A per-protocol analysis was undertaken
for the primary outcome to check the robustness of conclusions to major protocol deviations and a safety
analysis was conducted on AE data, which included participants in the group to which they had received
their insulin at the time of the event.
Economic evaluation
A cost–utility analysis estimated within-trial QALYs based on patients’ or their parents’ responses to the Health
Utilities Index questionnaire, which was administered at 3-monthly intervals. Resource use was measured
using questionnaires and by accessing prescription records and electronic patient-linked information costing
systems. These included the purchase of pumps or MDI injection devices and associated consumables,
cost of insulins and contact with health-care services, including with GPs, with school nurses, as a hospital
inpatient, as an outpatient and accident and emergency (A&E) department attendances. National tariff and
other standard unit costs were applied to calculate the total costs for the ITT population. A lifetime modelled
extrapolation was planned if differences were apparent in HbA1c concentrations between the intervention
groups at 12 months. The differences between intervention groups in costs and QALYs were compared, with
their joint uncertainty represented in cost-effectiveness acceptability curves.
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Results
Recruitment data from the internal pilot study showed acceptable consent rates and no evidence of patient
bias, and supported the parameters used in the sample size calculation. The Independent Data and Safety
Monitoring Committee recommended that the trial progress to the full study. Data from patients recruited
to the internal pilot study were included in the full study.
Participants
In total, 976 patients were diagnosed with T1D and assessed for eligibility in the 15 study centres, of
whom 689 were eligible and approached for consent. Of these, 294 (42.7%) consented to participate in
the trial; however, one participant withdrew consent for their data to be used immediately following
randomisation. Of those patients who declined (n = 395), 36 (9%) cited a strong preference for CSII
therapy and 259 (66%) cited a strong preference for MDI.
Age, sex and ethnicity did not differ between the group of patients who consented to participate and the
group of patients who declined. The median deprivation score for study participants was 17.0 overall
(minimum 1.62, maximum 77.23), 27.7 in those who declined owing to a strong preference for CSII
(range 3.9–63.9) and 18.0 in those who declined owing to a strong preference for MDI (range 1.2–74.4).
A higher score indicates a greater level of deprivation.
In total, 144 patients were randomised to CSII [mean age 9.0 years (SD 4.1 years); 71 (49.3%) female] and
149 patients were randomised to MDI [mean age 9.1 years (SD 4.1 years); 69 (46.3%) female]. Patient
characteristics did not differ between treatment arms. All participants received their allocated interventions.
One participant who was allocated to CSII and five who were allocated to MDI withdrew from the trial
prior to the 12-month follow-up but allowed data collected up to their withdrawal to be used.
Glycosylated haemoglobin levels at 12 months
Intention-to-treat analysis
Data from 97% (CSII, n = 143; MDI, n = 142) of participants were available. The HbA1c concentrations did
not differ between treatment arms: CSII, mean 60.9 mmol/mol (95% CI 58.5 to 63.3 mmol/mol); MDI,
mean 58.5 mmol/mol (95% CI 56.1 to 60.9 mmol/mol); and least mean squares-adjusted difference
(CSII – MDI), 2.4 mmol/mol (95% CI –0.4 to 5.3 mmol/mol; p = 0.09).
Per-protocol analysis
Data from 52.2% (CSII, n = 87; MDI, n = 66) of participants were included. The HbA1c concentrations did
not differ between treatment arms and the direction of results were consistent with those obtained under
the ITT analysis population: CSII, 60.2 mmol/mol (95% CI 56.4 to 63.9 mmol/mol); MDI, 59.3 mmol/mol
(95% CI 55.3 to 63.3 mmol/mol); and the least mean squares-adjusted difference between treatment
groups (CSII – MDI) was 0.9 mmol/mol (95% CI –3.2 to 5.0 mmol/mol; p = 0.67).
Percentage of patients with glycosylated haemoglobin levels within the target range
12 months after diagnosis
An ITT analysis was performed on two target values: (1) < 58 mmol/mol, the target set by the National
Institute for Health and Care Excellence until August 2015, and (2) < 48 mmol/mol, the new target set in
August 2015. Data for 97% (CSII, n = 143; MDI, n = 142) of participants were available for analysis.
There was no difference between treatment arms for either target. For the target HbA1c value of
< 58 mmol/mol: CSII, n = 66 (46.2%); MDI, n = 78 (54.9%); relative risk (CSII to MDI ratio), 0.84 (95% CI
0.67 to 1.06); and percentage difference (CSII – MDI), –8.8% (95% CI –2.9% to 20.4%). For < 48mmol/mol:
CSII, n = 22 (15.4%), MDI, n = 29 (20.4%); relative risk (CSII to MDI ratio), 0.75 (95% CI 0.46 to 1.25); and
percentage difference (CSII –MDI), –5.0% (95% CI –14.0% to 3.9%).
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Related adverse events
Eight episodes of severe hypoglycaemia were reported: six in participants who were treated with CSII
and two in participants who were treated with MDI (relative risk 3.1, 95% CI 0.6 to 15.1; p = 0.17).
Two episodes of DKA occurred in two participants, both of whom were treated with CSII (relative risk 5.2,
95% CI 0.3 to 106.8; p = 0.24).
Under the safety analysis population, there were 54 related AEs in 36 participants who were treated with
CSII, of which 29 were related to the insulin pump; eight participants had infections at the site of catheter
insertion. There were 17 related AEs in 16 participants who were treated with MDI, of which two events
were related to injection device; there were no AEs related to injection sites. AEs relating to meter errors,
carer errors and incidental illnesses were balanced more evenly across treatment arms.
Change in body mass index and height standard deviation score from diagnosis to
12 months following diagnosis
Data were available for 87% of participants: CSII, n = 124; MDI, n = 132. There was no significant
difference in change in BMI or height SDS between study arms. The mean change in BMI SDS in the CSII
group was 0.6 (SD 0.8) and in the MDI group was 0.5 (SD 0.8); the mean difference was 0.1 (95% CI 0.0
to 0.3; p = 0.13). The mean change in height SDS was –0.1 (SD 0.5) in the CSII group and 0.0 (SD 0.4) in
the MDI group; the mean difference was –0.1 (95% CI –0.2 to 0.0; p = 0.10).
Insulin requirements
Data relating to insulin doses were available for 52% of participants (CSII, n = 87; MDI, n = 64); the
least mean squares-adjusted difference for age demonstrated that insulin requirements were higher for
participants in the CSII arm than for those in the MDI arm (difference, 0.1 unit/kg/day, 95% CI 0.0 to
0.2 unit/kg/day; p = 0.01).
Percentage of participants in each study arm in partial remission
Partial remission was defined as insulin dose-adjusted HbA1c (IDAA1c) level of ≤ 9. Data relating to insulin
dose and HbA1c concentration at 12 months were available for 51% of participants (CSII, n = 86; MDI,
n = 64). The percentage of participants in partial remission at 12 months was higher in the MDI arm, but
the difference was not statistically significant: CSII, 24.4% (21/86 participants); MDI, 32.8% (21/64
participants); and relative risk 0.74 (95% CI 0.45 to 1.24; p = 0.28).
Quality of life 12 months after diagnosis of type 1 diabetes
The PedsQL score (diabetes module), as reported by children at 12 months, was available for 71% or
participants (CSII, n = 104; MDI, n = 104), with 26 children in each treatment group being too young to
complete the questionnaire. Least mean squares-adjusted difference at 12 months (3.1, 95% CI –0.6 to
6.8) favoured CSII but the result was not statistically significant. Data were available from 86% of parents
(CSII, n = 128; MDI, n = 123). The results for overall QoL favouring CSII, as reported by parents, were
statistically significant at 12 months (least mean squares-adjusted difference 4.1, 95% CI 0.6 to 7.6).
Parent- and child-reported results are largely consistent and should be considered against a difference of
5 being considered the minimum worthwhile.
Cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple
daily injections
Patients randomised to the CSII arm had more than twice as many A&E department visits and inpatient
stays relating to the management of T1D than those in the MDI arm. Over the 12-month study period,
health-care professionals had a mean of 4.3 (95% CI 0.6 to 8.0) more contacts (texts, e-mails and
telephone calls) with patients treated with CSII than with those treated with MDI. The mean total costs
were £1863 (95% CI £1620 to £2137) higher for CSII than for MDI, with the majority of this difference
being attributable to the additional cost of consumables (£1177) and the device (£520). There were no
significant differences in QALYs between the CSII and MDI groups (mean difference –0.006 QALYs,
95% CI –0.031 to 0.018 QALYs). None of the sensitivity analyses affected the base-case result of CSII
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being dominated by MDI. The probability of dominance was 69%, with no likelihood of CSII being
cost-effective at a threshold of £30,000 per QALY.
Conclusions
Implications for health care
Study participants were recruited from diverse clinical settings, the retention rate exceeded 95% and the
characteristics of those recruited to the study did not differ from the background population of patients
diagnosed during this time. The findings of the study should therefore be applicable to the population of
children treated in the NHS. Treatment with CSII has been embraced widely by the NHS, despite the high
treatment cost and paucity of evidence of superior clinical outcomes. Our study shows that, during the first
year of treatment, CSII is not associated with better clinical outcomes and is not cost-effective.
Implications for research
The generalisability of our data beyond the first year of diagnosis is uncertain. The observation period
should be extended to determine whether or not treatment outcomes diverge over time and how factors,
including child development, influence treatment decisions.
Patient advocates and many health-care professionals have a strong belief in the benefits of CSII
treatment. In-depth qualitative research is required to learn more about the drivers influencing these
preferences and how they alter as children age.
Trial registration
This trial is registered as ISRCTN29255275 and EudraCT 2010-023792-25.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Type 1 diabetes (T1D) is one of the most common chronic diseases of childhood, affecting > 28,000children and young people in the UK.1 In Europe, the incidence of childhood T1D is rising, and it is
estimated that between 2005 and 2020 the number of children diagnosed per year will increase from
15,000 to 24,400 and will double in children aged < 5 years.2
The treatment of T1D and its complications presents a considerable burden to patients, the NHS and
society, and, as the number of affected patients increases, so do the projected costs. Currently, there is
no cure for T1D, and so it is essential that insulin therapies are optimised to enable the best possible
quality of life (QoL) for patients and effective use of NHS resources, while minimising the risk of acute and
long-term complications.
The use of intensive insulin treatment regimens, in the form of multiple daily injections (MDI) (≥ 4) and
continuous subcutaneous insulin infusion (CSII; or ‘insulin pumps’), is associated with a reduction in the risk
of developing long-term vascular complications of T1D3 and both treatments are used widely in the NHS.
Treatment with MDI utilises insulin analogues with different pharmacokinetic properties. Once or twice a
day, a long-acting insulin is administered using a pen injection device, which delivers insulin just beneath
the skin into the subcutaneous tissues. This gives a relatively stable concentration of insulin throughout a
24-hour period. Additional injections of a short-acting insulin analogue are given every time ≥ 10 g of
carbohydrates is consumed or when blood glucose concentrations rise above an acceptable level.
The term ‘CSII’ refers to the use of a small pump that infuses insulin, via a fine catheter and needle,
to the subcutaneous tissues just under the skin. Using this technology, there is the potential to deliver
insulin with a more physiological profile than can be achieved by treatment with MDI. Background insulin
infusion rates can be increased and decreased to mimic the normal diurnal patterns of insulin secretion
and physiological responses to exercise, illness, fasting, etc. Insulin boluses are infused by patients when
> 5 g of carbohydrates is consumed or when blood glucose concentrations increase above an acceptable
level. It seems logical to assume that the more physiological profile of insulin that can be achieved from
CSII, together with a markedly reduced need to self-inject, would result in improved glycaemic control,
reduced frequency and severity of hypoglycaemic events and improved QoL.
In 2008, a National Institute for Health and Care Excellence (NICE) guideline4 recommended that children
aged ≥ 12 years who cannot achieve glycosylated haemoglobin (HbA1c) concentrations of < 8.5% without
disabling low blood glucose concentrations (hypoglycaemia), despite a high level of care, should be offered
a trial of CSII. Children aged < 12 years should be offered CSII therapy from diagnosis of T1D if MDI is
considered impractical or inappropriate. Data from 28,400 paediatric patients were submitted to the
2015/16 National Paediatric Diabetes Audit (NPDA),1 of whom 30% were treated with CSII, compared
with 23% in the previous year. Of the 18,500 patients aged < 14 years, most would fulfil the age criteria
for CSII therapy, and data reporting HbA1c concentrations suggest that many of the older children would
also qualify for treatment on the basis of poor glycaemic control.
Glycaemic control, intensive insulin therapy and complications
of diabetes
In the short term, failure to manage T1D adequately may result in episodes of hypoglycaemia that may
result in seizures in the most extreme circumstances or high blood glucose concentrations (hyperglycaemia),
which may result in life-threatening episodes of diabetic ketoacidosis (DKA) if left untreated. However, it is
the long-term vascular complications of T1D that have the greatest impact on morbidity, mortality and
well-being. These can be broadly classified as macrovascular complications (coronary artery disease,
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peripheral arterial disease and stroke) and microvascular complications (diabetic nephropathy, neuropathy
and retinopathy).
The risk of acquiring these complications of T1D is directly related to glycaemic control, duration of T1D,
insulin sensitivity and weight. By the time patients enter adult health-care services, many will have lived
with T1D for ≥ 10 years, including a period of pubertal growth and development when changes in
lifestyle, relationships within families and with peers, normal risk-taking behaviour and physiological insulin
resistance make glycaemic control particularly challenging.
In 1993, The Diabetes Control and Complications Research Group3 published conclusive evidence that
both the degree and duration of hyperglycaemia are critical determinants of the risk of both microvascular
complications and macrovascular complications. The median HbA1c concentration was lower in patients
treated intensively with either MDI or CSII (7.3%) than in patients treated using conventional insulin
regimes (9.1%). In patients with established T1D who were observed over a period of 6.5 years, the risk
of acquiring retinopathy or nephropathy was reduced by 76% and 39%, respectively, and of having a
cardiovascular event was reduced by 41% in those treated with CSII or MDI. Glycaemic control exerted
greatest influence on acquisition or progression of complications; however, following correction for the
HbA1c concentration, those patients who were treated with intensive regimes demonstrated a persistent
benefit.
Data from historical paediatric cohorts have confirmed that the link between glycaemic control and
microvascular complications is established in childhood.5 Furthermore, there is a strong relationship
between improved glycaemic control in children and young people and a fall over time in the prevalence
of childhood-onset retinopathy and nephropathy.6
Glycaemic control in the first year after diagnosis has a long-lasting effect on glycaemic control in later life
and, independently of glycaemic control, on the prevalence of complications. Two British, single-centre,
retrospective studies, together reporting data from > 300 patients, reported that HbA1c concentration at
6 months following diagnosis of T1D was an independent predictor of long-term glycaemic control up to
10 years later.7,8 In a larger Swedish cohort of > 1550 children, HbA1c concentrations at 3–15 months
following diagnosis was related to poorer glycaemic control and increased risk of microalbuminaemia and
retinopathy in young adult life.9 These data highlight the importance of researching interventions that may
influence glycaemic control during the critical first year of diagnosis.
Data relating to glycaemic control in childhood and macrovascular complications in adult life are sparse
because of the long natural history of the disease. However, markers of an increased risk of cardiovascular
complications have been validated and used to identify modifiable risk factors in childhood and adolescence.
The SEARCH for Diabetes in Youth (SEARCH) study10 has produced evidence that T1D affects (increases)
arterial stiffness, a validated measure of risk for cardiovascular events and mortality in adult life, by late
adolescence and early adult life. When data from a mixed cohort of patients with T1D and healthy
control participants were analysed using multivariate analyses, other correlates of increased arterial stiffness
included adiposity, blood pressure, lipid profile, ethnicity (black and hispanic ethnicities), blood pressure and
microalbuminuria. In addition to the long-term vascular complications of poor glycaemic control, patients
are subject to a number of health and social disadvantages during childhood. Hospital admission rates are
nearly five times higher for children with T1D than for the background population, with the poorest children
and those in the youngest age group being most likely to require admission.11 Frequent episodes of severe
hypoglycaemia and sustained hyperglycaemia have been associated with changes on functional brain
magnetic resonance imaging, impaired memory and poorer cognitive outcomes.12,13 Patients with poor
glycaemic control may experience poor growth, particularly during puberty,14 and poor glycaemic control has
also been associated with an increased risk of childhood depression and use of antidepressants.15
INTRODUCTION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
2
Prevalence of vascular complications of type 1 diabetes
In the UK, data describing patient demographics, insulin treatment regimes, compliance with NICE
guidelines and clinical outcomes are collected in the NPDA. In the 2015/16 NPDA report,1 9.7% of patients
had microalbuminuria, an early marker of evolving diabetic nephropathy, and 13.8% had an abnormality
on screening for retinopathy. Nearly one-third of patients were hypertensive, 20% had elevated blood
cholesterol and 21% of those aged ≥ 12 years were obese. In a quantitative epidemiological systematic
review of data from young adults (aged 18–30 years),16 there was some evidence of diabetic retinopathy
in 50% of patients, with more severe features presenting in 10% of patients. In the same population,
one in six patients had evidence of evolving diabetic nephropathy and half were hypertensive.16
The data for adult patients for 2014/15 have yet to be reported in the National Diabetes Audit. However, the
2012/13 audit17 reported that, compared with the background population, adults with T1D are 139% more
likely to be admitted to hospital with angina, 94% more likely to be admitted to hospital with myocardial
infarction, 126% more likely to be admitted to hospital with heart failure, 63% more likely to be admitted
to hospital with a stroke, 400% more likely to be admitted to hospital for a major amputation, 817% more
likely to be admitted to hospital for a minor amputation and 272% more likely to be admitted to hospital for
renal replacement therapy.
There can be little doubt that the burden of T1D complications has a profound impact on the QoL
and career prospects of patients. In a study of 91 young adults in their mid-thirties who had lived with T1D
for nearly 30 years,18 the mortality rate was 10 times higher than in a control population, owing to diabetic
nephropathy and trauma, including suicide. People with T1D were less likely to be employed and more
likely to need social welfare. Long-term complications of T1D were the primary predictor of an adverse
outcome, with patients with T1D and no complications showing no significant differences from the
control population.18
Treatment of childhood type 1 diabetes and glycaemic
control in the NHS
In 2015/16, the NPDA reported data from approximately 28,400 patients aged < 19 years.1 Intensive
insulin regimes were used by 82% of patients: 54% were treated with MDI, having four or more insulin
injections a day, and 28% were treated with CSII, an increase from 14% in 2011.
The NPDA also reports trends of improving glycaemic control over time, with the number of patients
achieving the target HbA1c concentration of < 58 mmol/mol, rising from 15.8% in 2012/13 to 27.0%
in 2015/16. In the current NICE guideline for the treatment of childhood T1D, the target HbA1c
concentration has been reduced to 6.5% (48 mmol/mol).19
The Paediatric Diabetes Best Practice Tariff Criteria20 were introduced in the UK in 2012. These allow for
a payment of £3189 per patient per year, linked to the provision of core clinical services for paediatric T1D
care. For most children’s diabetes services, the additional funding made available by the Paediatric Diabetes
Best Practice Tariff Criteria20 enabled the recruitment of more specialist staff and the relative impact of this
increase in resources compared with the introduction of CSII therapy on the improvement in glycaemic
control reported in the NPDA is unknown.
National databases of children and young people with T1D are maintained in a number of other countries
worldwide, enabling clinical outcomes to be compared between countries. In general, data from the UK
compare poorly with those from other countries: a publication reported data from 201221 that were held
in the NPDA data set, the Prospective Diabetes Follow-up Registry (DPV) from Germany and Austria, and
the T1D Exchange database (T1D Exchange) from the USA. The data showed that glycaemic control was
the poorest in the NPDA, which also had the lowest rate of CSII usage. In Britain, the disadvantage of poor
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glycaemic control during childhood appears to persist into adult life. When HbA1c concentrations were
compared between national registries, reporting data from all age groups, from the UK, Germany,
Denmark, Latvia and Austria, only Latvian patients had poorer glycaemic control.22
Evidence for the use of continuous subcutaneous insulin infusion
in childhood
Evidence for CSII therapy comes from three areas: single-centre observational studies, national database
reports and randomised controlled trials (RCTs).
Single-centre observational studies
A number of observational studies examining the effect of CSII therapy on glycaemic control have
been published.23–33 In these studies, authors report longitudinal data examining within-patient change
in HbA1c concentrations following the introduction of CSII or cross-sectional data comparing glycaemic
control in patients treated with MDI with those treated with CSII. In general, the introduction of CSII therapy
is associated with an improvement in glycaemic control in longitudinal observational studies,23–27,34 coupled
with a reduction in the number of severe hypoglycaemic episodes23–25 and, in some studies, weight loss,25,26
a reduction in insulin requirements26,27 and an improvement in QoL.23,24 Other authors have reported a
transient improvement in glycaemic control, with a return to baseline values 6 months after the start of CSII
therapy.28 Transient improvements in markers of vascular function, blood pressure, HbA1c concentration and
glycaemic variability have also been reported 3 weeks after the introduction of CSII; however, at 12 months
these measurements returned to baseline values and HbA1c concentrations deteriorated.29
Cross-sectional studies report a less favourable effect of CSII on glycaemic control and QoL.30,31,35 This
difference may be explained by the fact that longitudinal studies followed patients who were changing
from MDI to CSII, presumably because treatment outcomes with MDI were unsatisfactory, whereas those
who were treated with MDI in cross-sectional studies are more likely to be satisfied with their treatment
and to have acceptable glycaemic control.
Reduced glycaemic variability, but not HbA1c concentration was reported in a cross-sectional study of
22 children treated with CSII compared with 26 children treated with MDI.32 Insulin requirements and
high-density lipoprotein cholesterol levels were also lower in those treated with CSII. Adolescents with
established T1D treated with CSII for > 12 months have been reported to have reduced glycaemic
variability and a reduction in the prevalence of microvascular disease compared with those treated
with MDI.33
National database reports
An association between superior glycaemic control and CSII treatment has been reported in the DPV,
T1D Exchange and NPDA data sets.36 Higher rates of CSII use are reported in girls, whereas those from
ethnic minorities and the most deprived patients are least likely to use CSII, even in health-care settings
with universal funding.37–39 In these studies, lower socioeconomic status and ethnicity were also predictors
of poorer glycaemic control, even when the effect of CSII use was accounted for. This demonstrated that
the characteristics of those who use CSII are the same as the characteristics that facilitate good glycaemic
control, raising important issues of bias.
Randomised controlled trials
A number of small RCTs have been undertaken in children and young people,2,7,35,40–48 and these are
summarised in Table 1. A meta-analysis49 of RCTs investigating the outcomes of children with T1D treated
with CSII compared with those treated with MDI assessed six small studies.34,35,44–47 The largest number of
children included in a single study was 32. In total, 165 children and young people were included in these
six studies, of which three included pre-school children only, and 78 children in total were aged > 5 years.
INTRODUCTION
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TABLE 1 Randomised controlled trials of CSII versus MDI in infants, children and young people with T1D
Study design Observation period
Baseline characteristics
Between-treatment findings at study
completionn Age (years)a HbA1c (%)
a Duration of T1D (years)a
Crossover RCT40 (2003) 6 months for each
arm
16 Median: 14.2
(range 14.1–17.5)
CSII: 8.6± 0.8 Not reported No difference in HbA1c concentrations or severe
hypoglycaemia
CSII: greater treatment satisfaction
MDI: 8.5± 1.4
Parallel RCT35 (2004) 16 weeks 32 CSII: 12.5± 3.2 CSII: 8.2± 1.1 CSII: 6.8 ± 3.8 HbA1c: 7.2% (CSII) vs. 8.1% (MDI); p< 0.05
Insulin doses: 0.9 unit/kg/day (CSII) vs.
1.2 unit/kg/day (MDI); p< 0.003
No difference in QoL
MDI: 13.0± 2.9 MDI: 8.1± 1.2 MDI: 5.6 ± 4.0
Parallel RCT41 (1982) 6 days 16 CSII: 13.3± 4.0 CSII: 10.5± 2.9 Not reported No significant difference in blood glucose (mean
of seven samples/day) or 24-hour glycosuria
MDI arm: more frequent morning hypoglycaemia
MDI: 12.9± 2.4 MDI: 10.7± 1.1
Parallel RCT42 (2008) CSII: 10.5 months 38 CSII: 10.0± 3.0 CSII: 8.3± 0.8 CSII: 5.6 ± 3.3 No significant difference in QoL or glycaemic
control
MDI: 3.5 months,
then 7 months for CSII
MDI: 10.0± 3.7 MDI: 8.4± 1.1 MDI: 4.7 ± 2.9
Parallel RCT43 (2008) 2 years 72 CSII: 11.8± 4.9 CSII: 8.2± 0.4 CSII: 12.2± 2.0 (number of
days between diagnosis and
entering the trial)
No difference in HbA1c concentrations or severe
hypoglycaemia
Insulin doses: 0.7 unit/kg/day (CSII) vs.
1.1 unit/kg/day (MDI); p= 0.001
CSII: greater treatment satisfaction
MDI: 12.3± 4.5 MDI: 8.4± 0.5 MDI: 10.4± 1.7 (between
diagnosis and entering the trial)
Crossover RCT43 (2004) 3.5 months for each
arm
23 Arm A: 11.9 ± 1.4 Arm A: 8.0 ± 1.1 Arm A: 5.3 ± 1.9 No significant difference in HbA1c concentrations
severe hypoglycaemia, DKA or QoL
CSII: greater treatment satisfaction
Arm B: 11.9± 1.5 Arm B: 8.3± 0.7 Arm B: 6.3 ± 2.6
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TABLE 1 Randomised controlled trials of CSII versus MDI in infants, children and young people with T1D (continued )
Study design Observation period
Baseline characteristics
Between-treatment findings at study
completionn Age (years)a HbA1c (%)
a Duration of T1D (years)a
Parallel RCT44 (2004) 6 months 42 CSII: 3.8 ± 0.8 CSII: 9.0± 0.6 CSII: 1.8 ± 0.6 No difference in HbA1c concentrations or severe
hypoglycaemia
MDI: 3.7 ± 0.7 MDI: 9.0± 0.6 MDI: 1.8 ± 0.6
Parallel RCT45 (2005) 24 weeks 26 CSII: 3.9 ± 0.4 CSII: 7.4± 0.5 CSII: 1.2 ± 0.3 No difference in HbA1c concentrations or severe
hypoglycaemia
MDI: 3.8 ± 0.4 MDI: 7.6± 0.3 MDI: 1.6 ± 0.3 CSII: fathers reported greater improvement in QoL
Crossover RCT46 (2003) 3.5 months for
each arm
23 Median: 11.9
(range 9.3–13.3)
Median: 8.9
(range 6.1–10.1)
Median: 6.0
(range 2.5–11.0)
No difference in HbA1c concentrations
Continuous glucose monitoring during CSII:
greater duration target range, less time in
hypoglycaemic range, more frequent
hyperglycaemic readings
Parallel RCT47 (2005) 12 months 22 3.6 ± 1.0 8.0± 0.8 1.4± 0.6 No difference in HbA1c concentrations QoL,
episodes of severe hypoglycaemia or DKA
Parallel RCT48 (2009) CSII: 12 months
MDI: 6 months for
then 6 months for CSII
35 3.7 ± 0.8b 8.9± 0.6a 1.6± 0.6a No difference in HbA1c concentrations
neurocognitive or parenting stress parameters
a Values are mean ± SD, unless stated otherwise.
b Baseline characteristics were reported together in this study, rather than by arm.
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In general, the period of observation was brief: ≤ 7 months in five studies. A statistically significant
difference in HbA1c concentrations between children treated with CSII and MDI was demonstrated at
3 months, but this was modest [–0.24%, 95% confidence interval (CI) –0.41% to –0.07%; p < 0.001].
The insulin dose, reported in three out of the six studies, was significantly lower in children treated with
CSII [0.22 international units (IU)/kg/day, 95% CI 0.31 to 0.14 IU/kg/day; p < 0.001], whereas the
incidences of ketoacidosis and severe hypoglycaemic events did not differ.
In summary, there is no conclusive evidence that treatment with CSII is or is not superior to MDI for
glycaemic control or other clinical outcomes. This was in part attributable to the small number of patients
studied, short observation periods and issues of bias.
Acceptability of continuous subcutaneous insulin infusion and multiple
daily injections
The success of treatment with either MDI or CSII is likely to be heavily influenced by patients’ and parents’
views on the acceptability of each treatment modality. Studies examining this aspect of treatment are very
limited. Data reporting parental stress and QoL in studies comparing clinical outcomes during treatment
with MDI and CSII are summarised in Table 1.
Discontinuation rates for CSII are reported to be < 20%, implying a high level of satisfaction with CSII
therapy.50–52 Older children, girls and those with poor glycaemic control are more likely to revert to MDI.
Reasons for discontinuing CSII therapy include greater sense of disease, difficulties in doing sports, poorer
sense of well-being during CSII therapy, wearing an insulin pump, embarrassment, pain at the site of
needle insertion, poor glycaemic control, fear and dislike of frequent blood glucose monitoring.53–55
Qualitative work undertaken in a study of 19 parents with children aged < 12 years who had changed
from MDI to CSII reported the benefits of CSII therapy to include no longer having to administer painful
injections, fewer dietary restrictions, improved quality of family life and improved glycaemic control.56
When patients and parents were interviewed in another study, they also reported improved glycaemic
control, in addition to increased lifestyle flexibility and participation in social activities, during CSII therapy.57
However, parents also reported increased demands on them during CSII therapy, primarily relating to
increased blood glucose monitoring. These data give only a limited insight into the acceptability of either
treatment. It is likely that patients who participated in these studies changed from MDI to CSII treatment
because MDI treatment was unsatisfactory, and studies of unselected cohorts of patients are required to
examine acceptability of both treatments.
Costs of treatment of childhood type 1 diabetes and its complications
The cost of T1D to the NHS in the UK is significant: estimates of expenditure range from £1B to £1.8B per
year,58,59 and this is expected to rise further, and is projected to account for 2% of total NHS expenditure
over the next two decades.58 The proportion of this cost that is attributable to paediatric T1D services and the
budgetary implications of switching patients to CSII is unknown. The number of children and young people
aged < 19 years old in the UK with a diagnosis of diabetes is 31,500;60 however, this may be a conservative
estimate as not all children aged > 15 years old are managed in paediatric care settings and the true
prevalence could be as high as 42,000. The majority of paediatric patients (95.1%) have T1D60 requiring
insulin therapy, which is currently administered by CSII in 24% of 10- to 14-year-olds and by MDI in 67%,
with the remainder on mixed-methods treatment (three injections per day or fewer).61 Based on published
estimates of MDI and CSII costs62 and the modelled costs of mixed insulins,19 the current annual treatment
costs for children and young people with T1D range from £52M to £70M. This would rise to between £79M
and £106M if all were converted to using CSII. Additional costs relating to the management of T1D and its
complications may be more than three times higher than treatment costs alone,58 suggesting total current
annual costs of between £179M and £241M, rising to between £272M and £366M if all patients used CSII.
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In 2011, the year that the SubCutaneous Insulin: Pumps or Injections? (SCIPI) study opened to recruitment,
it was also estimated that patients with T1D took 830,000 sickness days from work at a cost of £94M, and
additional costs associated with T1D during work were > £91M. Premature death accounted for a further
37,000 lost working years, at an estimated cost of £0.6B.58
It is clear from these observations that T1D represents a significant threat to the well-being and life
expectancy of affected patients, a significant cost to society in loss of productivity and economic output
and an increasing threat to the NHS as its prevalence continues to rise, particularly in the youngest
patients, who will require NHS treatment for the longest period of time. It is critical, therefore, to identify
and manage factors that may influence the natural history of the disease and the risk of complications.
Rationale for research
The role of intensive insulin therapy in optimising glycaemic control and thereby reducing the risk of
vascular complications of T1D is unquestioned. The optimal way in which to achieve this and the
cost-effectiveness of the tools currently available are unknown. A number of observational studies and
small RCTs have compared the outcomes of children and young people treated with CSII with those
treated with MDI. However, in studies reported to date, there are concerns relating to bias, small patient
numbers and short observation periods, and no RCT is directly applicable to the health-care environment
in the UK.
Aims and objectives
The SCIPI study is a pragmatic RCT that compares the outcomes of infants, children and young people
treated with CSII with those treated with MDI from the time of diagnosis of T1D. The study protocol
was developed during a period in which children’s diabetes care in the UK was changing rapidly with the
widespread introduction of CSII.
The aim of the SCIPI study was to provide robust clinical data, together with a careful health economics
appraisal, to inform the place of CSII therapy in the treatment of individual patients from diagnosis of T1D,
and within national diabetes treatment strategies. This study compared CSII with MDI during infancy,
childhood and adolescence to identify which treatment facilitates superior glycaemic control and to
examine the impact that treatment modalities have on other predictors of vascular complications of T1D,
adverse events (AEs) and QoL.
The study was designed with an internal pilot prior to progression to the full study. The objectives of the
pilot and full study are detailed in the following sections.
Internal pilot study
Primary objective
l To acquire an understanding of the acceptability of randomisation to MDI or CSII at diagnosis of T1D in
children and young people.
Secondary objectives
l To define the characteristics of patients who consent and those who do not consent to randomisation.
l To generate data to confirm the size of the standard deviation (SD) used in the sample size calculation
of the full study.
INTRODUCTION
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Full study
Primary objective
l To compare glycaemic control, assessed by HbA1c concentrations 12 months after diagnosis of T1D in
infants, children and adolescents receiving CSII with those receiving MDI.
Secondary objectives
To compare the following outcomes in children and adolescents receiving CSII with those receiving MDI:
l clinical effectiveness
l safety
l growth
l quality of life
l cost-effectiveness.
Summary
Type 1 diabetes is a common disease of childhood, associated with complex treatment regimens and
lifelong complications that pose a significant burden to individual patients. The cost to society and the NHS
is also significant, as patients may not fulfil their potential in the workplace, may be more dependent on
state assistance and may need intensive and expensive therapies throughout their lifetime.
There is the potential to modify the disease trajectory of patients by optimising treatment, particularly in
children who will live with T1D for many years. Data from national registries suggest that children in the
UK have less satisfactory glycaemic control than those in other health economies in which access to health
care is also unrestricted. Some researchers have linked improved glycaemic control to higher rates of CSII
use; however, the characteristics of those who are treated with CSII are the same as those that favour
good glycaemic control, and the relative contribution of these factors is unclear.
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Chapter 2 Trial design and methods
In developing the SCIPI study protocol, we aimed to address areas of potential bias identified in previousstudies, to recruit a population of patients that was sufficiently large to enable us to be able to report, with
confidence, differences in glycaemic control between treatment groups and to study secondary outcome
measures that should give some insight into the evolving risk profile for macrovascular complications. A key
part of the SCIPI study is the health economics assessment that examines how the additional investment in
CSII may be offset against long-term health costs and QoL; this is reported separately in Chapter 4. To ensure
acceptability of the study design and protocol across clinics in the UK, the study protocol was written in
close collaboration with the Endocrinology and Diabetes Clinical Study Group of the Medicines for Children
Research Network (MCRN). While developing the study protocol, we aimed to address three critical issues,
discussed in the following sections.
Measures taken to address bias in patient populations
Previous RCTs have recruited patients with established T1D who are treated with MDI and randomised
them to continue with treatment with MDI or to change to CSII. This recruitment strategy may introduce
bias in favour of CSII, as patients who are satisfied with treatment with MDI and who have good glycaemic
control are less likely to be approached or to participate in a study than those in whom treatment is less
satisfactory. Furthermore, previous experience of treatment success or failure is likely to have an impact on
the use of a treatment in the future. In order to address this potential bias, we recruited patients from the
time of diagnosis of T1D.
We continued to address the internal pilot study objectives throughout the full study, by maintaining
screening logs documenting patients’ demographic data (age, sex, ethnicity and deprivation score derived
from their postcode) and the reasons why patients were ineligible, why eligible patients were not approached
to participate and why they declined. This enabled us to identify differences in the characteristics of those
who consented to participate and those who declined and also to identify major barriers to recruitment.
Measures taken to address potential bias in treatment arms
There are two key areas of concern that were addressed within the SCIPI study design that could
otherwise lead to bias between treatment arms.
Education
At the introduction of CSII therapy, there is a period of intensive education in which patients and their
families consolidate their understanding of the relationship between insulin, carbohydrate consumption,
exercise and periods of ill health. Intensive blood glucose monitoring is undertaken to determine the
distribution of insulin infused across 24 hours, together with planned increases and decreases in infusion
rates to account for periods of illness, exercise, etc.
In previous studies, it was not possible to determine whether the beneficial effect of CSII on glycaemic
control was because of the method of insulin delivery or because of the period of intensive education and
insulin dose titration. To address this educational imbalance, the SCIPI study protocol was designed such
that both treatment arms were required to receive core diabetes education, as defined by the International
Society for Pediatric and Adolescent Diabetes.63 We then defined a minimum set of contacts between
members of the diabetes team, patients and families in the period following diagnosis, and documented
how long additional episodes of education or advice lasted. This information was included in the health
economics assessment and used to detect imbalance in education and support across treatment arms.
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Glucometers
The glucometers provided with insulin pumps advise patients of the dose of insulin required for a given
quantity of carbohydrate, accounting for the patient’s blood glucose concentration measured at that time.
If blood glucose is measured when carbohydrates are not going to be consumed, and the blood glucose
reading is high, the glucometer prompts the patient to take an additional dose of insulin, calculated to
return the blood glucose to the target range.
At the time that the SCIPI study opened to recruitment, glucometers issued routinely to patients treated
with MDI did not advise on insulin doses, placing them at risk of miscalculating doses or failing to recognise
when additional doses may be required. In the SCIPI study protocol, we addressed this potential source of
bias by ensuring that both treatment arms used the same F. Hoffman-La Roche AG’s Expert glucometer
(Basel, Switzerland).
Measures taken to ensure generalisability of study findings
It was important to generate data that could be used to inform local and national treatment strategies.
To achieve this, the SCIPI study needed to recruit and retain participants who were representative of
children and young people treated in the NHS. This required that the protocol be deliverable in a wide
range of clinics and patient populations, including large clinics in university hospitals and smaller clinics in
district general hospitals. To ensure a high retention rate, clinic, participant and parent acceptability
needed to be high. The trial design aimed to achieve minimal disruption to normal clinic routines and
appointments by drawing on clinical information collected routinely, ensuring that study visits coincided
with the times of routine clinic appointments and including minimal additional tasks for patients and
their carers.
Study design
The SCIPI study was designed as a pragmatic, open-label two-arm multicentre RCT comparing use of CSII
with use of MDI in children and young people aged 7 months to 15 years who were newly diagnosed with
T1D. The study included an internal pilot with a sample size of 30 participants to estimate the rate of
consent to randomisation and to define the characteristics of recruited participants.
Progression from the internal pilot to the full study was based on the following criteria:
1. At least 50% of patients who are eligible and are invited to participate in the pilot study are
successfully recruited.
2. Demographic characteristics that are significantly associated with glycaemic control (age, ethnicity, sex,
deprivation score) are not significantly different in the group of patients who are recruited compared
with those who decline.
The trial protocol has been published previously.64 A schematic representation of the study design is given
in Figure 1.
Ethics approval and research governance
This trial compared alternative methods of insulin delivery via Conformité Européenne (CE)-marked
medical devices employed for their intended purpose; therefore, this trial was not considered to be a clinical
investigation under The Medical Devices Regulations 2002.65 The trial did fall within the remit of the
European Union Directive 2001/20/EC,66 transposed into UK law as Medicines for Human Use (Clinical Trials)
Regulations 200467 as amended.
TRIAL DESIGN AND METHODS
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The protocol was approved by the Liverpool East Research Ethics Committee (reference number 10/H1002/80)
and the Medicines and Healthcare products Regulatory Agency (clinical trial authorisation number
21362/0002/001-0001). The trial was funded by the National Institute for Health Research Health Technology
Assessment programme (08/14/39) and included on the International Standard Randomised Controlled Trial
Number registry (ISRCTN29255275) and the European Union Drug Regulating Authorities Clinical Trials
database (EudraCT 2010-023792-25). Site-specific approval was obtained at all recruiting sites.
The study opened on protocol version 1.0 and the final approved version of the protocol was version 7.0.
Protocol amendments are summarised in Table 2, and full details are provided in the study protocol
(www.journalslibrary.nihr.ac.uk/programmes/hta/081439; accessed 15 February 2017).
Selection of study sites
Participants were recruited from 15 centres in England and Wales, which serve demographically diverse
populations. To be eligible to participate in the study, centres had to have ≥ 10 participants treated with
CSII within their clinic population and have sufficient resources to deliver the clinical aspects of the
study protocol.
To inform our selection of recruiting centres, we drew on the experience of the investigators of the
Delivering Early Care In Diabetes Evaluation (DECIDE) study,68 another RCT that recruited paediatric
patients at diagnosis of T1D. This study was delivered across eight children’s diabetes centres.
We invited the principal investigators who had recruited well to the DECIDE study to recruit patients
to the SCIPI study.
Participants
The study recruited infants, children and young people who were newly diagnosed with T1D.
Screen patients by criteria
Obtain informed consent, formal eligibility
assessment, obtain medical history,
complete baseline assessments
Randomise
1 : 1
MDI CSII
Followed up every 3 months for 12 months
At each time point: HbA1c concentration 
(primary outcome) safety (AEs), height, body mass 
index, insulin requirements, resource use and
HUI2 (secondary outcomes)
At baseline and at 6 and 12 months only: 
PedsQL (paediatric quality of life)
(secondary outcome)
FIGURE 1 Study design. HUI2, Health Utilities Index Mark 2; PedsQL, Pediatric Quality of Life Inventory.
DOI: 10.3310/hta22420 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 42
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Blair et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
13
TABLE 2 Key protocol amendments
Protocol version (date) Key amendments
2.0 (30 March 2011) Inclusion criteria amendment to include patients and parents able to complete study material
HbA1c samples will be collected, analysed and destroyed according to local clinical practice
rather than analysis at a central laboratory
Pharmacovigilance: only related SAEs and related AEs will be reported for this trial. RUSAEs
related to medical devices will be reported as per user vigilance reporting
3.0 (1 July 2011) The time period to start the randomised treatment was changed from within 3–5 days to
within 10 days. The study information will be provided and the consent should occur as close
to the time of diagnosis as possible, ideally between the time of diagnosis (day 0) and day 5
Timelines for providing information and approaching the patient for consent will be recorded
on the screening log
Internet randomisation system to be used instead of telephone, with randomisation envelopes
as a backup. Up to this point all randomisations were completed using backup envelopes
PedsQL (QoL) questionnaire booklets were removed from baseline and will only be
administered at 6- and 12-month study visit
4.0 (17 August 2012) Revision to the inclusion criteria, change to patients and parents able to comply with the
treatment regimen and study visits
Additions to exclusion criteria list:
g. Known thyroid condition in a non-euthyroid state
h. Known coeliac disease and unable to maintain a gluten-free diet
Exclusions previously specified within the protocol but not numbered within the exclusion
criteria
Revision to the exclusion criteria: change to a. have a sibling with existing T1D rather than first
degree relative
Additional guidance and change to recruitment window period to 14 days and further
guidance on patients being approached and consented as soon after diagnosis as possible
HbA1c samples to be collected, analysed and destroyed at a central laboratory
5.0 (21 January 2015) Removal of the following from the eligibility criteria: patients aged ≥ 8 years are able to comply
with the treatment regimen and study visits
Addition of Omnipod® (Ypsomed Ltd, Escrick, UK) as a pump that can be supplied in line with
normal clinical practice
Addition of text permitting use of the insulin detemir (Levemir®, Novo Nordisk Ltd, Gatwick, UK)
6.0 (16 February 2016) Update of contact members and their details
7.0 (1 August 2016) Updated the HbA1c concentration recommendations in line with the recent NICE guidance:
change to the secondary objective. HbA1c concentrations reduced from 7.5% to 6.5% and
HbA1c concentrations also provided in mmol
Change to secondary end point – percentage of participants in each group with HbA1c
concentrations reduced from < 7.5% to < 6.5%. Added partial remission and height as end
points
Outcomes may be presented as mmol/mol or equivalent %
PedsQL, Pediatric Quality of Life Inventory; RUSAE, related and unexpected serious adverse event; SAE, serious adverse event.
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Inclusion criteria
Participants were considered for inclusion in the trial if they met the following criteria:
l they have newly diagnosed T1D using standard diagnostic criteria69
l they are aged 7 months to 15 years (inclusive)
l parent/legal representative of the patient is willing to give consent for the study
l parent/legal representative of the patient is able to comply with the treatment regimen and study visits.
Exclusion criteria
Participants with the following characteristics were excluded from the trial:
l previous treatment for diabetes
l haemoglobinopathy
l co-existing pathology conditions likely to affect glycaemic control (e.g. cystic fibrosis)
l psychological or psychiatric disorders (e.g. eating disorder)
l receipt of medication likely to affect glycaemic control (e.g. systemic or high-dose topical corticosteroid)
or growth hormone therapy
l allergy to a component of insulin aspart (Novorapid®, Novo Nordisk Ltd, Gatnick, UK) or insulin glargine
(Lantus®, Sanofi, Guildford, UK)
l sibling with existing T1D
l known thyroid condition in a non-euthyroid state
l known coeliac disease and inability to maintain a gluten-free diet.
Recruitment procedure
At the time that the SCIPI study opened, children’s diabetes teams were notified within 72 hours of presentation
of all infants, children and young people who were newly diagnosed with T1D. This possible delay in the
identification of potential participants was addressed when the Paediatric Diabetes Best Practice Tariff Criteria20
were introduced in 2011/12, shortly after the study opened. It is a requirement for centres receiving this
additional payment that newly diagnosed patients are discussed with a senior member of the children’s diabetes
team within 24 hours of presentation, and that all new patients are seen by a member of the children’s diabetes
team on the next working day. All potentially eligible participants were therefore identified promptly.
Screening
Sites maintained detailed screening logs of all patients with newly diagnosed T1D. The screening logs
collected data on the number of patients who:
l were assessed for eligibility at diagnosis of T1D
l met the study inclusion criteria
l were eligible at screening, were invited to consent and, subsequently, gave consent to participate
l were eligible at screening, were invited to consent but did not consent to participate in the study
(with details of the reasons why consent was not given)
l were eligible at screening but consent was not sought (with details of the reasons for not seeking consent).
Dates and times of consent process milestones were also recorded along with the deprivation score
calculated from patients’ postcodes and ethnicity. These data were used to monitor and inform the
recruitment process and to fulfil the internal pilot objectives.
Informed consent
Participants and families were given verbal and written information about the study at the time of
diagnosis of T1D. Patient information leaflets were developed in collaboration with the MCRN Young
Person’s Advisory Group, ‘Stand Up, Speak UP!’ Three age-appropriate information leaflets for children
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aged < 8 years, 8–12 years and > 12 years were prepared to ensure that study information was accessible
to children of all ages. A separate information sheet was prepared for parents or legal guardians.
To support recruitment, and to address issues of patient preference, the SCIPI study team also produced a video.
This was aimed at patients and families interested in taking part in the study, and gave a balanced patient’s
perspective of treatment with both methods of insulin delivery from some of the children, young people and
their parents who had participated in the study. Four children and young people took part in the video; two
were treated with MDI and two with CSII. The video was intended to be viewed after the SCIPI study had been
introduced to the family by their diabetes team and the SCIPI information leaflet had been read.
The video was approved by the main research ethics committee in December 2013. The video went live on
the SCIPI study website on 14 February 2014 (www.scipitrial.org.uk/families.html; accessed 15 February 2017)
and was available for use at SCIPI study sites from 17 February 2014.
Consent was obtained by an appropriately trained and experienced member of the research or diabetes
staff. The timing of consent was dependent on the needs and wishes of the patient and family. However,
consent had to be obtained within a time frame that allowed for the randomised treatment to start within
14 days of diagnosis of T1D.
Randomisation, concealment and blinding
Once eligibility criteria were confirmed and informed consent, and assent when appropriate, had been
obtained, participants were randomised to treatment with MDI or CSII, using a secure (24-hour) web-based
randomisation programme controlled centrally by the MCRN division of the Clinical Trials Research Centre
Clinical Trials Unit (CTU). A personal login (username and password), provided by the MCRN CTU, was
required to access the randomisation system.
The randomisation code list was generated by a statistician within the MCRN CTU who was otherwise
independent of the study, using random variable block sizes of 2 and 4. Participants were randomised to
either MDI or CSII treatment in a ratio of 1 : 1, stratified by recruitment site and age using three bands
(7 months to < 5 years, 5 years to < 12 years and ≥ 12 years).
The allocated treatment arm was communicated immediately to the patient and family and the treating
health-care professionals, with the randomised treatment to start within 14 days of diagnosis.
Owing to the nature of the interventions, it was not possible to blind either the participants or clinical teams.
Treatment group allocation
Multiple daily injections
Participants randomised to treatment with MDI were treated with two insulin analogues: insulin aspart,
a short-acting insulin, and insulin glargine or insulin detemir, long-acting insulin analogues. Insulin was
delivered using ‘pen’ injection devices, which contain cartridges of insulin that are administered via a fine
needle at the tip of the pen and injected using a plunger at the top of the pen.
Insulin aspart is a short-acting insulin analogue licensed for the treatment of T1D in adults, adolescents
and children aged 2–17 years. It should be used in children aged < 2 years only under careful supervision;
however, the rapid onset and offset of action of this insulin make it particularly attractive in the management
of young children. For this reason, it is widely used in young children with T1D. Insulin aspart was
administered every time ≥ 10 g of carbohydrates was consumed.
Insulin glargine is a long-acting insulin analogue, administered once or twice daily. It is not currently
licensed for use in children aged < 6 years; however, the use of insulin glargine in this age group has been
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associated with a reduction in hypoglycaemia and improved metabolic control.70 For these reasons, it is
widely used in MDI treatment regimens in UK paediatric practice.
In protocol version 5.0, the use of detemir was added to the long-acting insulin analogues permitted at the
initiation of MDI therapy. This amendment was made in recognition that a number of recruiting sites
started treatment with MDI, using insulin detemir at the time of diagnosis, and were reluctant to change
to insulin glargine following randomisation to MDI. This insulin has been studied in the age group
recruited to the SCIPI study and found to be safe and effective.71
Continuous subcutaneous insulin infusion
Insulin aspart was administered using CSII insulin pumps. The F. Hoffman-La Roche AG insulin pump
(Basel, Switzerland) was selected at the start of the study, following discussion with the participating
centres. This pump was used widely at the time the study opened, and participating centres had
experience in its use. The use of the F. Hoffman-La Roche AG insulin pump also enabled us to use the
same glucometer across both treatment arms. This glucometer includes a ‘bolus wizard’, which calculates
insulin doses according to blood glucose readings and carbohydrate consumption. The use of this
glucometer ensured consistency in the insulin bolus doses across treatment arms.
The F. Hoffman-La Roche AG insulin pumps and consumables were provided at a 25% discounted price
for the study participants. However, this is a pragmatic study and treating clinicians were able to use other
insulin pumps when this was considered to be in the patient’s best interest. A small number of Medtronic
(Medtronic Ltd, Minneapolis, MI, USA) and Omnipod® pumps (Ypsomed Ltd, Escrick, UK) were also used in
some study centres. In these instances, patients used the appropriate glucometer for their pump.
Participants were given insulin aspart using basal insulin infusion with bolus doses of insulin aspart when
≥ 5 g of carbohydrate was consumed.
Starting dose calculations: multiple daily injections and continuous subcutaneous
insulin infusion
The initial total daily dose of insulin was calculated from body weight. In prepubertal participants, a dose of
0.5 units/kg body weight/day was used, and in pubertal participants 0.7 units/kg body weight/day was used.
For the MDI arm, 50% of the calculated dose was given as a single injection either as insulin glargine or
detemir, injected into the anterior-lateral aspect of the thigh, arm, abdomen or the upper outer quadrant
of the buttocks.
For the CSII arm, 50% of the calculated dose was given as a continuous 24-hour infusion [0.5 × body
weight (kg) ÷ 2 ÷ 24 = hourly rate].
The remaining 50% of the daily dose was given as three divided preprandial doses at mealtimes in both
arms. If the doses were not equal, more insulin was given before breakfast and the evening meal than at
lunchtime to account for diurnal variation in insulin sensitivity.
It was recommended that blood glucose readings should be undertaken at least four times a day: before
breakfast, before the midday meal, before the evening meal and before supper/bed.
Insulin dose modifications
Correction doses were calculated according to the ‘100’ rule.72 Insulin doses were titrated according to
home blood glucose readings, as per local routine clinical advice. The diabetes clinical team supported
insulin dose titration according to participant needs. Telephone contact was also used as an opportunity to
provide support and education regarding the management of T1D. The frequency and duration of all
contact between participants and their local clinical service were logged. All participants and their parents
had 24-hour telephone access for support and advice throughout the study, as is standard practice.
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Participants on CSII treatment also had 24/7 access to the pump manufacturer’s helpline for assistance for
technical problems relating to the pump.
Education
At entry to the study, all participants completed a structured educational programme delivered to
participants and their families in accordance with the standards of the International Society for Pediatric
and Adolescent Diabetes.63
Participants and their families were educated in:
l type 1 diabetes
l the use and administration of insulin
l hyperglycaemia and correction doses
l hypoglycaemia symptoms and treatment
l exercise
l sick day rules
l carbohydrate counting
l the benefits of maintaining optimal glycaemic control for long-term health
l blood glucose monitoring.
All the participants were trained in the use of the MDI regimen and the F. Hoffman-La Roche AG Expert
glucometer; participants undergoing CSII treatment were also trained in the use of CSII pumps.
Additional diabetic education was organised to suit individual needs of the participant and family.
The dietitian met the participant and their family to assess their diet and educate them in carbohydrate
counting. All contact was recorded within the participant follow-up.
To support recruiting sites in the initiation of CSII so soon after diagnosis of T1D, treatment guidelines and
written patient information were available from the lead site. These resources were used at the discretion
of the recruiting sites.
Baseline assessment
At entry to the study, we collected the following routine biochemical data recorded in medical case notes:
l blood pH at diagnosis
l blood glucose at diagnosis
l presentation with DKA
l glycosylated haemoglobin
l thyroid function tests
l tissue transglutaminase antibody titres, or other screening test for coeliac disease
l titres of anti-glutamic acid decarboxylase and anti-islet cell antibodies.
These baseline tests were not required as part of the SCIPI study protocol, but results were collected
if available.
Baseline measurements of height and weight were recorded on the day that the participants commenced
randomised treatment to allow for rehydration in participants who were dehydrated at diagnosis of T1D.
The Health Utilities Index (HUI) questionnaire was completed and information was collected relating to prescribed
concomitant medications. The Health Utilities Index Mark 2 (HUI2) was used for the base-case analysis and the
Health Utilities Index Mark 3 (HUI3) (based on a Canadian tariff) was used in the sensitivity analysis.
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Follow-up
Study visits were timed to coincide with the times of routine clinic appointments at 3, 6, 9 and 12 months
from the date of randomisation. A window of 15 days either side of the appointment time was permitted
to allow for holidays, clinic availability and other commitments. A schematic representation of follow-up
assessments is given in Table 3. At each visit, permanent and temporary changes in the delivery of insulin
were recorded under the heading ‘Review of insulin use’.
Measures
Primary end point
The primary outcome measure was glycaemic control (HbA1c) concentrations 12 months after diagnosis.
Capillary blood samples were collected from finger-pricks into small capillary tubes and were analysed in
two separate locations. At study sites, most samples were analysed using portable instrumentation at
outpatient clinics. Samples were also analysed at the clinical pathology laboratory in Alder Hey Children’s
NHS Foundation Trust. Samples were transported to the central laboratory through the post or via bespoke
courier systems that ensure that the samples are received the next day.
Quality assurance of the measurement of glycosylated haemoglobin levels
Portable instrumentation is calibrated regularly with local laboratories. All laboratories involved in the
measurement of HbA1c concentrations are obliged to participate in external quality assurance schemes,
ensuring that laboratories with equivalent equipment are able to produce results that are comparable to
each other. For almost all HbA1c measurements (local and central), the biochemical methodology employed
was immunoassay.
Since June 2009, HbA1c assays have been calibrated against the International Federation of Clinical Chemistry
and Laboratory Medicine standardised values,73 and centralised analysis should no longer be necessary;
therefore, costs to support central analysis were not provided within the study budget. However, the preference
in the trial design was for central analysis and this was included when funds were identified to support this
(changed from local to central analysis in protocol version 4.0, August 2012).
To determine whether or not central analysis was required, a limits of agreement analysis was performed
when 590 paired samples were available. Based on the results of this analysis,74 samples continued to be
analysed both locally and centrally.
Data from local samples were usually recorded in two units of measurement: mmol/mol and % (percentage of
total haemoglobin). The HbA1c concentration measured at the central laboratory was recorded in mmol/mol
only. The following formula was used for conversion between the two units of measurement:
HbA1c (%) =
HbA1c (mmol/mol)
10:929
+ 2:15: (1)
Secondary end points
Percentage of participants in each group with a glycosylated haemoglobin level of
< 48 mmol/mol at 12 months after diagnosis
At the time the SCIPI study protocol was written, the target HbA1c concentration was < 58mmol/mol. However,
in the most recent NICE guideline, the target has been reduced to 48mmol/mol.19 This lower figure was used in
our analysis to ensure that the findings are relevant to current clinical practice; however, as sites would have
previously worked to the 58-mmol/mol threshold, the results for this are also presented.
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TABLE 3 Trial assessments
Procedures
Time point
Baseline (randomisation)
Follow-up (months after
randomisation)
Diagnosis
Prior to start
of treatment 3 6 9 12
Assessment of eligibility criteria ✗
Signed consent form ✗a
Randomisation ✗
Review of concomitant medications ✗ ✗ ✗ ✗ ✗
Review of insulin use (insulin requirements)
Treatment diaries ✗ ✗ ✗ ✗
Prescriptions ✗ ✗ ✗ ✗
CSII pumps download ✗ ✗ ✗ ✗
Blood glucose measurement ✗b ✗ ✗ ✗ ✗
Blood pH measurement ✗
Demographics ✗
Study intervention ✗c
Physical examination
Height ✗ ✗ ✗ ✗ ✗
Weight ✗ ✗ ✗ ✗ ✗
Injection sites ✗ ✗ ✗ ✗
Symptom-directed (✗) (✗) (✗) (✗)
Assessment of related AEs
Incidence of severe hypoglycaemia (✗) (✗) (✗) (✗)
Incidence of DKA (✗) (✗) (✗) (✗)
Other AEs (✗) (✗) (✗) (✗)
Related to diabetes (✗) (✗) (✗) (✗)
Clinical laboratory
HbA1c analysis
d ✗ ✗ ✗ ✗ ✗
Other routine testse (e.g. chemistry, haematology, urinalysis) (✗) (✗) (✗) (✗) (✗)
Questionnaires
Participant-completed PedsQL (✗) (✗)
Parent-completed PedsQL ✗ ✗
Participant-completed HUI Questionnairef (✗) (✗) (✗) (✗) (✗)
Parent-completed HUI Questionnairef ✗ ✗ ✗ ✗ ✗
Resource use
RN-completed CRF ✗ ✗ ✗ ✗ ✗
✗, the time point at which a procedure was performed; (✗), as indicated/appropriate; CRF, case report form;
PedsQL, Pediatric Quality of Life Inventory; RN, research nurse.
a Recruiting staff were encouraged to provide information, discuss the study and obtain informed consent as close to the
time of diagnosis as possible, ideally between the time of diagnosis and day 5 (diagnosis date+ 5 days).
b Blood glucose at the time of diagnosis was measured as per local policy and the results recorded from patient medical
records. It was measured by glucometer at the remaining time points.
c Study intervention: randomised treatment should be commenced within 14 days of diagnosis.
d Glycosylated haemoglobin was collected and analysed according to local clinical practice and a sample sent for central analysis.
e Routine clinical tests were conducted as part of routine clinical management and, when appropriate, results recorded
from patient medical records.
f The HUI2 algorithm was used for the base-case analysis and HUI3 algorithm (based on a Canadian tariff) was used in the
sensitivity analysis.
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Incidence of severe hypoglycaemia
Severe hypoglycaemia was defined according to the criteria of the American Diabetes Association:
a hypoglycaemic episode that required the assistance of another person to administer carbohydrate,
glucagon or other treatments.75
Incidence of diabetic ketoacidosis
Diabetic ketoacidosis was defined according to the criteria of the European Society of Paediatric
Endocrinology and the Lawson Wilkins Pediatric Endocrine Society:76 blood glucose level of > 11 mmol/l,
with a venous pH of < 7.3 and/or bicarbonate concentration of < 15 mmol/l.
Change in body mass index standard deviation score
Height was measured using a fixed stadiometer and weight was measured using electronic scales. Body
mass index (BMI) was calculated according to the formula:
BMI =
weight (kg)
height (m)2
. (2)
Standard deviation scores (SDSs) were derived from 2007 World Health Organization growth data.77,78
Insulin requirements (unit/kg/day)
Insulin usage was downloaded from F. Hoffman-La Roche AG’s Expert glucometers for participants in both
treatment arms. For participants who were treated with CSII, insulin usage was also downloaded from
insulin pumps, and for participants who were treated with MDI, data were retrieved from patient-held
records. Finally, to guard against significant over-reporting and for the health economics assessment,
the general practitioner (GP) of the participant was contacted for details of issued prescriptions.
Percentage of patients in partial remission at 12 months
Rates of partial remission were calculated at each time point, according to insulin dose-adjusted HbA1c
(IDAA1c) level. This measure is calculated according to the formula:
IDAA1c = HbA1c + 4 ×
daily insulin dose (unit)
weight (kg)
. (3)
Health-related quality of life
Health-related QoL was assessed using version 3 of the diabetes module of the Pediatric Quality of Life
Inventory (PedsQL) questionnaire,79,80 completed at routine clinic appointments at 6 and 12 months.
The questionnaire was not completed at baseline because patients and parents are asked to rate their
experience of living with T1D in the previous month. Given that patients were recruited at diagnosis of
T1D, these questions were not relevant.
The PedsQL has age-specific questionnaires to be completed by children (aged 5–7 years old, 8–12 years
old and 13–16 years old). The parent-reported PedsQL includes an additional age band for children aged
2–4 years.
Sample size
A difference in HbA1c concentration of 0.5% is widely recognised as the threshold used by the US Food
and Drug Administration and the pharmaceutical industry to determine effectiveness of any new oral
hypoglycaemic agents. A meta-analysis of 20 studies comparing CSII with MDI detected an improvement of
0.61% in adults, suggesting that, in addition to this estimate being the minimum clinically important, it is
also a realistic difference to detect.81–100 To achieve 80% power, a sample size of 143 in each group was
required to detect a difference in means of 0.50, assuming that the common SD is 1.50 using a two-group
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t-test with a 0.05 two-sided significance level. Allowing for 10% loss to follow-up increased the sample size
to a total of 316 participants (158 per group). The estimate used for the SD in the sample size calculation
was taken from an unpublished audit at Alder Hey Children’s NHS Foundation Trust (Joanne Blair,
Mohammed Didi, Princy P, Atrayee Ghatak, Alder Hey Children’s NHS Foundation Trust, 2009, personal
communication) based on children matching the inclusion criteria for this proposed study.
Statistical methods
The analysis and reporting of the SCIPI study was undertaken in accordance with the Consolidated
Standards of Reporting Trials (CONSORT)101 and the International Conference on Harmonisation E9
guidelines.102 The main features of the statistical analysis plan are included here with a full and detailed
statistical analysis plan provided as a separate document [URL: www.journalslibrary.nihr.ac.uk/programmes/
hta/081439/# (accessed 26 July 2018)]. All statistical analyses were undertaken using SAS® software
(version 9.2; SAS Institute Inc., Cary, NC, USA). SAS and all other SAS Institute Inc. product or service
names are registered trademarks or trademarks of SAS Institute Inc. in the USA and other countries.
® indicates US registration.
A two-sided p-value of ≤ 0.05 was used to declare statistical significance for all analyses. Similarly, all CIs
were calculated at the 95% level. No adjustment for multiplicity was made to adjust the type 1 error rate
for secondary outcomes. Relevant results from other studies already reported in the literature were taken
into account in the interpretation of results.
The primary analysis followed the intention-to-treat (ITT) principle as far as practically possible; a secondary
analysis using the per-protocol approach was conducted for the primary outcome. The purpose of the
per-protocol approach is to consider the robustness of the conclusions reached from the analysis using the
ITT principle, which includes protocol deviations.
Glycosylated haemoglobin, a continuous outcome, was compared between the trial groups using
mixed-model regression with 12-month HbA1c as the dependent variable, treatment group as an
explanatory factor and the randomisation stratification variables (age group and centre) as covariates;
centre was fitted as a random effect. The mean and SD of HbA1c concentrations were reported for each
age group and treatment group. The mean difference in HbA1c concentrations and 95% CI between
treatment groups was given as the estimated age group- and centre-adjusted treatment effect calculated
by the fitted mixed-model regression. Central measures of HbA1c concentration were used in preference to
local measurements; local measurements were used if central ones were not available.
Secondary continuous outcomes were analysed as per the primary outcome methods. For binary outcomes,
the number and percentage of participants with the outcome are reported overall and for each treatment
group. The difference between groups is tested using the chi-squared test. Relative risks with 95% CI
are presented.
The safety analysis data set contains all participants who were randomised and received at least one dose
of insulin via the randomised treatment. Participants’ AEs/serious adverse events (SAEs) were included
in the treatment group the participant was actually receiving at the time of AE/SAE onset to take into
account any participants who permanently changed their mode of insulin delivery at any point during the
trial. The number of related AEs occurring and the number and percentage of participants involved were
reported by treatment arm. The incidence rates of total numbers of AEs/SAEs were calculated for each
treatment group in person-days using the incidence density ratio (IDR). The IDR is the number of patients
with at least one new AE per population at risk in a given time period. The denominator is the sum of the
person-time in years for each treatment group (accounting for treatment switches) of the at-risk population.
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The statistical analysis of the data follows the standard operating procedures of the Clinical Trials Research
Centre, which requires independent programming of the primary outcome and safety analyses by an
independent statistician.
Study oversight and role of funders
The Trial Management Group (TMG), comprising the chief investigator, other lead investigators (clinical
and non-clinical), members of the MCRN CTU and three parent contributors, was responsible for the
day-to-day running and management of the trial. The membership of the oversight committees was
suggested by members of the TMG to the trial funders and appointed by the funders with their
constitution following funder requirements.
The Trial Steering Committee (TSC) consisted of an independent chairperson, Dr Peter E Clayton, two
independent experts in the fields of diabetes and endocrinology, Dr Christine P Burren and Dr Ian Craigie,
an expert in medical statistics, Professor Gordon D Murray, and a parent contributor, Mrs Christina McRoe.
The role of the TSC was as the executive decision-making committee considering the recommendations of
the Independent Data and Safety Monitoring Committee (IDSMC). Monitoring reports viewed by the TSC
were not split by treatment group.
The IDSMC consisted of an independent chairperson, Professor Stephen Greene, plus two independent
members, Professor John Wilding, an expert in the field of endocrinology, and Dr Arne Ring, an expert in
medical statistics. The IDSMC was responsible for reviewing and assessing recruitment, interim monitoring
of safety and effectiveness, trial conduct and external data. The IDSMC provided recommendations to the
TSC concerning the continuation of the trial and viewed accumulating data split by treatment group.
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Chapter 3 Results
Recruitment
The study opened to recruitment on 16 May 2011 and was closed on 30 January 2017.
At the outset of the study, we planned to recruit 316 patients within 30 months across eight study sites.
The recruitment rate had been informed by the DECIDE trial68 and the study sites were selected to build on
the experience and expertise acquired by local researchers during the DECIDE trial.
All study sites had to secure funds to meet the excess treatment costs of the study protocol. This process
incurred some considerable delays, and in some centres was not possible. Recruitment rates were also
slower than expected and, consequently, the recruitment curve was revised in month 18 to allow for an
additional 12 months of recruitment and again in month 40 to allow a further 6 months. The number of
study sites was increased from 8 to 15. The recruitment graph showing the initial, and revised, predictions
and the observed recruitment numbers is displayed in Appendix 1.
To increase recruitment, key protocol amendments were made (protocol version 3.0 to 4.0) that increased
the permitted time window for recruitment from diagnosis to 14 days and softened eligibility criteria to
place emphasis on ability to comply with treatment regimens rather than complete study questionnaires and
to support inclusion of children with parents with T1D but to maintain exclusion of siblings with T1D.
To optimise consent rates, screening log data were used to inform the recruitment strategy. Screening data
indicated that patients who consented to participate were approached sooner after diagnosis than those
who declined. In the light of these data, clinical teams and research nurses (RNs) were encouraged to
share information about the study as soon as possible following diagnosis.
In total, 976 patients were diagnosed with T1D in the 15 study centres in England and Wales during the
48-month recruitment period, of whom 98 (10%) did not meet the study eligibility criteria. One hundred and
eighty-nine patients (22%) were not approached about participation. Of these, 115 (61%) were considered
to be unsuitable by treating clinicians for reasons other than the study exclusion criteria, 52 patients (28%)
were not approached because staffing levels at the site were too low at the time of diagnosis to deliver
the study protocol and no reason was recorded for 22 (12%). Of the remaining 689 patients, 294 (42.7%)
consented to participate in the study; however, one randomised participant withdrew consent for their data
to be used immediately following randomisation, leaving 293 randomised participants.
Patients and families were invited to share their reasons for declining to participate in the study. The
main reason given was patient preference for one of the trial arms. Strong patient preference had been
expected at the design stage, and of the 395 eligible participants who declined consent, 36 (9%) cited a
preference for CSII therapy and 259 (66%) cited a preference for MDI.
In response to this strong patient preference and to support an informed decision, we made a short film in
which four SCIPI study participants (two randomised to CSII and two randomised to MDI) and their parents
shared their experiences of diagnosis and living with T1D and the treatment in each of the study arms.
Although the film was generally well received, we did not observe any increase in recruitment rates
following its introduction and the issue of patient preference persisted throughout the trial.
A CONSORT flow diagram illustrating the pathway of patients from diagnosis to consent and
randomisation and through the study protocol is given in Figure 2.
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The purpose of the SCIPI study was to generate evidence that could be applied to the population of patients
treated in children’s diabetes services in the NHS. For this reason, it was important to demonstrate that
patient characteristics, in particular those known to be associated with glycaemic control, did not differ
between those who consented and those who declined to participate. The baseline characteristics of patients
who were invited to participate in the study are given in Appendix 1, Table 28. There was no difference in
age, sex or ethnicity between the group of patients who consented and the group of patients who declined.
The median deprivation score for those who declined because they had a strong preference for CSII was
27.7 (range 16.6–63.9), compared with 17.0 (range 1.62–77.23) for those who consented and 17.96
(range 1.18–74.35) for those who stated a strong preference for MDI.
Internal pilot
The internal pilot was planned after 30 patients had been recruited. Of the 89 eligible patients approached for
consent, 30 provided consent and 59 declined (33.7% consent rate, 95% CI 23.9% to 43.5% consent rate).
The first patient was randomised on 31 May 2011, and 30 patients were randomised by 3 July 2012. A review
of the consent rates by recruiting centre identified lower consent rates in one centre that started patients on
Assessed for eligibility
(n = 976)
Randomised
(n = 294)
Allocated to CSII
(n = 144)
Withdrew from trial
(n = 1)
Analysed
(n = 143)
Allocation
Follow-up
Analysis
• Received CSII, n = 144
• No longer wished to
   participate, n = 1
• Withdrew from trial prior to
   12 months, n = 1
Excluded from analysis
(n = 1)
Allocated to MDI
(n = 149)
Withdrew from trial
(n = 5)
Analysed
(n = 144)
• Received MDI, n = 149
• Relocated, n = 2
• Coeliac disease, unable to
   comply with gluten-free 
   diet, n = 1
• Personal circumstances, n = 1
• Lost to follow-up, n = 1
• Withdrew from trial prior to
   12 months, n = 5
Excluded from analysis
(n = 5)
Excluded
(n = 682)
Withdrew consent for collected
data to be used
(n = 1)
• Eligibility criteria not met, n = 98
• Declined to participate, n = 395
• Other reasons, n = 189
FIGURE 2 The CONSORT flow chart.
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three daily injections at diagnosis, rather than MDI. Excluding this site, the consent rate increased (26/60
patients; 43.3%, 95% CI 30.8% to 55.9%). Screening data comparing characteristics of eligible consenting
participants did not differ from those declining for age, sex, ethnicity or deprivation score. A review of
the SD used in the sample size calculation to the accrued data indicated that the study should continue to
the planned sample size. The recommendation of the IDSMC was that the SCIPI study should progress to the
full study.
Baseline comparability
There was no difference in age, sex, ethnicity or deprivation score between treatment arms (Table 4).
Baseline data also showed that auxological and biochemical characteristics did not differ between
treatment groups at baseline (Table 5).
The measurement of autoantibodies was determined by local protocols, with some centres testing only
patients in whom the diagnosis of T1D was felt to be uncertain. Eleven patients randomised to the MDI arm
tested positive for coeliac disease on antibody testing, compared with four randomised to the CSII arm.
TABLE 4 Baseline demographics
Demographic variable
Treatment arm
TotalCSII MDI
Age at randomisation (years)
n (missing) 144 (0) 149 (0) 293 (0)
Median (IQR) 9.9 (5.7–12.2) 9.4 (5.8–12.5) 9.8 (5.7–12.3)
Minimum, maximum 0.8, 16 0.7, 15.4 0.7, 16
Age category, n (%)
n (missing) 144 (0) 149 (0) 293 (0)
7 months to < 5 years 33 (22.9) 32 (21.5) 65 (22.2)
5 years to < 12 years 71 (49.3) 76 (51) 147 (50.2)
12 years to 15 years 40 (27.8) 41 (27.5) 81 (27.6)
Sex, n (%)
n (missing) 144 (0) 149 (0) 293 (0)
Female 71 (49.3) 69 (46.3) 140 (47.8)
Male 73 (50.7) 80 (53.7) 153 (52.2)
Ethnicity, n (%)
n (missing) 143 (1) 146 (3) 289 (4)
Asian or Asian British 4 (4.2) 7 (6.1) 10 (5.6)
Black or British black 0 (0) 3 (2.1) 3 (1)
British white 124 (86.7) 118 (80.8) 242 (83.7)
Mixed 4 (2.8) 6 (4.1) 10 (3.5)
Other white 9 (6.3) 10 (6.9) 19 (6.0)
Deprivation scorea
n (missing) 137 (7) 143 (6) 280 (13)
Median (IQR) 19.4 (8.9–37.9) 14.7 (7.8–31.8) 17 (8.4–35.8)
Minimum, maximum 1.8, 77.1 1.6, 77.2 1.6, 77.2
IQR, interquartile range.
a Deprivation score range: 0–100, with 100 indicating greater deprivation.
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TABLE 5 Baseline auxological and biochemical characteristics
Demographic variable
Treatment arm
TotalCSII MDI
BMI SDS
n (missing) 124 (20) 132 (17) 256 (37)
Mean (SD) 0.2 (1.3) 0.1 (1.4) 0.1 (1.3)
Median (IQR) 0.2 (–0.7 to 0.9) 0.1 (–0.8 to 1) 0.2 (–0.8 to 1)
Minimum, maximum –2.9, 4.2 –4.6, 3.5 –4.6, 4.2
Height SDS
n (missing) 124 (20) 132 (17) 256 (37)
Mean (SD) 0.3 (1.1) 0.3 (1.1) 0.3 (1.1)
Median (IQR) 0.1 (–0.4 to 1.1) 0.4 (–0.3 to 1.1) 0.3 (–0.4 to 1.1)
Minimum, maximum –2.3, 3.3 –4.8, 2.4 –4.8, 3.3
Local HbA1c measurement (mmol/mol)
n (missing) 122 (22) 122 (27) 244 (49)
Mean (SD) 105.9 (24.2) 103.6 (26.3) 104.7 (25.2)
Median (IQR) 105 (87 to 122) 103 (83 to 126) 104.7 (85.5 to 125)
Minimum, maximum 58, 184 55, 172.1 55, 184
Central HbA1c measurement (mmol/mol)
n (missing) 64 (80) 71 (78) 135 (158)
Mean (SD) 101.2 (24.9) 96.4 (24) 98.7 (24.4)
Median (IQR) 102.5 (81.5 to 127) 93 (79 to 119) 100 (80 to 126)
Minimum, maximum 38, 130 50, 130 38, 130
HbA1c concentration
a (mmol/mol)
n (missing) 132 (12) 131 (18) 263 (30)
Mean (SD) 104.6 (24.4) 102.6 (26.7) 103.6 (25.5)
Median (IQR) 105 (87.5 to 127) 103 (81 to 127) 105 (84 to 127)
Minimum, maximum 38, 184 50, 172.1 38, 184
Blood glucose (mmol/l)
n (missing) 141 (3) 146 (3) 287 (6)
Mean (SD) 26.8 (9.2) 26.9 (10) 26.9 (9.6)
Median (IQR) 26.2 (20.2 to 32.5) 25.6 (19.5 to 32.6) 25.7 (19.7 to 32.5)
Minimum, maximum 5.1, 56.0 5.7, 69.5 5.1, 69.5
Blood pH
n (missing) 127 (17) 133 (16) 260 (33)
Mean (SD) 7.3 (0.2) 7.3 (0.1) 7.3 (0.2)
Median (IQR) 7.4 (7.3 to 7.4) 7.4 (7.2 to 7.4) 7.4 (7.3 to 7.4)
Minimum, maximum 6, 7.6 6.8, 7.5 6, 7.6
IQR, interquartile range.
a When available, central laboratory HbA1c measurements were taken in preference of local laboratory HbA1c measurements.
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Retention and adherence
Figure 3 summarises the time point and number of patients who made a permanent change to their
randomly allocated insulin delivery method, the time point and number of patients who decided to end
their follow-up in the SCIPI study and the number of patients who attended each scheduled follow-up. In
total, only six participants withdrew from the SCIPI study prior to the 12-month follow-up, and all remaining
287 patients (97.0%) attended the 12-month follow-up visit. See Figure 2 for a summary of the reasons
for withdrawals.
Permanent changes to insulin delivery
All participants initially received their insulin via their randomly allocated device.
Twenty-two patients (15%) randomised to CSII changed to MDI, and 31 patients (21%) randomised to
MDI changed to CSII. Table 6 summarises the time point and age group of participants who switched
between treatment arms.
In the youngest age group, more than one-third of patients randomised to treatment with MDI switched
to CSII, whereas only one patient (3%) switched from CSII to MDI. In the oldest age group, the converse
was true, with more than twice as many participants switching from CSII to MDI; however, in the middle
age group, switching between treatment arms was more balanced.
Randomised to
CSII
(n = 144)
3-month follow-up
Attended, n = 138
6-month follow-up
Attended, n = 136
9-month follow-up
Attended, n = 139
12-month follow-up
(n = 143)
Baseline
Attended, n  = 144
Randomised to
MDI
(n = 149)
3-month follow-up
Attended, n = 148
6-month follow-up
Attended, n = 142
9-month follow-up
Attended, n = 130
12-month follow-up
(n = 144)
Baseline
Attended, n = 149
Permanent change to insulin
deliverya
Time point = 0 months
(n = 3 CSII, 0 MDI)
Time point = 0–3 months 
(n = 0 CSII, 0 MDI)
Time point = 3–6 months 
(n = 0 CSII, 0 MDI)
Time point = 6-month visit
(n = 0 CSII, 1 MDI)
Time point = 6–9 months 
(n = 0 CSII, 1 MDI)
Time point = 9–12 months 
(n = 1 CSII, 3 MDI)
Time point = 0–3 months 
(n = 11 CSII, 5 MDI)
Time point = 3 months
(n = 2 CSII, 0 MDI)
Time point = 3–6 months 
(n = 0 CSII, 11 MDI)
Time point = 6–9 months 
(n = 4 CSII, 7 MDI)
Time point = 9 months
(n = 0 CSII, 1b MDI)
Time point = 9–12 months 
(n = 2 CSII, 7 MDI)
Discontinued follow-up
FIGURE 3 Retention and adherence. a, Permanent change of insulin delivery from randomised treatment but
continuing follow-up; b, patient changed from MDI to injections ter die sumendus (TDS) regime.
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When movement between treatment arms was examined by study centre, we found two centres in which
there was dominance for switch from MDI to CSII, with one centre switching four out of five patients
from MDI to CSII and none from CSII to MDI. In another centre, 9 out of 16 patients randomised to MDI
switched to CSII and 3 out of 14 patients randomised to CSII switched to MDI. In other centres, movement
between treatment arms was more balanced (see Appendix 2, Figure 12).
Data were collected relating to the decision to switch treatment arms and a summary is displayed in Table 7,
with more detailed data in Appendix 2, Table 29. The most frequently cited reasons for switching treatment
arm were parent or patient preference. The majority of the participants moving from CSII to MDI had a last
HbA1c measurement above the NICE recommendations applicable at the time of the switch; however, a larger
proportion of those moving from MDI to CSII had HbA1c measurements within the NICE recommendations.19
TABLE 6 Permanent changes to insulin delivery by age and time point
Age (years)
CSII to MDI MDI to CSII
n
Time point (months)
Total (%) n
Time point (months)
Total (%)0 0–3 3–6 6–9 9–12 0–3 3–6 6–9 9–12
< 5 33 1 0 0 0 0 1 (3.0) 32 3 4 2 3 12 (37.5)
5–11 71 2 5 0 2 1 10 (14.1) 76 1 5 4 4 14 (18.4)
≥ 12 40 0 6 2 2 1 11 (27.5) 41 1 2 1 0 4 (9.8)
Total 144 3 11 2 4 2 22 (15.3) 149 5 11 7 7 30 (20.1)
TABLE 7 Decision-making for permanent change to insulin deliverya
Age (years) N
HbA1c
concentration
higher than
recommended
guideline (n)
Decision-makers
Reasons (frequency)Parent Patient Clinician Frequency
Permanent change from CSII to MDI
< 5 1 1 ✗ 1 Parent preference (n= 1)
5–11 10 9 ✗ 4 Patient/parent preference
(n= 10)
Poor concordance with
treatment (n= 1)
Poor control, frequent
hyperglycaemia (n= 1)
Pain at cannula site (n= 1)
Did not want pump (n= 1)
✗ 1
✗ ✗ 3
✗ ✗ ✗ 1
✗ ✗ 1
≥ 12 10 9 ✗ 2 Patient/parent preference
(n= 10)
Poor concordance with
treatment (n= 1)
Poor control, frequent
hyperglycaemia (n= 1)
✗ ✗ 4
✗ ✗ ✗ 4
✗ ✗ 1
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Protocol deviations
Protocol deviations are summarised in Table 8. The most common major protocol deviation was the
12-month visit taking place outside the preferred time window. The median number of days outside the
visit window was 2.0 [interquartile range (IQR) –5 to 10 days] and 2.5 (IQR –7 to 9.5 days) for the CSII and
MDI arms, respectively.
Primary outcome: glycosylated haemoglobin measured at 12 months
Data on HbA1c concentrations were available for 97% of participants (CSII, n = 143; MDI, n = 142).
The results for the primary outcome for the primary ITT analysis and the per-protocol analysis are provided
in Table 9. The per-protocol analysis population excludes participants who had a major protocol deviation
(see Table 8) or three or more minor deviations.
TABLE 7 Decision-making for permanent change to insulin deliverya (continued )
Age (years) N
HbA1c
concentration
higher than
recommended
guideline (n)
Decision-makers
Reasons (frequency)Parent Patient Clinician Frequency
Permanent change from MDI to CSII
< 5 12 10 ✗ 2 Age related (n= 2)
Patient/parent preference
(n= 7)
Poor control, frequent
hyperglycaemia (n = 5)
Bruising at injection site
(n= 1)
✗ 2
✗ ✗ 8
5–11 14 5 ✗ 2 Patient/parent preference
(n= 13)
Poor concordance with
treatment (n= 2)
Poor control, frequent
hyperglycaemia (n = 1)
✗ ✗ 2
✗ ✗ ✗ 9
✗ ✗ 1
≥ 12 4 1 ✗ 1 Patient/parent preference
(n= 4)
✗ ✗ 1
✗ ✗ ✗ 1
✗ ✗ 1
Permanent change from MDI to injections TDS regime
5–11 1 1 ✗ ✗ 1 Patient/parent preference
(n= 4)
a Not prespecified analysis in the statistical analysis plan.
DOI: 10.3310/hta22420 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 42
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Blair et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
31
TABLE 8 Protocol deviations
Protocol deviations
Treatment arm, n (%)
Overall
(N= 293),
n (%)
CSII
(N= 144)
MDI
(N= 149)
Relating to inclusion and exclusion criteria 0 (0) 0 (0) 0 (0)
Relating to treatment and follow-up visits
At least one major 57 (39.6) 77 (51.7) 134 (45.7)
Start of study treatment from diagnosis being > 10 days (protocol version 3.0) 1 (0.7) 1 (0.7) 2 (0.7)
Start of study treatment from diagnosis being > 14 days (protocol version 4.0) 1 (0.7) 3 (2) 4 (1.4)
36 (25) 49 (32.9) 85 (29)
22 (15.3) 31a (20.8) 53a (18.1)
10 (6.9) 13 (8.7) 23 (7.8)
70 (48.6) 87 (58.4) 157 (53.6)
    Scheduled 12-month follow-up visit falling outside the ± 15-day window 
    Permanent change of insulin delivery
     Usage of non-protocol-specified insulinb
At least one minor
At least three minor 0 (0) 0 (0) 0 (0)
34 (23.6) 44 (29.5) 78 (26.6)
43 (29.9) 48 (32.2) 91 (31.1)
Scheduled 3-month follow-up visit falling outside the ± 15-day window 
Scheduled 6-month follow-up visit falling outside the ± 15-day window 
Scheduled 9-month follow-up visit falling outside the ± 15-day window 44 (30.6) 39 (26.2) 83 (28.3)
At least one major and/or at least three minor 57 (39.6) 77 (51.7) 134 (45.7)
a One permanent switch of insulin delivery method was from MDI to ‘injections TDS regime’.
b Does not include insulin detemir.
Of the 134 protocol deviations, two deviations took place in two participants (CSII, n= 1; MDI, n = 1) who withdrew prior
to 12 months.
TABLE 9 Glycosylated haemoglobin levels measured at 12 months
HbA1c
concentration
(mmol/mol) at
12 months
Treatment arm
Total
Meana,b (95% CI) Meana difference
between treatment
groups (CSII – MDI)
(95% CI) p-valueCSII MDI CSII MDI
Primary analysis: ITT analysis (age group)
7 months to < 5 years
n (missing)c 33 (0) 31 (1) 64 (1) 60.9
(58.5 to 63.3)
58.5
(56.1 to 60.9)
2.4
(–0.4 to 5.3)
0.09
Mean (SD) 63.9 (12.1) 58.4 (9.9) 61.2 (11.3)
5 years to < 12 years
n (missing)c 70 (1) 72 (4) 142 (5)
Mean (SD) 58 (11.4) 59.3 (11.4) 58.7 (11.4)
12 years to < 16 years
n (missing)c 40 (0) 39 (2) 79 (2)
Mean (SD) 61.3 (13.3) 54.7 (14.7) 58.1 (14.3)
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The HbA1c measurement was marginally higher in the CSII group than in the MDI group (mean difference
2.4 mmol/mol; 95% CI –0.4 to 5.3 mmol/mol), although the observed difference was not statistically
significant. This result was consistent when compared with the per-protocol analysis (see Tables 4 and 5 for
comparison of baseline characteristics of all randomised participants and Appendix 2, Table 30, for baseline
characteristics of the per-protocol analysis population). A summary of the data sources (local or central
laboratory) used in the primary ITT analysis and the per-protocol analysis is provided in Table 10.
TABLE 9 Glycosylated haemoglobin levels measured at 12 months (continued )
HbA1c
concentration
(mmol/mol) at
12 months
Treatment arm
Total
Meana,b (95% CI) Meana difference
between treatment
groups (CSII – MDI)
(95% CI) p-valueCSII MDI CSII MDI
Per-protocol analysis (age group)
7 months to < 5 years
n (missing)d 23 (10) 11 (21) 34 (31) 60.2
(56.4 to 63.9)
59.3
(55.3 to 63.3)
0.9
(–3.2 to 5)
0.67
Mean (SD) 62.6 (13.1) 56.2 (11) 60.5 (12.6)
5 years to < 12 years
n (missing)d 41 (30) 32 (44) 73 (74)
Mean (SD) 57.9 (11.8) 59.7 (10.8) 58.7 (11.3)
12 years to < 16 years
n (missing)d 23 (17) 23 (18) 46 (35)
Mean (SD) 57.6 (14.2) 57.8 (16.8) 57.7 (15.4)
a Least mean squares.
b This was not prespecified in the statistical analysis plan but has been added to aid interpretation.
c There were missing values in the ITT analysis owing to five withdrawals prior to 12 months and one missing value.
d There were missing values in the per-protocol analysis owing to six withdrawals prior to 12 months, two with missing
values, and 132 protocol deviations.
TABLE 10 Data source of HbA1c concentration measured at 12 months
Laboratory value used for primary
outcome analysis
Analysis, n (%)
ITT Per-protocol
CSII MDI CSII MDI
Aged < 5 years
Central 22 (66.7) 26 (83.9) 15 (65.2) 11 (100)
Local 11 (33.3) 5 (16.1) 8 (34.8) –
Aged 5–11 years
Central 58 (82.9) 58 (80.6) 34 (82.9) 27 (84.4)
Local 12 (17.1) 14 (19.4) 7 (17.1) 5 (15.6)
Aged ≥ 12 years
Central 32 (80) 33 (84.6) 18 (78.3) 20 (87)
Local 8 (20) 6 (15.4) 5 (21.7) 3 (13)
Total
Central 112 (77.8) 117 (78.5) 67 (77.0) 58 (87.9)
Local 31 (21.5) 25 (16.8) 20 (23.0) 8 (12.1)
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Exploratory analyses including HbA1c concentrations measured at baseline as a continuous explanatory
variable in the age-adjusted model did not alter the SCIPI study conclusions for CSII compared with MDI
at 12 months [least square mean difference between treatment groups (CSII – MDI) 2.9; 95% CI –0.02
to 5.9], but did suggest the importance of early baseline values for 12-month measurements (HbA1c
concentration baseline coefficient estimate 0.07; standard error 0.03; 95% CI 0.01 to 0.13).
An additional exploratory analysis considered the impact of the deprivation score by including it in the age
strata-adjusted model and found that it did not alter conclusions [least square mean difference (CSII –MDI)
2.2; 95% CI –0.7 to 5.0]. The model suggested that higher deprivation score was associated with higher
HbA1c concentrations at 12 months (0.03, standard error 0.04, 95% CI –0.05 to 0.12).
Mean profile plots are provided for each age stratum in Figure 4. The results from including an age
stratum by treatment group interaction with age as a main effect in the model are provided in Table 11.
The least mean square estimates are 61.5 (95% CI 59.1 to 63.9) for CSII, 57.9 (95% CI 55.5 to 60.3)
for MDI and 3.6 (95% CI 0.6 to 6.6) for the difference (CSII – MDI).
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FIGURE 4 Glycosylated haemoglobin (mmol/mol) mean profile plots by age stratum. (a) Participants aged < 5 years;
(b) participants aged 5–11 years; and (c) participants aged ≥ 12 years. Not a prespecified analysis in the statistical
analysis plan. (continued )
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Figure 5 displays the consistency of treatment effect across the SCIPI study centres. The consistency
of treatment effect across sites is evident by the overlapping CIs. There is no statistical evidence for
differences between sites from the chi-squared test for heterogeneity (p = 0.51) and I2 (0%). Figure 6
displays the treatment effect in 6-month periods to consider potential presence of a learning curve from
the first randomisations. The period of 0–6 months includes the first 6 months of randomisations within
each centre. The graph does not suggest a pattern of reducing treatment effect by time.
Secondary outcomes
The target HbA1c value that was recommended by NICE19 at the start of the SCIPI study was < 58mmol/mol.
In August 2015, this was revised to be < 48mmol/mol. To reflect current practice, the secondary outcome
that had previously been < 58mmol/mol was changed in a protocol amendment (version 7.0). However,
as the majority of the SCIPI study participants would have been randomised and followed up with diabetes
teams aiming to attain HbA1c values of < 58mmol/mol, the results for both are presented in Table 12.
Greater proportions of participants on the MDI arm attained values below the target thresholds; however,
results are not statistically significant.
The incidences of severe hypoglycaemia and DKA were low, with only eight and two participants
experiencing these events, respectively. Although participants on CSII had a greater event rate, for both
events, the wide CIs reflect the low number of event rates and, hence, a high level of uncertainty.
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FIGURE 4 Glycosylated haemoglobin (mmol/mol) mean profile plots by age stratum. (a) Participants aged < 5 years;
(b) participants aged 5–11 years; and (c) participants aged ≥ 12 years. Not a prespecified analysis in the statistical
analysis plan.
TABLE 11 Exploratory analysis including treatment by age strata as a covariate
Effect (CSII –MDI) Estimatea Standard error 95% CI
Treatment × ≥ 12 years 6.5001 2.7026 1.1788 to 11.8213
Treatment × 5–11 years –1.2540 2.0148 –5.2210 to 2.7130
Treatment × < 5 years 5.5902 3.0029 –0.3223 to 11.5027
a Not prespecified analysis in the statistical analysis plan.
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– 100 – 50 0
Mean difference
IV, fixed, 95% CI
Mean difference
IV, fixed, 95% CI
MDICSII
Study or subgroup Mean SD Total Mean SD Total
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– 4.42 (– 15.17 to 6.33)
Not estimable
3.08 (– 7.39 to 13.56)
1.94 (– 8.92 to 12.81)
8.33 (– 2.56 to 19.23)
Not estimable
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A higher proportion of participants randomised to MDI were in partial remission at 12 months. However,
levels of missing data were high for this outcome because of the lack of availability of the daily insulin
dose data required to calculate its occurrence. The formula used to calculate partial remission is available
in the statistical analysis plan, which is available on the National Institute for Health Research website
(www.journalslibrary.nihr.ac.uk/programmes/hta/081439/#/; accessed 13 February 2018).
There was no significant difference in change in BMI SDS or height SDS between those randomised to CSII and
those randomised to MDI (Table 13). Insulin requirements were significantly lower for those randomised to MDI
than for those randomised to CSII (see Table 13). Similarly, with partial remission, the low availability of dose data
increased levels of missing data. Owing to the availability of CSII data, levels of missing data are higher in the
MDI arm.
Quality of life
Tables 14 and 15 present results for QoL as measured by the PedsQL instruments for parents and children,
respectively, stratified by instrument age category. Results for each domain are available in Appendix 2,
Tables 31 and 32.
In parent-reported QoL, there was a tendency for parents with children randomised to CSII to report higher
QoL scores than those on MDI. This was consistent across instrument age strata, the 6- and 12-month
follow-up time points and the child-reported scores. Estimates of the least mean squares difference between
treatment groups (CSII – MDI) were 4.1 (95% CI 0.6 to 7.6; p = 0.02) for parent-reported and 3.1 (95% CI
–0.6 to 6.8; p = 0.1) for child-reported QoL. It should be noted, however, that child-reported QoL starts
from age 5 years but the parent-reported QoL starts from age 2 years and that, in general, the size of the
differences and CI widths are similar.
TABLE 12 Secondary outcomes: target HbA1c concentration, severe hypoglycaemia, DKA and partial remission
Target HbA1c
concentration
Treatment arm, n (%)
Overall (N= 293),
n (%)
Relative risk
(95% CI) p-valueaCSII (N= 144) MDI (N= 149)
< 48mmol/mol 22 (15.4) 29 (20.4) 51 (17.9) 0.75 (0.46 to 1.25) 0.28
Missing 1 5
< 58mmol/mol 66 (46.2) 78 (54.9) 144 (50.5) 0.84 (0.67 to 1.06) 0.16
Missing 1 5
Severe hypoglycaemiab 6 (4.2) 2 (1.3) 8 (2.7) 3.1 (0.6 to 15.1) 0.17
Missing 10 0
DKA 2 (1.4) 0 2 (0.7) 5.2 (0.3 to 106.8) 0.24
Missing 10 0
Partial remission 21 (24.4) 21 (32.8) 42 (28.0) 0.74 (0.45 to 1.24) 0.28
Missing 58 85
a Chi-squared test.
b The statistical analysis plan says ‘Severe hypoglycaemia is a type of related AE . . . Cases of hypoglycaemia mild or
moderate in severity are not counted as events for this analysis’. ‘Severe hypoglycaemia’ is the type of AE and this
terminology is used in general clinical practice regardless of AE severity so it is, thus, possible to have a moderate or mild
‘severe hypoglycaemia’. Prior to the final analysis being undertaken all cases of ‘severe hypoglycaemia’ were queried
with the site again to double-check whether or not it was happy with the AE type and severity.
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TABLE 13 Secondary outcomes: change in BMI SDS, change in height SDS and insulin requirements
Summary
Treatment arm
Total CSII –MDIa (95% CI) p-valueCSII MDI
Change in BMI SDS
7 months to < 5 years
n (missing) 124 (20) 132 (17) 256 (37) 0.1 (0 to 0.3) 0.13
Mean (SD) 0.2 (1.3) 0.1 (1.3) 0.1 (1.3)
Median (IQR) 0.2 (–0.7 to 0.9) 0.1 (–0.8 to 1) 0.2 (–0.8 to 1)
Minimum, maximum –2.9, 4.2 –4, 3.5 –4, 4.2
5 years to < 12 years
na (missing) 142 (1) 138 (6) 280 (7)
Mean (SD) 0.8 (1.1) 0.7 (1) 0.7 (1.1)
Median (IQR) 0.8 (0.1 to 1.5) 0.6 (0 to 1.4) 0.6 (0 to 1.4)
Minimum, maximum –1.8, 4.1 –2.7, 3 –2.7, 4.1
12 years to < 16 years
na (missing) 122 (21) 122 (22) 244 (43)
Mean (SD) 0.6 (0.8) 0.5 (0.8) 0.5 (0.8)
Median (IQR) 0.5 (0.1 to 1) 0.4 (–0.1 to 0.9) 0.5 (0 to 0.9)
Minimum, maximum –1.4, 3.4 –1.1, 5.3 –1.4, 5.3
Change in height SDS
7 months to < 5 years
n (missing) 124 (20) 132 (17) 256 (37) –0.1 (–0.2 to 0) 0.10
Mean (SD) 0.3 (1.1) 0.3 (1) 0.3 (1)
Median (IQR) 0.1 (–0.4 to 1.1) 0.4 (–0.3 to 1.1) 0.3 (–0.3 to 1.1)
Minimum, maximum –2.3, 3.3 –2.9, 2.4 –2.9, 3.3
5 years to < 12 years
na (missing) 142 (2) 138 (11) 280 (13)
Mean (SD) 0.2 (1.1) 0.3 (1) 0.3 (1)
Median (IQR) 0.1 (–0.6 to 1) 0.3 (–0.3 to 1) 0.2 (–0.5 to 1)
Minimum, maximum –2.1, 3.5 –2.7, 2.3 –2.7, 3.5
12 years to < 16 years
na (missing) 122 (22) 122 (27) 244 (49)
Mean (SD) –0.1 (0.5) 0 (0.4) 0 (0.4)
Median (IQR) 0 (–0.2 to 0.2) 0 (–0.2 to 0.2) 0 (–0.2 to 0.2)
Minimum, maximum –2.8, 0.7 –1.7, 1.6 –2.8, 1.6
Insulin requirements (unit/kg/day)
7 months to < 5 years
n (missing) 24 (9) 13 (19) 37 (28) 0.1 (0.0 to 0.2) 0.01
Mean (SD) 0.7 (0.2) 0.7 (0.1) 0.7 (0.2)
Median (IQR) 0.8 (0.6 to 0.8) 0.6 (0.6 to 0.7) 0.7 (0.6 to 0.8)
Minimum, maximum 0.3, 1.2 0.4, 0.9 0.3, 1.2
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TABLE 13 Secondary outcomes: change in BMI SDS, change in height SDS and insulin requirements (continued )
Summary
Treatment arm
Total CSII –MDIa (95% CI) p-valueCSII MDI
5 years to < 12 years
n (missing) 45 (26) 38 (38) 83 (64)
Mean (SD) 0.6 (0.2) 0.6 (0.3) 0.6 (0.3)
Median (IQR) 0.6 (0.5 to 0.8) 0.6 (0.4 to 0.7) 0.6 (0.4 to 0.8)
Minimum, maximum 0.2, 1.2 0, 1.2 0, 1.2
12 years to < 16 years
n (missing) 18 (22) 13 (28) 31 (50)
Mean (SD) 0.8 (0.2) 0.5 (0.4) 0.7 (0.3)
Median (IQR) 0.8 (0.6 to 0.9) 0.7 (0 to 0.8) 0.7 (0.5 to 0.9)
Minimum, maximum 0.4, 1.2 0, 0.9 0, 1.2
a Adjusted mean difference, adjusted for age group and centre as random effects.
TABLE 14 Overall PedsQL parent-reported scores
Summary
Time point
6 monthsa 12 months
CSII MDI Total CSII MDI Total
Parents/carers of 2- to 4-year-old children
n 24 18 42 20 17 37
Median (IQR) 72.8
(62.9–77.2)
61.8
(55.5–74.1)
68.8
(57–76.8)
75
(62.1–82.1)
70.5
(54.7–79.5)
73.2
(60.7–80.4)
Minimum, maximum 54.5, 98.6 46.7, 81.6 46.7, 98.6 52.4, 99.1 40.2, 90.2 40.2, 99.1
Parents/carers of 5- to 7-year-old children
n 13 23 36 16 17 33
Median (IQR) 70.5
(63.5–85.7)
69.6
(65.2–80.4)
69.8
(65.1–80.8)
75.6
(60.4–86.6)
72.3
(64.7–76)
73.2
(63.4–81.3)
Minimum, maximum 51.8, 90.2 54.7, 84.4 51.8, 90.2 45.5, 94.6 49.1, 86.6 45.5, 94.6
Parents/carers of 8- to 12-year-old children
n 58 56 114 54 55 109
Median (IQR) 73.2
(65.2–84.2)
68.8
(63.4–78.8)
70.5
(64.3–81.5)
74.5
(65.9–81.3)
67.9
(57.1–77.7)
70.5
(61.6–80.4)
Minimum, maximum 31.3, 94.6 34.8, 95.8 31.3, 95.8 39.5, 100 34.2, 99.1 34.2, 100
Parents/carers of 13- to 16-year-old children
n 29 28 57 38 34 72
Median (IQR) 73.2
(59.8–84.3)
67.6
(55.6–74.9)
69.6
(58.9–80.4)
67.3
(58–80.7)
67.4
(59.8–79.5)
67.3
(58.9–80.1)
Minimum, maximum 42, 99.1 35.1, 98.2 35.1, 99.1 41.1, 96.4 19.6, 91.1 19.6, 96.4
a Not prespecified in the statistical analysis plan to present data at 6 months.
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Safety analysis
Table 12 reports on incidences of hypoglycaemia and DKA in the ITT analysis population. In this section, the
data set contains all participants who were randomised and received at least one dose of trial medication.
For AEs, the method of insulin delivery that the participants were receiving at the time of AE onset was used,
rather that the allocated treatment, to take into account that participants could temporarily or permanently
switch treatment. The total number of events experienced and the number of participants experiencing at
least one event are provided along with the IDR (the number of patients with at least one new AE per
population at risk in a given time period):
l The incidence of related AEs by treatment group was 54 in 36 patients who were on CSII at the time of the
AE. IDR was 25.0 patients with at least one event per 100 person-years and 17 AEs in 16 patients who were
on MDI at the time of the AE. IDR was 10.5 patients with at least one event per 100 person-years.
l The incidence of related SAEs by treatment group was 14 SAEs in nine patients who were on CSII at
the time of the SAE. IDR was 6.2 patients with at least one event per 100 person-years and eight SAEs
in eight patients who were on MDI at the time of the SAE. IDR was 5.3 patients with at least one event
per 100 person-years.
Tables 16 and 17 provide the summary of related AEs and SAEs, respectively.
TABLE 15 Overall PedsQL child-reported scoresa
Summary
Time point
6 months 12 months
CSII MDI Total CSII MDI Total
5- to 7-year-old children
n 11 21 32 13 18 31
Median (IQR) 75
(51.5–80.4)
70.9
(67.9–80.4)
71.4
(67–80.4)
78.6
(60.7–85.7)
76.4
(60.7–81.6)
76.8
(60.7–82.1)
Minimum, maximum 41.1, 83.4 55.4, 87.5 41.1, 87.5 39.3, 89.3 30.4, 85.7 30.4, 89.3
8- to 12-year-old children
n 58 54 112 54 53 107
Median (IQR) 79.1
(66.6–84.8)
71.5
(64.3–80.4)
75.9
(66.3–83.6)
81.7
(70.7–88.4)
76.8
(64.3–85.7)
77.7
(70.5–87.8)
Minimum, maximum 45.5, 94.1 40.2, 99.1 40.2, 99.1 44.6, 100 39.8, 96.4 39.8, 100
13- to 16-year-old children
n 29 29 58 37 33 70
Median (IQR) 79.5
(71.4–87.6)
75.9
(67–82.1)
76.9
(69.6–85.7)
75
(63.4–84.8)
73.2
(60.7–79.3)
74.7
(60.7–84.8)
Minimum, maximum 43.8, 99.1 50, 98.2 43.8, 99.1 47.3, 95.5 35.7, 94.6 35.7, 95.5
a Not prespecified in the statistical analysis plan to present data at 6 months.
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TABLE 16 Summary of related AEs
Description
Treatment arm
Total (296.1 total person-
years, N= 293 patients)
CSII (144.1 total person-
years, N= 144 patients)
MDI (151.9 total person-
years, N= 149 patients)
Events (n)
Patients,
n (IDR) Events (n)
Patients,
n (IDR) Events (n)
Patients,
n (IDR)
All
DKA 2 2 (1.4) 0 0 (0) 2 2 (0.7)
Insulin administration error 2 2 (1.4) 5 5 (3.3) 7 6 (2)
Pump failure 4 3 (2.1) 0 0 (0) 4 3 (1)
Severe hypoglycaemia 6 6 (4.2) 2 2 (1.3) 8 8 (2.7)
Site infections 8 7 (4.9) 0 0 (0) 8 7 (2.4)
Other – specify 32 22 (15.3) 10 10 (6.6) 42 32 (10.8)
Device
DKA 1 1 (0.7) 0 0 (0) 1 1 (0.3)
Pump failure 4 3 (2.1) 0 0 (0) 4 3 (1)
Severe hypoglycaemia 2 2 (1.4) 0 0 (0) 2 2 (0.7)
Site infections 8 7 (4.9) 0 0 (0) 8 7 (2.4)
Other – specify 14 11 (7.6) 3 3 (2) 17 14 (4.7)
Carer error
Insulin administration error 1 1 (0.7) 4 4 (2.6) 5 5 (1.7)
Other – specify 5 2 (1.4) 0 0 (0) 5 2 (0.7)
Meter error
Other – specify 3 3 (2.1) 1 1 (0.7) 4 4 (1.4)
Incidental illness
Insulin administration error 1 1 (0.7) 0 0 (0) 1 1 (0.3)
Other – specify 5 5 (3.5) 3 3 (2) 8 8 (2.7)
Other
DKA 1 1 (0.7) 0 0 (0) 1 1 (0.3)
Insulin administration error 0 0 (0) 1 1 (0.7) 1 1 (0.3)
Severe hypoglycaemia 4 4 (2.8) 2 2 (1.3) 6 6 (2)
Other – specify 5 4 (2.8) 3 3 (2) 8 7 (2.4)
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TABLE 17 Summary of related SAEs
Description
Treatment arm
Total (296.1 total person-
years, N= 293 patients)
CSII (144.1 total person-
years, N= 144 patients)
MDI (151.9 total person-
years, N= 149 patients)
Events (n)
Patients,
n (IDR) Events (n)
Patients,
n (IDR) Events (n)
Patients,
n (IDR)
All
DKA 2 2 (1.4) 0 0 (0) 2 2 (0.7)
Insulin administration error 2 2 (1.4) 3 3 (2) 5 4 (1.4)
Pump failure 0 0 (0) 0 0 (0) 0 0 (0)
Severe hypoglycaemia 1 1 (0.7) 0 0 (0) 1 1 (0.3)
Site infections 1 1 (0.7) 0 0 (0) 1 1 (0.3)
Other – specify 8 6 (4.2) 5 5 (3.3) 13 11 (3.7)
Device
DKA 1 1 (0.7) 0 0 (0) 1 1 (0.3)
Pump failure 0 0 (0) 0 0 (0) 0 0 (0)
Severe hypoglycaemia 0 0 (0) 0 0 (0) 0 0 (0)
Site infections 1 1 (0.7) 0 0 (0) 1 1 (0.3)
Other – specify 0 0 (0) 0 0 (0) 0 0 (0)
Carer error
Insulin administration error 1 1 (0.7) 2 2 (1.3) 3 3 (1)
Other – specify 0 0 (0) 0 0 (0) 0 0 (0)
Meter error
Other – specify 0 0 (0) 0 0 (0) 0 0 (0)
Incidental illness
Insulin administration error 1 1 (0.7) 0 0 (0) 1 1 (0.3)
Other – specify 5 4 (2.8) 2 2 (1.3) 7 6 (2)
Other
DKA 1 1 (0.7) 0 0 (0) 1 1 (0.3)
Insulin administration error 0 0 (0) 1 1 (0.7) 1 1 (0.3)
Severe hypoglycaemia 1 1 (0.7) 0 0 (0) 1 1 (0.3)
Other – specify 3 2 (1.4) 3 3 (2) 6 5 (1.7)
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Chapter 4 Economic evaluation
Introduction
Economic evaluations
Economic evaluations of CSII versus MDI have been reviewed by Cummins et al.103 and, more recently,
by Roze et al.,104 Pozzilli et al.105 and ourselves using targeted searches of the PubMed, Web of Science,
Scopus, Cumulative Index to Nursing and Allied Health Literature, ProQuest and Cochrane databases.
In total, 10 fully reported economic evaluations were identified.62,81,103,106–112 Most are limited in their
transferability to the paediatric setting, as they relate to adult populations, and only two evaluations consider
children and adolescent populations.106,107
Cohen et al.106 examined the cost-effectiveness of CSII with MDI in adults and in children/young adults
with T1D from the perspective of the Australian single-payer health-care system. They applied the
Center for Outcomes Research (CORE) diabetes model (CDM) to simulate the lifetime progression of
diabetes in adolescent patients with the following baseline characteristics: a mean age of 17.1 years,
a mean duration of diabetes of 6.3 years and a mean HbA1c concentration of 8.9%.113
,114
The effectiveness of CSII in the base-case analysis was based on the results of a meta-analysis of 52
studies that included 1500 patients of all ages.115 Compared with MDI, the meta-analysis suggested that
treatment with CSII for ≥ 1 year was associated with a mean decrease in baseline HbA1c concentration
of 1.2%. The base-case analysis assumed no differences between interventions in the frequency of
hypoglycaemic events. Annual costs of CSII and MDI were based on pump costs (and assumed an 8-year
pump life), insulin costs, consumables, self-monitoring of blood glucose and medical professional assistance
with pump initiation, maintenance and operation. The costs of managing complications and health state
utilities were taken from published sources. All costs and outcomes were discounted at an annual rate of 5%.
The results indicated gains in discounted quality-adjusted life-years (QALYs) of 0.560 and a cost increase
of AU$41,779 in CSII compared with MDI. The incremental cost per QALY gained was AU$74,661, which is
marginally cost-effective at the Australian threshold for cost-effectiveness. This was sensitive to change in HbA1c
concentration: a reduction to 0.51% for CSII versus MDI increased the incremental cost-effectiveness ratio
(ICER) to AU$114,818. Reducing the effective lifespan of the insulin pump from 8 to 6 years increased the ICER
by 11%.
St Charles et al.107 modelled the cost-effectiveness of CSII in T1D populations, including children and
young adults, based on a third-party US payer perspective. Patients’ baseline demographics, risk factors
and pre-existing complications were taken from Doyle et al.35 and the Diabetes Control Complications
Trial Research Group secondary intervention cohort,3 with a mean age of 13.0 years (range 8–21 years),
a mean duration of diabetes of 5.6 years and a mean HbA1c concentration of 8.2%.
For their base-case analysis, the authors assigned a greater reduction in HbA1c concentration to CSII (0.9%)
than to MDI (0.1%), based on a 16-week randomised trial of 32 children and young adults with T1D.35 They
further assumed an insulin pump lifetime of 7 years and 50% lower hypoglycaemia event rates in CSII based
on an observational study116 and reviews of outpatient insulin therapy in T1D patients.117–119 Costs and
outcomes were extrapolated over a lifetime using the CDM and discounted at a rate of 3% per annum.
The base-case ICER, of US$27,195 per QALY gained, was sensitive to (1) the lifespan of the pump, rising
to US$40,652 per QALY gained for a 4-year lifetime, (2) the HbA1c concentration improvement with CSII,
rising to US$37,326 per QALY gained with a reduction in HbA1c concentration of 0.675%, and (3) the
hypoglycaemia event rate, with the ICER increasing to US$45,595 per QALY gained and no improvement
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in CSII over MDI. The model was less sensitive to changes in the discount rate. The higher treatment costs
associated with CSII in comparison with MDI (US$37,636 over a lifetime) were more than twice the
expected savings from fewer complications (US$16,172).
An important limitation of both studies106,107 was that they modelled the costs and consequences of CSII and
MDI using data from disparate sources. They relied on small studies for the estimated improvement in HbA1c
concentration and made assumptions relating to the frequency of hypoglycaemic events and lifetime rates of
T1D-related complications. The modelled outputs were very sensitive to these assumptions. Other long-term
issues, including adherence and patient preference, could also potentially influence the cost-effectiveness of
CSII, and although the CDM is a widely validated120 and widely accepted103 model in adult diabetes, there is
no supporting evidence of validity in paediatric populations.19
Aim
The aim of the economic evaluation of the SCIPI study was to estimate the cost–utility, based on an assessment
of the incremental costs per QALY gained, of treating paediatric T1D patients with CSII versus MDI. The costing
perspective was that of the NHS in England. Within-trial QALYs were derived from patients’, parents’ or
guardians’ responses to the HUI Quetionnaire using the HU12 algorithm. Costs were derived by measuring
health-care resource use associated with both CSII and MDI, including (1) purchase of pumps and pen devices,
(2) consumables, (3) management of AEs, (4) procedures, (5) insulin, (6) hospitalisations and (7) contact with
health-care professionals including GPs, school nurses, as an outpatient and at the accident and emergency
(A&E) department. Differences between intervention groups in the primary outcome would indicate the need
for a lifetime extrapolation using the CDM, otherwise a 12-month time horizon would be adopted.
Methods
Resource use
The perspective of the analysis was that of the NHS in England, with the expectation the major cost drivers
would be devices and consumables, such as cartridge sets, batteries and infusion sets for CSII, insulin
use, glucose self-monitoring and outpatient visits.104,106 Other potential high-cost resource usages were
considered, including A&E department attendance, hospital inpatient stays (including intensive care units)
and all contacts with health-care professionals, including GPs, hospital doctors, school nurses and other
specialists in person, and by telephone, fax, text or e-mail.
The measurement of resource use required complementary approaches using data collected as part of the
trial and as part of routine care. Patients’ use of health-care services was obtained from:
1. Electronic patient-linked information costing system (PLICS) data and/or patient administration system
(PAS) data of participating hospitals – PLICS and PAS data were used as a primary source for identifying
inpatient stays and use of a paediatric intensive care unit (PICU) or high-dependency unit (HDU).
2. Baseline forms – RNs completed the relevant sections of the baseline forms to identify the devices that were
assigned to SCIPI study patients [Medtronic pump, F. Hoffman-La Roche AG pump, MDI, F. Hoffman-La
Roche AG Expert glucometer, Contour® Glucometer (Ascensia Diabetes Care, Newbury, UK)]. The baseline
forms also recorded patients’ self-reported contact with hospital services and health-care professionals in the
3 months prior to randomisation. When the patient was unsure of this, RNs contacted the patient’s GP or
referred to the patient’s hospital notes. These forms were the primary source of baseline resource used.
3. Three-monthly patient questionnaires – RNs completed the relevant sections of the patient
questionnaires in face-to-face interviews with trial participants, their parents or guardians to identify
overnight hospital stays, number of nights, reason for admission and type of ward. Another section of
the patient questionnaire was used to identify contacts with health-care professionals including GPs,
consultants, non-consultant grade medical doctors, nurses, dietitians, psychologists, infusion specialists,
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social workers as well as the places or means of contact: A&E department, outpatient, general practice,
school visits, home visits telephone, fax, text and e-mail. When the patient was unsure, RNs contacted
the patient’s GP or referred to the patient’s hospital notes. Patient questionnaires were used as a
primary source of data for treatment as an outpatient, in an A&E department, by a GP or by other
health-care professional contacts. They were used as a secondary source of data for inpatient, PICU or
HDU stays, which was especially relevant if the patients had attended a different hospital for treatment.
4. Adverse event or SAE forms – RNs completed AE and SAE forms when trial participants were admitted
to hospital with severe hypoglycaemia, DKA, site infections, pump failures, insulin administration errors
or other diabetes and device-related causes. This information was used as a secondary source of data
for inpatient stays and use of PICU or HDU stays, especially relevant if the patients had attended a
different hospital for treatment.
5. Insulin prescription forms – insulin prescription forms were used as a primary source of insulin usage, as
these are more likely to reflect the quantity of insulin dispensed and, therefore, the true cost of insulin.
RNs contacted GPs and hospital personnel at 3-monthly intervals to record the number of boxes or vials of
insulin prescribed to patients, along with the dates and insulin type. Each box contained five × 300-unit
cartridges or five × 300-unit pens and each vial contained 1000 units. For young children, GPs occasionally
prescribe two or three cartridges or pens; however, no part-boxes were reported in the case report form
(CRF) and no assumptions were made based on patient age.
6. Three-monthly insulin usage forms – RNs documented patient usage of insulin in the 4 weeks prior to
each 3-monthly visit through face-to-face interviews with trial participants, their parents and/or guardians.
These data were used if their projected 12-month insulin usage exceeded the usage implied in the insulin
prescription form.
7. Electronic pump download data – RNs downloaded insulin usage data from the patient insulin pumps
and these were entered into an electronic database. These data were used if the 12-month insulin
usage exceeded the usage implied in the insulin prescription and/or insulin usage forms.
Unit costs
All resource use was valued in monetary terms using appropriate unit costs estimated at the time of analysis
(cost year was 2016). Healthcare Resource Group (HRG) codes were used as the main currency of the
economic analysis for inpatient stays and were obtained directly from electronic PLICS/PAS data or assigned
based on the description of the condition and complications when recorded in the patient questionnaire, AE
or SAE forms. HRG codes have the advantage of most closely reflecting actual payments, with cost codes
being allocated based on the latest available national tariff121 (these being bundled care packages, reimbursed
at a national level according to the NHS Payment by Results scheme; Table 18). The scheduled 3-monthly
visits were also costed using the national tariff because these formed part of the ongoing multidisciplinary
team integrated package of care approach recommended by NICE19 and were not costed elsewhere.
Unbundled care packages reimbursed at a local level, such as PICU and HDU stays, were costed using the
latest available National Schedule costs.122 Standard sources were used for the unit costs of all other primary
health-care, A&E and outpatient contacts,123 with consultation time estimated by discussing with 15 RNs
representing all recruiting sites (Table 19). The costs of needles, test strips and insulin were based on those
detailed in the British National Formulary124 and the costs of pumps and estimated annual consumables were
obtained from the suppliers (F. Hoffman-La Roche AG and Medtronic) (Tables 20 and 21). For the base-case
analysis, insulin pump costs were divided by four to represent a 4-year lifetime and, for MDI patients, two
refillable pens (1 × basal and 1 × bolus) were factored in at an estimate of £40 each per year.
Cost analysis
All hospital stays recoded in patient questionnaires and the baseline form were costed irrespective of whether
or not they were related to diabetes. Bundled national tariff costs were based on the hospital spell and
incorporated excess ward days and whether the case was elective or emergency.125 Tariff codes were obtained
primarily from PLICS and PAS data supplied by the participating hospitals but, if unavailable, were referenced to
the associated form (AE, SAE, baseline or patient questionnaire) and an appropriate HRG code was assigned
based on reason for admission, condition and any complications. Locally negotiated unbundled costs were
similarly identified and costs were assigned directly from the National Schedule.
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TABLE 18 Inpatient costs for the main HRGs
HRG
code HRG name
Elective Non-elective
Costs for
excess days
(£ per day)
Cost
(£)
Trim-point
(days)
Cost
(£)
Trim-point
(days)
BZ01Z Enhanced cataract surgery 982 5 1944 12 242
CZ05T Tonsillectomy, 18 years and under without CC 1083 5 1013 5 330
FZ20E Appendicectomy procedures, 18 years and
under without major CC
2403 5 2379 5 268
FZ24E Major therapeutic endoscopic upper or lower
GI tract procedures, between 2 and 18 years
1366 5 1177 5 268
FZ62Za Endoscopic or intermediate upper GI tract
procedures, between 2 and 18 years
864 5 893 5 268
FZ63Z Combined upper and lower GI tract diagnostic
endoscopic procedures
513 5 694 5 209
HA73B Minor elbow and lower arm procedures for
trauma, 18 years and under
1192 5 1192 5 317
PA03B Febrile convulsions, 1 year and over 659 5 584 5 288
PA04A Headaches and migraines, with CC 883 5 697 5 288
PA04B Headaches and migraines, without CC 673 5 550 5 288
PA11Z Acute upper respiratory tract infection and
common cold
566 5 484 5 288
PA12Z Asthma or wheezing 599 5 702 5 288
PA17A Intermediate infections with CC 1121 5 1261 8 288
PA19A Viral infections with length of stay 1 day or less 435 5 455 5 288
PA21A Infectious or non-infectious gastroenteritis,
with CC
1728 8 913 5 288
PA25B Major gastrointestinal disorders without CC 1352 5 1103 5 288
PA26B Other gastrointestinal disorders without CC 835 5 589 5 288
PA28B Feeding difficulties and vomiting, without CC 828 5 551 5 288
PA29Z Abdominal pain 691 5 580 5 288
PA50Z Ingestion poisoning or allergies 453 5 503 5 288
PA58Z Examination, follow-up, special screening or
other admissions, with length of stay 0 days
427 5 346 5 288
PA63B Head, neck and ear disorders with length of
stay 1 day or more, with CC
1524 5 994 5 288
PA67Z Diabetes, with ketoacidosis or coma 1459 10 1055 6 288
PA68Z Diabetes, without ketoacidosis or coma 1207 5 954 5 288
PA69Z Nephritic and nephrotic renal diseases 662 5 1350 9 288
WA21Y Other procedures or health-care problems,
without CC
467 5 579 5 198
XB07Zb Paediatric critical care high dependency 1004 N/A N/A N/A N/A
XB05Zb Paediatric critical care intensive care basic 1670 N/A N/A N/A N/A
CC, complication and comorbidity; GI, gastrointestinal; N/A, not applicable.
a Superseded in 2014/15 by FZ62A.
b Unbundled intensive-care and high-dependency HRG costs taken from the National Schedule 2014–15122 and uplifted by
a Hospital and Community Health Services index value of 1.7% per annum.
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If a hospitalisation spanned a period preceding and following randomisation, an adjustment was made to
apportion costs between baseline and post-baseline values. Patients who were admitted to hospital n days
before randomisation and spending N days in hospital after randomisation had their total costs calculated as:
Post-randomisation cost = (N/n + N) × (ward cost derived from HRG). (4)
Pre-randomisation cost = (n/n + N) × (ward cost derived from HRG). (5)
TABLE 19 Unit costs of patient contacts with health care123
Profession
Cost (£)
Surgery Home
Telephone,
e-mail and texts
Hospital
outpatient A&E School visit
Advanced nurse including
infusion specialist and diabetes
nurse
22.75 37.92 9.10 45.50 30.33 37.92
GP 64.50 87.75 26.63 – – –
Social worker (children’s services) 39.50 39.50 39.50 – – 39.50
Hospital consultant – – 22.83 68.50 45.67 –
Specialist registrar – 13.68 12.00 36.00 24.00 –
Community nurse 38.00 38.00 38.00 38.00 – 38.00
General practice nurse 14.75 – 5.60 – – –
Dietician 19.00 19.00 6.33 19.00 12.67 19.00
Psychologist 69.50 69.50 23.17 69.50 46.33 69.50
TABLE 20 Unit costs of devices and consumables
Consumable or device
Annual
cost (£) Rationale Source
F. Hoffman-La Roche AG pump 594 Unit cost of £2375 with a 4-year lifespan Supplier
F. Hoffman-La Roche AG pump
consumables (e.g. reservoirs,
cannula, batteries)
1818 Supplier
Medtronic pump 749 Unit cost of £2995 with a 4-year lifespan Supplier
Medtronic pump consumables
(e.g. reservoirs, cannula, batteries)
2377 Supplier
Pen injectors (various) 80 1 × basal and 1 × bolus at £40 each Based on children’s pen
device suppliers in the UK
Needles for pen devices 87 Four injections a day at a cost of £5.95
per 100 needles
British National Formulary124
Blood glucose monitoring 577 NICE recommendation of five tests a
day, Accu-Chek Aviva test strips
(F. Hoffman-La Roche AG, Basel,
Switzerland), at £15.79 per 50 tests
British National Formulary124
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Training comprised multiple sessions covering single visits. Although full details of how many patients and
their family members attended each training session were not recorded, the majority were believed to be
one-to-one sessions. However, because the majority of training was conducted in outpatient clinics, the
costs of training were excluded from the total to avoid the potential for double-counting.
Blood glucose monitoring was costed on the minimum NICE recommendation of five tests per day.19
Identical blood glucose monitoring costs were added to the consumables costs supplied by the pump
manufacturers for the CSII intervention group. The costs of consumables in the MDI intervention group
comprised blood glucose monitoring and disposable needles, based on an estimate of four insulin
injections a day.19 Total costs for each patient were calculated from the sum of the costs of ward,
outpatient care, A&E, primary care, device, consumables and prescribed insulin.
Patients’ use of health-care resources and total costs were calculated for the ITT population, with summary
statistics generated by intervention group.
Outcomes
Within-trial QALYs were calculated as the area under the utility–time curve over 12 months, with
utilities calculated from patients’ (aged ≥ 12 years) or their parents’ or guardians’ responses to the HUI
questionnaire taken at baseline and then at 3-, 6-, 9- and 12-month visits. The HUI questionnaire has been
validated in paediatric populations126,127 and was previously suggested by NICE for use in children,128 and
considers the six attributes of sensation, mobility, emotion, cognition, self-care and pain. These further
expand into vision, hearing, speech, ambulation, dexterity, emotion, cognition and pain using the Sheffield
algorithm, which was used to generate a single UK-derived preference-based utility score.129
The parents of patients < 3 years of age at randomisation were not required to answer the HUI
questionnaire. Proxy assessment is recommended for the 3- to 12-year-old category, and self-assessment
and/or proxy is recommended for patients > 12 years of age.
The minimum requirements for the base-case calculation of QALYs were utility measurements at baseline and
at 12 months, with linear interpolation for any missing data points in between. When both parents and patients
completed a HUI questionnaire in the same visit, base-case preference was given to the patient if they were
aged 12 years and over at randomisation, and to the parent or guardian if the patient was under 12 years old.
Incremental analysis
In the base-case analysis, the cost-effectiveness of CSII was evaluated by its ICER calculated according to
the formula:
ICER = ΔCosts/ΔQALY, (7)
TABLE 21 Unit costs of insulins taken from the British National Formulary124
Insulin Type Cost (£ per unit)
Insulin aspart (Novorapid®, Novo Nordisk Ltd, Gatwick, UK) Short acting 0.0141
Insulin detemir (Levemir®, Novo Nordisk Ltd, Gatwick, UK) Intermediate/long acting 0.0290
Insulin aspart/protamine-crystallised insulin aspart in the ratio 30 : 70
(NovoMix 30, Novo Nordisk Ltd, Gatwick, UK)
Short/intermediate acting 0.0199
Insulin lispro (Humalog®, Eli Lilly and Company Ltd, Basingstoke, UK) Short acting 0.0166
Insulin glargine (Lantus®, Sanofi, Guildford, UK) Intermediate/long acting 0.0307
Biphasic isophane insulin (Humulin® M3, Eli Lilly and Company Ltd,
Basingstoke, UK)
Short/intermediate acting 0.0166
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in which, ΔCosts is the difference in mean total costs between intervention groups and ΔQALY is the
difference in mean QALYs between intervention groups.
Uncertainty analysis
Mean costs and QALYs and differences between intervention groups in costs and QALYs were based on a
bootstrapped analysis (bias-corrected and accelerated) using 10,000 replicates. The 95% central range was
based on the 2.5 and 97.5 percentiles of the bootstrap values.
Uncertainty in the ICER was represented in cost-effectiveness acceptability curves, which presented the
probability of CSII being cost-effective for given ceiling thresholds of costs per QALY.130. Estimates of ICERs
were compared with the £20,000 to £30,000 per QALY threshold of cost-effectiveness set by NICE.131
Sensitivity analysis
Robustness of the base-case analysis was tested with respect to costs by (1) applying 2- and 6-year life
cycles to the pumps, whereby the purchase cost of the pump was divided by 2 and 6 and (2) considering
insulin costs based on quantity administered.
Sensitivity analyses concerning outcomes used (1) utilities and QALYs based on HUI3-derived Canadian
tariff scores132 and (2) mean baseline utility imputation and multiple imputation with chained equations
(MICE)133 to assess the impact of missing data on HUI2-derived scores. Explanatory variables considered
included (1) utility at baseline and at 3 and 6 months; (2) QALYs calculated up to 9 months, centre,
baseline cost, age, ethnicity, sex, weight, blood pH, blood glucose and HbA1c concentration; (3) mean
baseline utility imputation and the last observation carried forward (LOCF) approach, as recommended in
the HUI manual;132 and (4) HUI2-derived full parental or full patient responses to the HUI questionnaires.
All analyses adhered to the health economics analysis plan (see Appendix 3), and were performed using
Stata® version 13 (StataCorp LP, College Station, TX, USA), and reported in accordance with the
Consolidated Health Economic Evaluation Reporting Standards (CHEERS).134
Exploratory analysis
The contribution of the baseline variables, of age group, centre, BMI, sex, baseline cost and ethnicity
to total costs and of age group, centre, BMI, sex, baseline utility and ethnicity to QALYs, were tested
separately in regression models. This allowed for identification of any particular high-cost subgroup and
adjustment for any imbalanced covariates to account for their confounding effect.135 Given the expected
non-normality of both costs and QALYs, generalised linear models were implemented using a range of
families and links and goodness of fit established using the Modified Park test.
A further planned exploratory analysis was to extrapolate the trial results to estimate lifetime costs and
benefits and to capture long-term microvascular and macrovascular complications using the CDM model.136
This extrapolation was to use a 3.5% annual discount rate for costs and outcomes accruing after the first
year.131 Clinical and physiological progression parameters were to be as presented in the NICE guideline19
and updated with relevant data from the SCIPI study.
Results
Resource use and costs
Complete resource use data were available for all patients.
Patients’ use of health-care resources and corresponding NHS costs were comparable in both intervention
groups for the 3 months preceding randomisation (Table 22). The mean cost in the CSII group was £1530
(95% CI £1408 to £1779), compared with £1392 (95% CI £1267 to £1530) in the MDI intervention
group. Although there were more hospital outpatient visits in the CSII group, there was no difference in
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the mean total costs of these visits (£189, 95% CI –£29 to £417). The main cost drivers for the 3 months
preceding randomisation were inpatient stays (contributing to 69% of the total) and training sessions
(contributing to 14%), which were carried out primarily as outpatient appointments.
Resource use for the 12 months following randomisation is reported in Table 23. Inpatient stays and A&E
department visits decreased considerably relative to the 3 months preceding randomisations, although
health-care professional contacts, especially outpatient and GP clinic visits, and contacts via texts, e-mails
and telephone calls increased.
Patients who were randomised to CSII had more than twice as many A&E department visits and inpatient
stays relating to the management of diabetes (HRG code PA68Z) as those in the MDI group, although the
absolute numbers of attendances were low (Table 24). Over the 12-month period, health-care professionals
made an average of 4.3 (95% CI 0.6 to 8.0) more contacts by text, e-mail or telephone with patients in the
CSII group than with patients in the MDI group.
Data on prescribed insulin were available for all but seven patients; for these patients, data on dose
administered were used in the analysis. There were no significant differences in either the quantity or the
cost of prescribed insulin between the two intervention groups.
TABLE 22 Resource use in the 3 months prior to randomisation
Item of resource use (units)
Treatment arm, mean (95% CI)
Difference (95% CI)CSII (n= 144) MDI (n= 149)
Health-care professional contacts (number of
telephone calls, faxes, texts or e-mails)
3.32 (2.7 to 3.97) 2.58 (1.96 to 3.3) 0.74 (–0.18 to 1.65)
Scheduled outpatient (number of visits) 1 (1 to 1) 1 (1 to 1) 0 (0 to 0)
Unscheduled outpatient visits (number of visits) 2.19 (1.77 to 2.63) 1.12 (0.89 to 1.37) 1.07 (0.6 to 1.59)
A&E department (number of attendances) 0.77 (0.56 to 0.99) 0.62 (0.42 to 0.88) 0.15 (–0.18 to 0.46)
Other hospital (e.g. ward visits) (number) 0.49 (0.2 to 0.82) 0.44 (0.18 to 0.79) 0.04 (–0.38 to 0.47)
GP visits (number of contacts) 0.25 (0.17 to 0.34) 0.21 (0.14 to 0.28) 0.04 (–0.07 to 0.16)
Home visits (number of contacts) 1 (0.78 to 1.24) 0.99 (0.75 to 1.25) 0.01 (–0.33 to 0.34)
School visits (number of contacts) 0.3 (0.2 to 0.41) 0.24 (0.17 to 0.32) 0.06 (–0.07 to 0.19)
Training sessions (recorded sessions) 14.6 (12.99 to 16.22) 13.83 (12.7 to 14.99) 0.77 (–1.17 to 2.74)
HRG code
PA21A Infectious or non-infectious
gastroenteritis, with CC
0.02 (0 to 0.05) 0 (0 to 0) 0.02 (0 to 0.04)
PA67Z Diabetes, with ketoacidosis or coma 0.13 (0.07 to 0.2) 0.11 (0.06 to 0.17) 0.02 (–0.07 to 0.11)
PA68Z Diabetes, without ketoacidosis or
coma
0.74 (0.65 to 0.83) 0.72 (0.64 to 0.81) 0.02 (–0.1 to 0.14)
PA69Z Nephritic and nephrotic renal
diseases
0 (0 to 0) 0.01 (0 to 0.02) –0.01 (–0.02 to 0)
XB05Z Paediatric critical care intensive care
basic
0.01 (0 to 0.02) 0.02 (0 to 0.06) –0.01 (–0.06 to 0.03)
XB07Z Paediatric critical care high
dependency
0.15 (0.03 to 0.32) 0.05 (0.01 to 0.11) 0.09 (–0.04 to 0.27)
CC, complication and comorbidity.
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Mean total and disaggregated costs, with their 95% bootstrapped CIs, are reported in Table 25.
Consumables, devices (for insulin pumps) and inpatient stays were the main drivers of the differences in
costs between the groups. These contributed 63%, 28% and 9%, respectively. Each of these was higher
in the CSII group. The annualised cost of the devices differed by £520 between groups; consumables,
which included needles, infusion sets and reservoirs, differed by £1177 (£1841 CSII vs. £664 MDI).
The mean total 12-month costs for CSII were £4404 (median £4010, range £2995–13,175, 95% CI £4197
to £4642, n = 144) and for MDI were £2541 (median £2351, range £1295–5930, 95% CI £2412 to
£2672, n = 149).
Disaggregated costs for prescribed insulin, outpatient visits and GP visits were not significantly different
between the intervention groups and the extra costs associated with A&E department visits and electronic
communications made only a modest (2.3%) contribution to the overall difference in mean total costs
(£1863, 95% CI £1620 to £2137). The costs of training, covering the period from 15 days prior to
randomisation to the end of follow-up, were £1230 (95% CI £1125 to £1337) in the CSII group and
£1001 (95% CI £905 to £1100) in the MDI group.
TABLE 23 Resource use in the 12 months after randomisation
Item of resource use (units)
Treatment arm, mean (95% CI)
Difference (95% CI)CSII (n= 144) MDI (n= 149)
Health-care professional contacts (number of
telephone calls, faxes, texts or e-mails)
21.15 (18.31 to 23.99) 16.87 (14.62 to 19.25) 4.29 (0.64 to 7.98)
Scheduled outpatient (number of visits) 4 (4 to 4) 4 (4 to 4) 0 (0 to 0)
Unscheduled outpatient visits (number of
visits)
10.85 (9.6 to 12.08) 10.81 (9.65 to 11.98) 0.05 (–1.63 to 1.73)
A&E department (number of attendances) 0.85 (0.51 to 1.24) 0.4 (0.24 to 0.58) 0.44 (0.07 to 0.88)
Other hospital (e.g. ward visits) (number) 0.33 (0.1 to 0.67) 0.26 (0.11 to 0.44) 0.06 (–0.23 to 0.43)
GP visits (number of contacts) 1.46 (1.16 to 1.78) 1.2 (0.99 to 1.42) 0.26 (–0.11 to 0.64)
Home visits (number of contacts) 2.45 (1.91 to 3.1) 1.99 (1.6 to 2.42) 0.46 (–0.23 to 1.22)
School visits (number of contacts) 1.4 (1.14 to 1.69) 1.5 (1.19 to 1.85) –0.1 (–0.53 to 0.32)
Training sessions (recorded sessions)a 24.79 (21.87 to 27.92) 22.45 (19.38 to 25.54) 2.34 (–1.89 to 6.61)
Insulin (mean prescribed daily units) 71.61 (62.76 to 81.78) 66.32 (58.81 to 74.2) 5.05 (–6.6 to 17.53)
HRG code
FZ62Z Diagnostic and intermediate
procedures on the upper GI tract
0.01 (0 to 0.02) 0.02 (0 to 0.05) –0.01 (–0.04 to 0.02)
PA21A Infectious or non-infectious
gastroenteritis, with CC
0.01 (0 to 0.03) 0.01 (0 to 0.02) 0.01 (–0.01 to .b)
PA25B Major gastrointestinal disorders
without CC
0.02 (0 to 0.05) 0.01 (0 to 0.02) 0.01 (–0.01 to 0.05)
PA67Z Diabetes, with ketoacidosis or
coma
0 (0 to 0) 0.01 (0 to 0.02) –0.01 (–0.02 to .b)
PA68Z Diabetes, without ketoacidosis or
coma
0.17 (0.08 to 0.27) 0.07 (0.03 to 0.12) 0.09 (0 to 0.21)
Other HRGs 0.09 (0.04 to 0.15) 0.07 (0.03 to 0.12) 0.02 (–0.06 to 0.09)
CC, complication and comorbidity; GI, gastrointestinal.
a Training sessions were not included in the total cost, as they were recorded as contacts with health-care professionals.
b Not computable owing to small sizes.
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Health utilities and quality-adjusted life-years
The HUI questionnaires were not completed for all patients. Thirteen of the 14 patients for whom there
were no HUI data were aged < 3 years at randomisation and so were excluded from the analysis. Baseline
utilities were missing for 23 patients in the CSII group and 14 patients in the MDI group.
For patients with complete baseline utility assessment, mean values were 0.870 (95% CI 0.847 to 0.892,
n = 115) for the CSII group, compared with 0.888 (95% CI 0.866 to 0.909, n = 127) for the MDI group.
Two hundred and fourteen patients (CSII group, n = 109; MDI group, n = 105) were included in the base-case
analysis. Changes in utilities and each of the HUI domains (vision, hearing, speech, ambulation, dexterity,
emotion, cognition and pain) over the 12-month period are presented in Figures 7 and 8, respectively. Both
intervention groups provided improvements in patients’ happiness (emotion) and how they perceived pain
perception. However, there were no significant differences in QALYs between intervention groups. For the
CSII group, these were 0.910 QALYs (95% CI 0.892 to 0.927 QALYs), and for the MDI group these were
0.916 QALYs (95% CI 0.899 to 0.933 QALYs), which was a difference of –0.006 QALYs (95% CI –0.031 to
0.018 QALYs).
TABLE 24 Disaggregated and total costs in the 12 months after randomisation
Item of resource use
Treatment arm, mean cost (£) (95% CI)
Difference in mean
cost (£) (95% CI)CSII (n= 144) MDI (n= 149)
Consumables (e.g. needles, infusion sets,
reservoirs)
1841 (1826 to 1861) 664 (664 to 664) 1177 (1162 to 1197)
Device (pump 4-year lifespan or two pen
devices)
600 (596 to 606) 80 (80 to 80) 520 (516 to 526)
Insulin (prescribed) 422 (364 to 486) 482 (426 to 541) –60 (–142 to 24)
Health-care professional contacts
(telephone calls, faxes, texts or e-mails)
138 (117 to 162) 108 (92 to 124) 30 (3 to 59)
Scheduled outpatients visits 434 (434 to 434) 434 (434 to 434) 0 (0 to 0)
Unscheduled outpatient visits 309 (272 to 346) 328 (292 to 366) –19 (–71 to 33)
Inpatient stays costed from HRG codes 387 (245 to 553) 219 (142 to 306) 168 (5 to 352)
A&E 26 (16 to 39) 13 (8 to 19) 13 (2 to 27)
Other hospital (e.g. ward visits) 3 (1 to 7) 3 (1 to 5) 1 (–3 to 5)
GP visits 71 (56 to 88) 57 (45 to 69) 15 (–5 to 35)
Home visits 106 (80 to 138) 83 (66 to 100) 23 (–9 to 59)
School visits 53 (43 to 64) 56 (44 to 69) –3 (–19 to 13)
Concomitant medications 12 (8 to 17) 15 (8 to 23) –2 (–12 to 6)
Total cost 4404 (4197 to 4642) 2541 (2412 to 2672) 1863 (1620 to 2137)
TABLE 25 Incremental analysis of the cost-effectiveness of CSII
Treatment arm, mean (95% CI)
Difference, mean (95% CI) ICERCSII (n= 109) MDI (n= 105)
Costs (£) 4404 (4197 to 4642) 2541 (2412 to 2672) 1863 (1620 to 2137) CSII dominated
QALYs 0.910 (0.892 to 0.927) 0.916 (0.899 to 0.933) –0.006 (–0.031 to 0.018)
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Incremental analysis
The ICER is indeterminate, as CSII was dominated by MDI over the 12-month time horizon of analysis
(see Table 25). As the differences in costs favoured MDI (£1863 less expensive) and as there was no
difference in benefits (–0.006 QALYs), through cost minimisation, MDI is more cost-effective.
Uncertainty analysis
The cost-effectiveness plane, which presents the difference in costs on the vertical axis and difference in
effects on the horizontal axis, is shown in Figure 9. Sixty-nine per cent of iterations were in the north-west
quadrant, reflecting the probability of CSII being dominated by MDI. The corresponding cost-effectiveness
acceptability curve (Figure 10) indicates that CSII is not cost-effective, even at very high thresholds,
consistent with the certainty of there being a large cost difference with no improvement in QALYs.
Sensitivity analysis
An assumption of insulin pumps being replaced every 2 years increased the cost difference between CSII
and MDI to £2463 (95% CI £2218 to £2738), but although less frequent replacement (every 6 years)
lowered the cost difference to £1663 (95% CI £1420 to £1937), CSII remained dominated.
An analysis based on the quantity of insulin administered, as opposed to prescribed, resulted in a mean
cost of £4102 (95% CI £3915 to £4318) in the CSII group and £2192 (95% CI £2080 to £2310) in the
MDI group, which was a difference of £1910 (95% CI £1690 to £2151).
All sensitivity analyses concerning the calculation of QALYs consistently indicated that there was no
difference over 12 months (Table 26). Based on the Canadian tariff HUI3 scores, the difference between
group means (CSII – MDI) was –0.004 QALYs (95% CI –0.036 to 0.029 QALYs). Alternative approaches for
dealing with missing data, in which 29 additional patients in the CSII group and 36 additional patients in
the MDI group were included, yielded similar QALY differences. Using MICE, this was –0.004 QALYs
(95% CI –0.022 to 0.014 QALYs) and, based on LOCF, the difference was –0.001 QALYs (95% CI –0.022
to 0.020 QALYs). HUI2-derived QALY differences based on full parental and full patient responses to the
HUI questionnaires were, respectively, –0.001 QALYs (95% CI –0.024 to 0.023 QALYs) and –0.006 QALYs
(95% CI –0.031 to 0.018 QALYs).
None of the sensitivity analyses affected the base-case result of CSII being dominated by MDI.
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FIGURE 7 Mean utility values (95% CI) over 12 months for the base-case analysis.
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FIGURE 8 Distribution of responses to HUI domain, by intervention group, over time. (a) Vision; (b) hearing;
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Exploratory analysis
Cost distributions for both intervention groups deviated from normality, with p-values for both skewness
and kurtosis normality testing being < 0.01. However, based on the Akaike information criterion for
different model specifications, an ordinary least squares regression was optimal for both costs and QALYs.
In the cost regression, 46% of the variability in total costs could be explained, with intervention group,
recruiting centre and pre-randomisation costs being significant. The adjusted cost difference between the
intervention groups was comparable to the base-case analysis at £1850 (95% CI £1600 to £2100).
In the QALY regression, 41% of the variability in total costs could be explained, with only baseline utility
being significant. The adjusted difference in QALYs between intervention groups was consistent with the
base-case analysis at 0.000 QALYs (95% CI –0.019 to 0.020 QALYs).
As there were no differences between intervention groups in HbA1c concentrations at 12 months, and no
indication of CSII being cost-effective given the large difference in cost, longer-term extrapolation was
considered to be futile, especially given the lack of validation of diabetes models in children.
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FIGURE 9 Cost-effectiveness plane presenting the joint uncertainty in incremental costs and QALYs.
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FIGURE 10 Cost-effectiveness acceptability curve indicating the probability of CSII being cost-effective for different
thresholds of cost-effectiveness. (a) Proportion 0–1; and (b) proportion 0–0.01.
TABLE 26 Sensitivity analyses for different methods of calculating QALYs and consideration of missing data
Scenario
Treatment arm
Difference, mean (95% CI)
CSII MDI
n Mean (95% CI) n Mean (95% CI)
QALYs (base case) 105 0.910 (0.892 to 0.927) 109 0.916 (0.899 to 0.933) –0.006 (–0.031 to 0.018)
QALYs (Canadian tariffs)a 105 0.908 (0.884 to 0.929) 109 0.912 (0.887 to 0.933) –0.004 (–0.036 to 0.029)
MICE-imputed QALYs 138 0.910 (0.896 to 0.923) 141 0.915 (0.903 to 0.926) –0.004 (–0.022 to 0.014)
LOCF-imputed QALYs 138 0.911 (0.896 to 0.925) 141 0.912 (0.896 to 0.926) –0.001 (–0.022 to 0.020)
Parental QALYs 105 0.914 (0.897 to 0.930) 109 0.915 (0.899 to 0.931) –0.001 (–0.024 to 0.023)
Child QALYs 105 0.910 (0.892 to 0.927) 109 0.916 (0.899 to 0.932) –0.006 (–0.031 to 0.018)
a Derived using HUI3 algorithm, all other scores derived using HUI2 algorithm.
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Chapter 5 Discussion
Summary of findings
The results of the SCIPI study clearly demonstrate that, across the range of ages from 7 months to 15 years,
treatment with CSII is not superior to treatment with MDI during the first year of treatment for T1D and
is not a cost-effective treatment. At 12 months following diagnosis, HbA1c concentrations differed by only
2.4 mmol/mol (p = 0.1), being lower in participants treated with MDI and with our study having been
powered to detect a difference of > 0.5%, approximately 5 mmol/mol. The percentage of participants
whose HbA1c concentration was within the target range (< 48 mmol/mol) at 12 months differed between
the treatment arms by 5% (CSII, 15.4%; MDI, 20.4%) and was also not significantly different (p = 0.28).
The proportion of patients in the CSII group who experienced AEs (28%) was nearly three times that in
the MDI group (10%). During the course of the study, there were 11 severe AEs (nine episodes of severe
hypoglycaemia and two of DKA), of which nine occurred in patients treated with CSII.
Patient-reported disease-related QoL did not differ between treatment arms, although parent-reported
measures of QoL showed higher scores for patients who were treated with CSII, indicating a superior QoL.
However, it should be noted that child-reported QoL starts from age 5 years, whereas the parent-reported
QoL starts from age 2 years, and that, in general, the size of the differences and CI widths are similar
between child- and parent-reported measures.
Patients randomised to CSII had more than twice as many A&E department visits and inpatient stays
relating to the management of T1D as those in the MDI group. Over the 12-month period, health-care
professionals had, on average, 4.3 (95% CI 0.6 to 8.0) more contacts (texts, e-mails and telephone calls)
with participants in the CSII group than with those in the MDI group. The mean total costs were £1863
(95% CI £1620 to £2137) higher in the CSII group than in the MDI group, with the majority of this
difference (£1177) attributable to the additional cost of consumables and device (annualised cost of
£600 for CSII vs. £80 for pen devices). There were no significant differences in QALYs between the CSII
and MDI groups (–0.006 QALYs, 95% CI –0.031 to 0.018 QALYs).
In summary, the SCIPI study achieved excellent completeness of primary outcome data for assessment of
efficacy of CSII compared with MDI. There were no differences in key baseline characteristics between
groups at randomisation. There was no difference in efficacy between CSII and MDI in any of the primary
ITT analyses. In addition, there was no difference in efficacy between CSII and MDI in the per-protocol ITT
analyses. The economic evaluation indicated that CSII does not represent a cost-effective option for the
management of T1D in patients representative of the SCIPI study population. There was also no evidence
of a difference in QALY gain over the 12-month period of observation in participants treated with CSII
compared with those receiving MDI, and the cost differential was such that, even for willingness-to-pay
values far in excess of the NICE £30,000 per QALY threshold for cost-effectiveness, CSII remained
dominated by MDI.
Patient recruitment and retention
The large and diverse population of patients recruited to the SCIPI study, coupled with a high retention
rate (97%), enabled us to overcome elements of bias inherent in previous RCTs and observational studies.
The characteristics of study participants show that the treatment arms were well balanced for factors
known to influence glycaemic control, including deprivation score, sex and ethnicity. Screening log data
show that these characteristics were also well balanced between the groups of patients who consented to
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participate in the study and those who declined. The distribution of ages in the study population reflects
the known demographic of childhood T1D, with approximately 50% of participants being in the age range
of 5–12 years.
Of those who declined to participate, most (66%) cited a strong preference to continue treatment with MDI,
although a smaller number (9%) cited a strong preference for CSII. We noted that the small number of
patients and parents who declined to participate in the study, stating a strong preference for CSII (n = 36),
had a higher deprivation index (were more deprived) than those who declined stating a strong preference
for MDI (n = 259) and those who participated in the study. National database studies37–39 report an
association with CSII use and deprivation, with the most deprived patients being least likely to be treated
with CSII. Our data suggest that this association is established sometime later after the diagnosis of T1D.
Recruitment rates showed marked variability between study sites, ranging from 16% to 82% of eligible
patients. Both the highest- and lowest-recruiting centres had participated in the DECIDE trial68 and so were
experienced in the recruitment of paediatric patients to research studies at the time of diagnosis of T1D. In
the lowest-recruiting centre, intensive insulin therapy was introduced later in the first year of treatment
and patients were treated with four or fewer injections per day at the time of diagnosis. A requirement to
either increase the number of injections or to learn a new method of insulin delivery is likely to have been
least attractive to this population.
We recognised that patients who were given information about the study closest to the time of diagnosis
were more likely to consent than those who were approached later. This may be because a preference for
MDI had yet to be established or may reflect qualities of the research staff that increased the likelihood of
patients consenting to participate in the study.
We speculate that the strong preference that patients stated for MDI at the time they were invited to
participate in the study is likely to be temporary. It would have been ideal to undertake qualitative work
to understand more about the reasons for this preference and how it may change over time. A higher
recruitment rate may have been achieved had the window for recruitment been increased to 1 month
from diagnosis.
These observations underscore the difficulty in predicting recruitment rates to clinical trials. The target
recruitment rate of 50% was set, in part, to ensure that a highly selected cohort of patients was not
recruited. Despite our lower recruitment rate, we have been able to demonstrate that the characteristics
of those who consented to participate did not differ significantly from those who declined, and we are
confident that we have studied a population of patients representative of the background population of
paediatric patients treated for T1D in the NHS setting.
The non-participation of patients with a strong preference for one treatment arm may limit the
generalisability of our data. It would be interesting to learn more about the reasons behind this strong
preference early in the diagnosis of T1D and how this may change over time. A qualitative component
within the SCIPI study would have been beneficial.
By randomly allocating treatment to either MDI or CSII, we have overcome the bias in observational studies,
in which treatment selection by patients, carers and health-care professionals results in over-representation
of favourable patient characteristics in those treated with CSII and under-representation of these
characteristics in those treated with MDI.
Previous RCTs of CSII and MDI have recruited patients with established T1D already being treated with MDI,
and have randomised them to continue with MDI treatment or to change to CSII treatment. This recruitment
strategy may introduce bias in favour of CSII, as patients who are satisfied with treatment with MDI and who
have good glycaemic control are less likely to be approached or to participate in the study than those in
whom treatment is less satisfactory. Furthermore, previous experience of treatment success or failure with
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MDI may influence treatment outcomes: if a patient dissatisfied with MDI treatment consents to participate
in a RCT, it is possible that randomisation to CSII will result in renewed commitment to the management
of T1D; however, randomisation to continue unsatisfactory treatment with MDI may result in further
disengagement. Another factor to consider is the extent to which any studies reporting benefits of CSII
over MDI in established patients reflect the effects of the intensive education and increased contact with
health-care professionals required before starting CSII rather than inherent benefits arising directly from CSII.
These possible effects on outcomes were balanced in our study design by the selection of newly diagnosed
patients, all of whom would have required a similar intensity of education. We elected to recruit patients
at diagnosis of T1D to overcome this element of bias. However, it may be that the generalisability of our
findings beyond the first year of T1D is therefore limited.
Fifty-three patients moved between treatment arms: 30 changed from MDI to CSII, 22 from CSII to MDI
and one from MDI to ‘injections TDS regime’. In one study site, four out of five patients who were randomised
to MDI were changed to CSII and none from CSII to MDI, and, in another site, 9 out of 16 patients who were
randomised to MDI were changed to CSII and 3 out of 14 changed from CSII to MDI. It is likely that there
is a degree of bias towards CSII in these centres and this may account, in part, for the minor imbalance in
movement between treatment arms. We also observed an imbalance in movement between treatment arms in
the youngest age group, favouring a switch from MDI to CSII. This may also reflect a bias towards treatment
with CSII in this age group, perhaps because of the difficulties of administering frequent injections in children
in an age group who eat frequently and unpredictably throughout the day. The administration of very small
insulin doses in the youngest children can also be difficult using MDI and this can be accommodated more
easily using CSII.
When we examined the reasons for changing between treatment arms, we found that HbA1c concentration
was above the target range in 20 out of 22 patients (90.9%) at the time of changing from CSII to MDI and in
16 out of 30 patients (53%) at the time of changing from MDI to CSII. Severe or frequent hypoglycaemia was
not reported as a reason for changing treatment arm. Our data suggest that, following randomisation, patient
and parent preference was the strongest determinant of insulin delivery device.
Effectiveness of continuous subcutaneous insulin infusion and multiple
daily injections therapy
Glycaemic control
We selected glycaemic control, measured as HbA1c concentration 1 year after the diagnosis of T1D,
as the primary outcome measure of treatment efficacy and the percentage of patients in whom HbA1c
concentrations were within the target range as a secondary outcome measure. Since the publication of
the findings of the Diabetes Control Complications Trial Research Group,3 HbA1c concentration has been
recognised as the most robust predictor of the risk of long-term T1D complications, and there is some
evidence that this is particularly true during the first year after diagnosis.7–9 Using this measurement of
glycaemic control, we found no difference between treatment arms, at either 6 or 12 months following
diagnosis. Previous RCTs comparing MDI and CSII have reported similar findings.43,45,47,48 The significance of
our results for the management of patients beyond 1 year is uncertain. However, there is good evidence
that glycaemic control in the first year following diagnosis is a predictor of long-term glycaemic control
and the risk of vascular complications in young adult life.7–9
A number of alternative outcome measures could have been used to compare the effectiveness of MDI
and CSII, including glycaemic variability and preservation of pancreatic function. In vitro and animal studies
have demonstrated that fluctuating glucose concentrations cause more cell damage and oxidative stress
generation and induce monocyte–endothelial adhesion and atherogenesis to a greater degree than
sustained hyperglycaemia.137,138 It has also been reported that decreased, as well as increased, glycaemic
variability may influence the expression of genes that protect cells from the toxic effects of hypoglycaemia,
when compared with normal blood glucose profiles.139
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Glycaemic variability has been seen to be lower in children treated with CSII than in those treated with
MDI, despite there being no difference in HbA1c concentrations.32
,140 In one cross-sectional cohort study,
surrogate markers of oxidative stress and cyclo-oxygenase activity were also favourable and glycaemic
control was superior in patients treated with CSII than in those treated with MDI. However, in studies in
which treatment arms are not randomly assigned it may be difficult to determine whether the observed
differences in glycaemic control and variability are a result of the mode of insulin delivery or patient
characteristics that cluster with each treatment arm.
Although there is good evidence linking glycaemic variability and microvascular and macrovascular
complications in type 2 diabetes, the evidence is less convincing for T1D.141,142 This may be, in part,
because the best measure of glycaemic variability (e.g. coefficient of variation of fasting plasma glucose,
mean amplitude of glycaemic excursions, SD of blood glucose) has yet to be determined and because
previous studies have used self-monitored blood glucose readings rather than continuous blood glucose
monitoring. For now, it seems that HbA1c concentrations remains the most appropriate primary outcome
measure in studies of treatment effectiveness but measures of glycaemic variability should be considered
as important secondary outcomes measures in future studies.
Partial remission and insulin dose
During the partial remission phase (PRP), there is some recovery of pancreatic islet cell function, insulin
requirements fall and incidents of hypoglycaemia and hyperglycaemia occur less frequently and are less severe.
Glycaemic control may be near perfect on minimal doses of insulin. In a study of over 3000 children with
newly diagnosed T1D, approximately 70% experienced a PRP, which lasted 9 months (range 0–21 months).
Younger age at diagnosis and female sex were associated with a lower prevalence of PRP.143 Those who
present with DKA or who have a lower pH or higher antibody titres at diagnosis are also less likely to
experience PRP.
The longer-term implications of the PRP are unclear, although a recent study related PRP with the risk of
microvascular complications; 7 years following diagnosis, young adults who did not experience a PRP were
more likely to have one or more microvascular complication.144
A number of measures of beta cell function have been proposed for the definition of PRP, including
measurements of basal and stimulated C-peptide.145,146 However, these measurements require an
early-morning attendance at hospital, which requires a delay in eating breakfast and the administration of
the first morning dose of insulin. It may be especially difficult and inconvenient for patients treated with
MDI to ensure an adequate ‘washout’ period following a dose of a long-acting insulin analogue for
measurements of C-peptide to be meaningful.
In our original study protocol, we had not intended to undertake studies of residual pancreatic function.
However, the publication of a new, validated method of assessing pancreatic reserve, based on insulin
dose and HbA1c concentration gave us the opportunity to explore this phenomenon in our population
using data collected to inform other study outcomes.147 This measure of residual pancreatic function was
defined from a group of 275 patients aged < 16 years at diagnosis of T1D. Residual β-cell function was
assessed by stimulated C-peptide measured 1, 6 and 12 months following diagnosis. To develop the
definition, a multivariate analysis was performed, which demonstrated a negative correlation between
stimulated C-peptide, HbA1c concentration and insulin dose. From these observations, the authors
developed a formula for IDAA1c, in which a C-peptide response of > 300 pmol/l correlated well with IDAA1c
≤ 9 (R2 = 31%).
Using this method, IDAA1c, we found no difference in the percentage of patients in PRP at either 6 or
12 months. When considering these data, it is important to note that the determination of IDAA1c relies on
accurate recording of insulin doses.
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For both treatment arms, insulin doses were downloaded from the F. Hoffman-La Roche AG Expert
glucometer. For those randomised to CSII, insulin doses were also downloaded from insulin pumps and for
those randomised to MDI data were obtained from patient-held records. The amount of insulin prescribed
by the patients’ family practitioners was also recorded. Data from these multiple sources showed that
patients treated with MDI received significantly lower doses than those treated with CSII; this is in contrast
to previous studies in which patients treated with MDI received higher doses of insulin.35,46,82
Patients randomised to the MDI arm of the study were advised that an insulin injection should be given
every time ≥ 10 g of carbohydrates was consumed. It is likely that this will deter some patients from
consuming carbohydrates between mealtimes. Patients randomised to the CSII arm of the study were
given a lower threshold for the administration of an insulin bolus, 5 g of carbohydrate, in part because the
administration of an insulin bolus is less intrusive than the administration of an injection. By giving this
advice, we may have encouraged higher insulin usage in children treated with CSII.
Insulin usage differed between treatment arms only in patients aged ≥ 12 years, when those treated with CSII
reported greater insulin use than those treated with MDI. This may reflect poorer reporting during adolescence
and/or a reduction in the intensity of insulin injections as patients become increasingly independent.
Our data are subject to these methodological limitations, but, although recognising that these exist, we
found no evidence that patients treated with CSII have lower insulin requirements than those treated with
MDI or that the prevalence of the PRP was different between treatment arms at any time point.
Growth and weight gain
In common with previous studies, children recruited to the SCIPI study had a height SDS that was just
above the mean (0.3, SD 1.0) of our reference population at diagnosis of T1D.148 Growth during the first
year of T1D was normal in both treatment arms and there was no difference in either baseline height SDS
or change in height SDS between treatment arms.
Gain in weight has been reported to be greater in children treated with MDI than in those treated with CSII,46
and this may be important, as obesity increases the risk of long-term macrovascular complications. In the SCIPI
study protocol, baseline weight measurements were taken on the day that the randomised treatment was
started, to allow time for adequate rehydration in children who were dehydrated at diagnosis. The baseline
BMI SDS was normal and, similar to height SDS, it was just above the mean for the reference population
(0.1, SD 1.3). In both treatment arms, BMI SDS increased: to 0.8 (SD 1.1) in the CSII arm and 0.7 (SD 1.0) in
the MDI arm. This trend for weight gain may be of clinical concern if it continues in subsequent years.
Adverse events
The incidence of severe AEs was too low for us to draw any meaningful conclusions regarding the relative
risk or benefits of either treatment. However, it is noteworthy that, of the 11 severe AEs that were reported
(nine episodes of severe hypoglycaemia and two of DKA), nine occurred in patients treated with CSII.
Previous RCTs have also reported a low prevalence of severe hypoglycaemia and DKA and concluded that
there is no significant difference between treatment arms.43–47
It is possible that AEs were under-reported. This is unlikely for DKA but may be more likely for episodes of
hypoglycaemia, which may be considered to be an inevitable part of T1D treatment. We recorded only
severe hypoglycaemia, and frequent and less severe episodes of hypoglycaemia may also be debilitating.
A perceived advantage of CSII therapy is a reduction in the number of episodes of severe hypoglycaemia
compared with treatment with MDI.42,149 In 2010, Health Technology Assessment published a report that
compared the clinical effectiveness and cost-effectiveness of CSII and MDI, which concluded that there were
fewer problems with hypoglycaemic episodes in patients treated with CSII than those treated with MDI.81
However, this systematic review included studies of MDI using Neutral Protamine Hagedorn insulin, which is
associated with a higher incidence of hypoglycaemia than the insulin analogues used in modern MDI regimens.71
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More than twice as many patients randomised to treatment with CSII as those randomised to treatment
with MDI experienced AEs (28% vs. 10%, respectively), with the IDR being 24 for patients treated with
CSII and 9 for patients treated with MDI.
A number of studies describing AEs during CSII therapy in childhood have been reported. In a large clinic
population of 235 children, 45% of patients had experienced at least one insulin pump-related AE in the
preceding 12 months, 8% required hospital treatment and 25% required a replacement insulin pump.150
A very similar prevalence of CSII-related AEs (46% of treated patients) has been reported independently by
another group,151 and these data were supported further by a systematic review152,153 of AEs in adult and
childhood CSII therapy, which found that > 40% of patients per year had an insulin pump-related AE,
with hyperglycaemia and DKA occurring most commonly. The risk of AEs is reported to be lower in those
who have used CSII for longer, higher in children than in adults and unrelated to socioeconomic status or
glycaemic control.151
We found no evidence of a reduced risk of severe hypoglycaemia, DKA or other AEs in patients treated
with CSII.
Quality of life
It was our intention to minimise disruption to the routines of patients and the clinics in order to achieve
a high level of recruitment and retention. For this reason, the number of additional tasks patients and
parents were asked to perform was kept to a minimum. We decided to restrict assessments of QoL to a
simple questionnaire-delivered tool, the diabetes module of the PedsQL instrument.79 Patients who were
aged ≥ 5 years completed questionnaires according to age (5–8, 9–12 and ≥ 13 years) and parents
completed questionnaires for children aged 2–4, 5–8, 9–12 and ≥ 13 years.
We observed some discordance in the reports from parents and patients, as parents reported higher scores
and, therefore, better QoL in those treated with CSII than in those treated with MDI but there was no
difference in the scores reported by patients. The differences in parental scores were most notable in the
youngest children, and particularly in the treatment domains for the youngest children.
Discordance in parental and patient reporting in measures of QoL is well recognised. In a large study154 of
3402 children with T1D who were aged 5–18 years, which also used the PedsQL questionnaire, children
reported a better QoL than that reported by their parent/proxy, except children aged 5–7 years in whom
parent/proxy QoL reports were higher. The authors of this study concluded that both sources of reporting
are valuable but that when discrepancies exist between patients and parent/proxy reports, preference
should be given to the patient’s report.154
Economic evaluation
The economic evaluation indicates that CSII does not represent a cost-effective option for the management
of T1D in patients who were representative of the SCIPI study population. There was no evidence of a
difference in QALY gain over the 12-month period of observation compared with MDI, and the cost
differential was such that, even for willingness-to-pay values far in excess of the NICE £30,000 per QALY
threshold for cost-effectiveness, CSII remained dominated by MDI.
The principal cost drivers, accounting for 91% of the difference between intervention groups, were the
consumables and insulin pumps. These costs were not offset by any reduction in the prescribing of insulin
or lower use of health-care services. In fact, patients who were randomised to CSII had more than twice
as many A&E department visits and inpatient stays relating to the management of T1D as those in the MDI
group. This may be attributable to the higher number of AEs associated with the use of CSII.
Sensitivity analyses confirmed the robustness of the results to different assumptions regarding the lifetime
of the CSII insulin pump, the use of alternative methods for calculating utilities and of approaches to
estimate the overall costs of insulin.
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The analysis benefited from having complete cost data, achieved by obtaining resource use data from multiple
sources, including routinely collected data and questionnaires. There were some missing responses to the
HUI questionnaire, but different approaches of imputation and use of different tariff scores resulted in QALY
estimates that were consistent with the base-case analysis. It should be acknowledged, however, that the trial
was not powered to detect a statistically significant difference in QALYs between intervention groups.
The main limitation of the analysis concerns the short period of follow-up. The impacts of T1D and
treatment modalities on QALYs are unlikely to be evident in the first year of treatment. Rather, QALY
decrements are most likely to result from the long-term microvascular and macrovascular complications of
T1D, and their associated impacts on health-related QoL and survival. In the absence of data from
extended follow-up, the conventional approach of modelling life-long costs and consequences is usually
taken. However, models that are not validated in paediatric populations, especially in the context of
interventions that are not more clinically effective or likely to be cost-effective, would have limited
credibility and offer little contribution to the understanding of longer-term economic outcomes.
Strengths and limitations
It is a major strength of the SCIPI study that a large and diverse population of patients has been recruited
from a wide range of clinical settings across the UK, with near-complete retention at the conclusion of
the study protocol. Our patient population is representative of the background population of patients
diagnosed with T1D in study centres during the recruitment period of the study. We are confident that our
data are generalisable to children treated for T1D in the NHS setting. Our recruitment strategy has also
overcome the main sources of bias inherent in previous studies.
Using well-established and widely accepted measures of treatment effectiveness, we found no evidence
that treatment of diabetes in the first year after diagnosis with CSII therapy is superior to treatment with
MDI other than higher QoL on parent/proxy reporting.
We recruited patients at diagnosis of T1D to address important issues of bias inherent in some previous
studies. However, our findings may not be applicable beyond the first year of diagnosis. The presence and
duration of the PRP may mask subtle differences in therapeutic benefits and glycaemic control between
treatment groups. Patient and parent education and knowledge may enable more sophisticated use of CSII
over time and this may also confer an advantage compared with MDI in established patients, as suggested
by some other studies.
We also recognise that the use of CSII at diagnosis of T1D was not routine practice at the time that the
SCIPI study opened to recruitment, and outcomes may have improved over time as diabetes teams have
gained experience in the use of this treatment modality. However, we also note that the primary outcome
measurement was obtained 1 year after diagnosis, when all participants and professionals would have a
minimum of 12 months’ experience of both CSII and MDI, and was not a composite of measurements
taken over the first year.
It is important to recognise that there is a strongly held view among health-care professionals, patients and
families that CSII therapy is a valuable tool in the treatment of T1D, and is superior to treatment with MDI.
It may be that we have not used the correct tools to identify the reasons for this or that the tools we have
used are not sensitive enough to identify the benefits of treatment with CSII. This may be especially true
for measures of QoL, and the absence of a measure of treatment satisfaction. Anecdotal reports from
patients and parents often cite QoL as the main advantage of CSII therapy.
Qualitative work, examining the beliefs of physicians prescribing CSII, found there was acceptance that CSII
therapy was not necessarily associated with superior glycaemic control compared with MDI.155 This was
attributed to the complexity of CSII therapy and the failure of patients and families to use it to its full potential,
in part, owing to a lack of support in the community and at school. The same study found a strong attraction
to CSII because of its status as a novel technology, as a necessary step towards more sophisticated and
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successful therapies that should be embraced and encouraged. However, the authors also recognised that
parents may feel pressurised to allow use of CSII in their children, given the strong advocacy for CSII therapy
from support groups and some health-care providers. Perhaps most importantly, physicians reported social
benefits of the use of CSII: allowing adolescent patients to become more independent and reducing parental
stress around the unpredictable eating habits of young children and the need for frequent insulin injections.
The physicians also felt that CSII therapy facilitated the physician–patient relationship. In order to fully
understand the drivers behind the widespread adoption of CSII, tools will need to be developed that
accurately harness this information.
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Chapter 6 Conclusions
Implications for diabetes treatment strategies
The purpose of the SCIPI study was to generate objective data to inform national paediatric treatment
strategies and individual patient care. We speculated that, in the absence of benefit of CSII therapy,
resources may be better invested in services that are likely to benefit a wider range of patients.
In the NPDA of 2015/16,1 2800 children aged < 15 years were diagnosed with T1D. Given that 30% of
patients are currently treated with CSII, our data suggest that the additional cost to the NHS of treating
newly diagnosed patients with CSII in preference to MDI would reach approximately £1.5M per year,
with no objective evidence of benefit, at least in the year following diagnosis.
The data from the SCIPI study should reassure families that there is no evidence that MDI therapy is
inferior to CSII during the first year of T1D treatment. We have provided new evidence to clinicians that
the driver for the adoption of CSII therapy at diagnosis of T1D should not be improved glycaemic control
or AEs; indeed, we would encourage consideration of the increased prevalence of AEs in those treated
with CSII.
The social benefits of CSII have not been quantified in this study, and perhaps the balance between cost
and benefits in this domain is an issue for wider discussion between funders, health-care professionals,
patients and families.
Future research
The findings of the SCIPI study may be applicable only during the first year following diagnosis of T1D. On
completion of the study protocol, participants and their families were invited to consent for the collection
of routine clinical data for a further 9 years. We therefore have the opportunity to learn more about the
longer-term trajectories of this valuable and unique cohort of patients and whether or not outcomes
diverge between treatment groups over time.
It is important to recognise that many patient advocacy groups and health-care professionals have a strong
belief in the benefit of CSII. The measures of QoL used in the SCIPI study may not have been sensitive
enough to detect the QoL benefits reported by the advocates of CSII, and we have not measured generic
QoL or the impact of either treatment on social function across childhood and into adolescence. More
detailed investigation in these domains may contribute to the critical analysis of the place of CSII in
national diabetes strategies.
The need to examine how resources are distributed has become increasingly evident as relationships
between socioeconomic status, CSII therapy and glycaemic control are reported. Observational cohort
studies from across the world report superior glycaemic control and increased CSII use in children from
more affluent families, and their parents have lower unemployment rates and higher educational levels
than those children treated with MDI, whereas socioeconomic deprivation and ethnic minority status are
associated with poor glycaemic control, independent of CSII use.38,39,156,157 Unless efforts are made to
correct this disparity, health-care resources will continue to be drawn away from the most vulnerable
patients to support CSII therapy, with little evidence of benefit. We propose that research should now
focus on interventions that may help to address the disparity in outcomes between the most affluent and
disadvantaged children.
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There is currently no validated, structured education programme for paediatric patients who are newly
diagnosed with T1D, and previous studies of structured education have not demonstrated a beneficial
effect on glycaemic control.158 It may be that education to establish good management habits at the time
of diagnosis will be more effective than in established patients, in whom poor management habits are
likely to be entrained and instigating change may be difficult. The benefits of structured, validated
education at diagnosis of T1D deserve further evaluation.
In this study, we did not record whether or not patients used CSII to its full potential. It is possible that
enhanced CSII use would have resulted in improved glycaemic control and that this may be achievable
through further education, training and support in the community. There may be a place for researching
these elements of CSII use. However, such a package of care is likely to require increased investment,
and this additional cost needs to be considered in the light of the health economic data reported in the
SCIPI study. Very significant improvements in glycaemic control would be necessary for CSII to be seen as
cost-effective. Should such a project be undertaken, it would be essential to also examine the effect of
enhanced education and support in the community on glycaemic control in children treated with MDI.
CONCLUSIONS
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Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support. Using
patient data is vital to improve health and care for everyone. There is huge potential to make better use of
information from people’s patient records, to understand more about disease, develop new treatments,
monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone’s
privacy, and it’s important that there are safeguards to make sure that it is stored and used responsibly.
Everyone should be able to find out about how patient data are used. #datasaveslives You can find out
more about the background to this citation here: https://understandingpatientdata.org.uk/data-citation.
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Appendix 1 Recruitment
Screening and consent by site with the affect of protocol amendments that were aimed to improverecruitment are provided in Table 27.
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TABLE 27 Screening and consent by site (all protocol versions combined, but consent not sought broken down by protocol versions)
Site (initiation date)
[A] [B] [C] [D] [E] [F]
Randomised
Total
screens
Total not
eligible
(%) [dA]
Total
eligible
(%) [dA]
Eligible but consent not sought Eligible and consent sought but refused
Total
consented
(%) [dE+ F]
Lack of trained staff
(%) [dD]
Reason not recorded
(%) [dD]
Consultant decision
(%) [dD]
Total
(%) [dC]
MDI
preference
(%) [dE]
CSII
preference
(%) [dE]
Other
(%) [dE]
Total
(%) [E]≤ version 3 ≥ version 4 ≤ version 3 ≥ version 4 ≤ version 3 ≥ version 4
Total 976 98 (10) 878 (90) 18 (38.3) 34 (23.9) 0 (0) 22 (15.5) 29 (61.7) 86 (60.6) 189 (21.5) 259 (65.6) 36 (9.1) 100 (25.3) 395 (57.3) 294 (42.7) 294
Alder Hey (16 May 2011) 163 19 (11.7) 144 (88.3) 16 (94.1) 19 (55.9) 0 (0) 0 (0) 1 (5.9) 15 (44.1) 51 (35.4) 33 (80.5) 3 (7.3) 5 (12.2) 41 (44.1) 52 (55.9) 52
Newcastle (18 July 2011) 90 7 (7.8) 83 (92.2) 0 (0) 2 (18.2) 0 (0) 1 (9.1) 2 (100) 8 (72.7) 13 (15.7) 41 (69.5) 4 (6.8) 14 (23.7) 59 (84.3) 11 (15.7) 11
Birmingham
(27 October 2011)
97 9 (9.3) 88 (90.7) 1 (5.9) 3 (15) 0 (0) 4 (20) 16 (94.1) 13 (65) 37 (42) 12 (40) 12 (40) 6 (20) 30 (58.8) 21 (41.2) 21
Cardiff
(19 December 2011)
68 7 (10.3) 61 (89.7) 0 (0) 1 (50) 0 (0) 0 (0) 0 (0) 1 (50) 2 (3.3) 34 (85) 1 (2.5) 5 (12.5) 40 (67.8) 19 (32.2) 19
Oxford
(23 December 2011)
135 16 (11.9) 119 (88.1) 0 (0) 6 (40) 0 (0) 4 (26.7) 6 (100) 5 (33.3) 21 (17.6) 35 (56.5) 2 (3.2) 25 (40.3) 62 (63.3) 36 (36.7) 36
Doncaster
(26 April 2012)
39 3 (7.7) 36 (92.3) 1 (50) 0 (0) 0 (0) 1 (33.3) 1 (50) 2 (66.7) 5 (13.9) 9 (75) 2 (16.7) 1 (8.3) 12 (38.7) 19 (61.3) 19
Southampton
(12 June 2012)
77 11 (14.3) 66 (85.7) 0 (0) 0 (0) 0 (0) 0 (0) 3 (100) 12 (100) 15 (22.7) 14 (66.7) 0 (0) 7 (33.3) 21 (41.2) 30 (58.8) 30
Nottingham
(20 July 2012)
86 7 (8.1) 79 (91.9) 0 (0) 0 (0) 0 (0) 1 (20) 0 (0) 4 (80) 5 (6.3) 11 (84.6) 0 (0) 2 (15.4) 13 (17.6) 61 (82.4) 61
Blackburn (24 May 2013) 48 4 (8.3) 44 (91.7) 0 (0) 0 (0) 0 (0) 6 (60) 0 (0) 4 (40) 10 (22.7) 18 (78.3) 3 (13) 2 (8.7) 23 (67.6) 11 (32.4) 11
Mid Staffordshire
(16 July 2013)
22 2 (9.1) 20 (90.9) 0 (0) 2 (33.3) 0 (0) 1 (16.7) 0 (0) 3 (50) 6 (30) 6 (50) 2 (16.7) 4 (33.3) 12 (85.7) 2 (14.3) 2
East Surrey
(23 August 2013)
45 3 (6.7) 42 (93.3) 0 (0) 0 (0) 0 (0) 3 (50) 0 (0) 3 (50) 6 (14.3) 21 (75) 3 (10.7) 4 (14.3) 28 (77.8) 8 (22.2) 8
Ipswich
(23 October 2013)
26 2 (7.7) 24 (92.3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 6 (100) 6 (25) 6 (50) 1 (8.3) 5 (41.7) 12 (66.7) 6 (33.3) 6
Sheffield
(4 December 2013)
32 5 (15.6) 27 (84.4) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 5 (25) 2 (10) 13 (65) 20 (74.1) 7 (25.9) 7
Norfolk and Norwich (17
January 2014)
39 3 (7.7) 36 (92.3) 0 (0) 1 (12.5) 0 (0) 0 (0) 0 (0) 7 (87.5) 8 (22.2) 11 (57.9) 1 (5.3) 7 (36.8) 19 (67.9) 9 (32.1) 9
Preston (10 July 2014) 9 0 (0) 9 (100) 0 (0) 0 (0) 0 (0) 1 (25) 0 (0) 3 (75) 4 (44.4) 3 (100) 0 (0) 0 (0) 3 (60) 2 (40) 2
≤ version 3 refers to protocol versions 1–3 (covering recruitment period from 16 May 2011 to 16 August 2012) and ≥ version 4 refers to protocol versions 4–7 (covering recruitment period from
17 August 2012 to 31 March 2015). The columns [A]–[F] cells have been used for denominators in percentage calculations for other cells. [dx] denominator is [x]; [dx+ y] denominator is [x]+ [y].
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TABLE 28 Demographic characteristics of screened patients
Demographic variable Consent obtained
Patient declined
MDI preference CSII preference Other reason
Age (years)
N 293 259 36 100
Mean 8.98 10 8.1 8.85
SD 4.13 3.76 4.27 4.09
Median 9.69 10.48 8.075 9.08
Minimum 0.7 0.41 1.28 0.98
Maximum 16 16 15.15 15.7
Missing (n) 1 0 0 0
Age, n (%)
N 293 259 36 100
Birth to 6 months 0 (0) 1 (0.4) 0 (0) 0 (0)
7 months to 4 years 67 (22.9) 32 (12.4) 9 (25) 23 (23)
5–11 years 146 (49.8) 135 (52.1) 18 (50) 52 (52)
12–15 years 79 (27) 90 (34.7) 9 (25) 25 (25)
≥ 16 years 1 (0.3) 1 (0.4) 0 (0) 0 (0)
Missing 1 0 0 0
Sex, n (%)
N 293 259 36 100
Female 140 (47.8) 121 (46.7) 17 (47.2) 46 (46)
Male 153 (52.2) 138 (53.3) 19 (52.8) 54 (54)
Missing 1 0 0 0
Ethnicity, n (%)
N 292 259 36 100
Asian or Asian British 6 (2.1) 4 (1.5) 1 (2.8) 4 (4)
Black or British black 3 (1) 2 (0.8) 2 (5.6) 1 (1)
British white 242 (82.9) 228 (88) 25 (69.4) 81 (81)
Chinese 0 (0) 0 (0) 0 (0) 0 (0)
Indian 4 (1.4) 1 (0.4) 0 (0) 2 (2)
Mixed 10 (3.4) 6 (2.3) 2 (5.6) 1 (1)
Not stated 3 (1) 12 (4.6) 1 (2.8) 4 (4)
Other 5 (1.7) 1 (0.4) 0 (0) 1 (1)
Other white 14 (4.8) 3 (1.2) 1 (2.8) 5 (5)
Pakistani 5 (1.7) 2 (0.8) 4 (11.1) 1 (1)
Missing 2 0 0 0
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TABLE 28 Demographic characteristics of screened patients (continued )
Demographic variable Consent obtained
Patient declined
MDI preference CSII preference Other reason
Deprivation scorea
N 280 241 33 94
Mean 23.26 24.01 28.51 21.65
SD 18.53 18.19 16.57 16.17
Median 17.045 17.96 27.65 17.06
Minimum 1.62 1.18 3.9 2.95
Maximum 77.23 74.35 63.86 71.91
Missing (n) 14 18 3 6
a Deprivation score is measured from 0 to 100; 100 being worst possible deprivation.
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Appendix 2 Supplementary results
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Test for overall effect: z = 1.05 (p = 0.30)
FIGURE 12 Permanent change to insulin delivery method split by site: forest plot (ITT). There were 53 permanent changes in total (22 were randomised to CSII and 31 were
randomised to MDI). However, one permanent switch of insulin delivery method was from MDI to ‘Injections TDS regime’. This has not been included in the meta-analysis as
an event. M–H, Mantel–Haenszel.
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TABLE 29 Permanent change to insulin delivery line listingsa
Randomisation
number
Timing of
change
(months)
Age at
permanent
change
(years)
Last HbA1c
concentration
measurement
prior to switch
(mmol/mol)
Person(s) who
made decision Reason(s)
Permanent change from CSII to MDI
< 5 years
00213102 0 1.84 110 Parent Parent preference
5–11 years
00243224 0–3 6.55 72 Patient Participant preference
05042218 0–3 10.2 83 Patient Participant preference
00213218 6–9 10.35 68 Clinician; parent;
patient
Poor concordance with
treatment
Participant preference
Parent preference
05042212 0–3 10.55 117 Parent; patient Participant preference
Parent preference
00114207 0–3 10.58 105 Parent; patient Participant preference
Parent preference
Other: pain at cannula site
05042214 0 10.72 114 Clinician; parent Poor glycaemic control –
b. frequent hyperglycaemia
Parent preference
00133207 6–9 10.8 N/A Patient Participant preference
00133209 9–12 11.24 58b Patient Participant preference
05042207 0 11.71 38 Parent; patient Other: participant was not
sure he wanted a pump to
deliver insulin
00243219 0–3 11.95 98 Parent Participant preference
≥ 12 years
00133302 6–9 12.8 65 Parent; patient Participant preference
Parent preference
00114302 0–3 13.15 N/A Parent; patient Participant preference
Parent preference
00213313 3 13.28 59 Clinician; parent;
patient
Participant preference
Parent preference
00213307 0–3 13.32 105 Parent; patient Participant preference
Parent preference
01527305 0–3 13.46 103 Parent; patient Participant preference
05042301 0–3 14.05 129 Patient Participant preference
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TABLE 29 Permanent change to insulin delivery line listingsa (continued )
Randomisation
number
Timing of
change
(months)
Age at
permanent
change
(years)
Last HbA1c
concentration
measurement
prior to switch
(mmol/mol)
Person(s) who
made decision Reason(s)
00213304 6–9 14.7 89 Clinician; patient Poor concordance with
treatment
00248302 0–3 14.95 126 Clinician; parent;
patient
Participant preference
00213318 3 15.04 50 Patient Participant preference
00114306 0–3 15.13 130 Clinician; parent;
patient
Participant preference
00243313 9–12 15.38 63 Clinician; parent;
patient
Poor glycaemic control –
b. frequent hyperglycaemia
Participant preference
Parent preference
Permanent change from MDI to CSII
< 5 years
00213109 0–3 0.96 68 Clinician; parent Other: age related
00036102 0–3 2.2 90 Parent Parent preference
00243104 9–12 2.38 73 Clinician; parent Poor glycaemic control –
b. frequent hyperglycaemia
Parent preference
00213101 3–6 2.66 66 Clinician; parent Poor glycaemic control –
a. debilitating hypoglycaemia
Poor glycaemic control –
b. frequent hyperglycaemia
00133104 9–12 3.42 72 Clinician Poor glycaemic control –
b. frequent hyperglycaemia
00213107 0–3 3.54 89 Clinician; parent Poor glycaemic control –
a. debilitating hypoglycaemia
Parent preference
00213103 3–6 3.72 39 Clinician; parent Other: young age needs
smaller insulin quantities
00114105 9–12 3.98 79 Parent Other: bruising from
injections
00114101 3–6 4.15 51.9 Clinician; parent Parent preference
05042104 6–9 4.47 60 Clinician; parent Parent preference
Other: frequent
hypoglycaemia
00114103 6–9 4.78 78 Clinician; parent Participant preference
Parent preference
00036103 3–6 5.17 54 Clinician Parent preference
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TABLE 29 Permanent change to insulin delivery line listingsa (continued )
Randomisation
number
Timing of
change
(months)
Age at
permanent
change
(years)
Last HbA1c
concentration
measurement
prior to switch
(mmol/mol)
Person(s) who
made decision Reason(s)
5–11 years
00114202 0–3 5.36 58.5 Clinician; parent;
patient
Participant preference
Parent preference
00086210 9–12 6.39 59 Clinician; parent;
patient
Poor glycaemic control –
b. frequent hyperglycaemia
Participant preference
Parent preference
00213229 6–9 7.64 51b Clinician; parent Poor concordance with
treatment
00114206 3–6 7.67 46 Clinician; parent;
patient
Participant preference
Parent preference
00114213 6–9 8.01 53b Parent; patient Participant preference
Parent preference
00326201 3–6 8.59 53 Patient Participant preference
00114208 3–6 8.7 47 Clinician; parent;
patient
Participant preference
Parent preference
00213223 9–12 8.96 61 Clinician; parent;
patient
Participant preference
Parent preference
00326204 3–6 9.87 54b Clinician; parent;
patient
Participant preference
00213226 6–9 11.02 43b Clinician; parent;
patient
Poor concordance with
treatment
Participant preference
Parent preference
05042217 9–12 11.42 58 Patient Participant preference
00213211 3–6 12.02 43 Clinician; parent;
patient
Participant preference
Parent preference
00114209 6–9 12.31 64 Clinician; parent;
patient
Participant preference
Parent preference
05042216 9–12 12.42 44 Parent; patient Participant preference
Parent preference
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TABLE 29 Permanent change to insulin delivery line listingsa (continued )
Randomisation
number
Timing of
change
(months)
Age at
permanent
change
(years)
Last HbA1c
concentration
measurement
prior to switch
(mmol/mol)
Person(s) who
made decision Reason(s)
≥ 12 years
00213306 3–6 12.61 38 Clinician; parent;
patient
Participant preference
Parent preference
Other: fear of hypoglycaemia
00036303 0–3 12.69 133 Parent; patient Participant preference
Parent preference
00114301 3–6 14.44 38.8 Clinician; patient Parent preference
00036301 6–9 15.69 32 Patient Participant preference
Permanent change from MDI to injections TDS regime
5–11 years
12617501 9 10.06 66 Clinician; parent Participant preference
Parent preference
N/A, not applicable.
a Not prespecified analysis in the statistical analysis plan.
b NICE guidance changed in August 2015, lowering recommended HbA1c concentrations from 58mmol/mol to 48mmol/mol.
The date of permanent discontinuation was after the introduction of the lower threshold.
TABLE 30 Baseline characteristics for per-protocol analysisa
Baseline characteristic
Intervention arm
TotalCSII MDI
Age at randomisation (years)
n 87 66 153
Mean (SD) 8.6 (4.2) 9.7 (4.2) 9.1 (4.2)
Median (IQR) 9.1 (4.7–12.2) 10.1 (7.1–13.7) 9.3 (5.7–12.5)
Minimum, maximum 0.8, 16 0.9, 15.3 0.8, 16
Age (strata) category, n (%)
n 87 66 153
7 months to < 5 years 23 (26.4) 11 (16.7) 34 (22.2)
5 years to < 12 years 41 (47.1) 32 (48.5) 73 (47.7)
12–15 years 23 (26.4) 23 (34.8) 46 (30.1)
Age category (EudraCT), n (%)
n 87 66 153
Infants and toddlers 6 (6.9) 3 (4.5) 9 (5.9)
Children 58 (66.7) 40 (60.6) 98 (64.1)
Adolescents 23 (26.4) 23 (34.8) 46 (30.1)
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TABLE 30 Baseline characteristics for per-protocol analysisa (continued )
Baseline characteristic
Intervention arm
TotalCSII MDI
Sex, n (%)
n 87 66 153
Female 44 (50.6) 29 (43.9) 73 (47.7)
Male 43 (49.4) 37 (56.1) 80 (52.3)
Ethnicity, n (%)
n 86 65 151
Asian or Asian British 0 (0) 2 (3.1) 2 (1.3)
Black or British black 0 (0) 3 (4.6) 3 (2)
British white 78 (90.7) 51 (78.5) 129 (85.4)
Indian 2 (2.3) 1 (1.5) 3 (2)
Mixed 3 (3.5) 5 (7.7) 8 (5.3)
Not stated 0 (0) 0 (0) 1 (0.7)
Other 2 (2.3) 3 (4.6) 5 (3.3)
Pakistani 1 (1.2) 0 (0) 1 (0.7)
Deprivation score
n 82 62 144
Mean (SD) 21.7 (18.9) 21 (16.8) 21.4 (18)
Median (IQR) 13.7 (8.4–31.8) 15.1 (8.4–30.9) 14.4 (8.4–31.4)
Minimum, maximum 2.1, 67.9 1.6, 73.9 1.6, 73.9
a Converse to prespecified analysis in the statistical analysis plan, which was to summarise baseline characteristics for those
not included in the analysis.
TABLE 31 Child-reported QoL by domaina
Summary
Time point
6 months 12 months
CSII MDI Total CSII MDI Total
Child (diabetes)
Children 5–7 years old (6- and 12-month follow-up)
n 12 22 34 14 19 33
Mean (SD) 56.8 (13.4) 61 (10.4) 59.5 (11.5) 66.7 (16.9) 59.6 (16) 62.6 (16.5)
Median (IQR) 54.5
(50–63.6)
59.1
(50–72.7)
56.8
(50–68.2)
68.2
(63.6–79.3)
63.6
(50–72.7)
63.6
(54.5–72.7)
Minimum, maximum 31.8, 81.8 40.9, 77.3 31.8, 81.8 27.3, 90.9 22.7, 77.3 22.7, 90.9
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TABLE 31 Child-reported QoL by domaina (continued )
Summary
Time point
6 months 12 months
CSII MDI Total CSII MDI Total
Children 8–12 years old (6- and 12-month follow-up)
n 59 55 114 57 55 112
Mean (SD) 63 (16.9) 62.3 (15) 62.7 (15.9) 68.7 (15.8) 63.9 (16.1) 66.4 (16.1)
Median (IQR) 65.9
(49.6–77.3)
63.6
(50–74.4)
63.6
(50–75)
70.5
(54.5–79.5)
61.4
(50–77.3)
65.9
(52.3–79.5)
Minimum, maximum 25, 100 29.5, 100 25, 100 36.4, 100 37.2, 93.2 36.4, 100
Children 13–16 years old (6- and 12-month follow-up)
n 29 31 60 37 33 70
Mean (SD) 68.2 (16.4) 64.3 (15.3) 66.2 (15.8) 62.9 (16.8) 61.6 (17.3) 62.3 (16.9)
Median (IQR) 65.9
(56.8–75)
61.4
(56.8–72.7)
63.6
(56.8–73.9)
61.4
(54.5–71.9)
59.1
(52.3–72.7)
61.1
(52.3–72.7)
Minimum, maximum 40.9, 100 40.9, 100 40.9, 100 27.3, 100 29.5, 90.9 27.3, 100
Child (treatment I)
Children 5–7 years old (6- and 12-month follow-up)
n 12 22 34 14 19 33
Mean (SD) 77.3 (18.3) 79.8 (16.1) 79 (16.7) 81.3 (16.8) 75.7 (22.2) 78 (20)
Median (IQR) 76.6
(62.5–93.8)
82.8
(75–87.5)
78.1
(75–87.5)
75
(75–100)
75
(62.5–87.5)
75
(62.5–100)
Minimum, maximum 50, 100 37.5, 100 37.5, 100 50, 100 12.5, 100 12.5, 100
Children 8–12 years old (6- and 12-month follow-up)
n 59 54 113 57 55 112
Mean (SD) 79.3 (17.9) 74.7 (19.6) 77.1 (18.8) 83.7 (15.5) 77.2 (20.5) 80.5 (18.3)
Median (IQR) 87.5
(68.8–93.8)
75
(68.8–87.5)
81.3
(68.8–93.8)
87.5
(75–93.8)
81.3
(62.5–93.8)
81.3
(75–93.8)
Minimum, maximum 31.3, 100 12.5, 100 12.5, 100 25, 100 18.8, 100 18.8, 100
Children 13–16 years old (6- and 12-month follow-up)
n 29 31 60 38 33 71
Mean (SD) 79.7 (21.2) 79.5 (14.2) 79.6 (17.8) 76.6 (21.2) 74.8 (15.3) 75.8 (18.6)
Median (IQR) 87.5
(75–93.8)
81.3
(75–87.5)
81.3
(75–93.8)
81.3
(68.8–93.8)
75
(62.5–87.5)
75
(68.8–87.5)
Minimum, maximum 6.3, 100 43.8, 100 6.3, 100 25, 100 31.3, 100 25, 100
Child (treatment II)
Children 5–7 years old (6- and 12-month follow-up)
n 12 22 34 13 19 32
Mean (SD) 80.1 (19.3) 83.2 (12.9) 82.1 (15.3) 82.3 (18.1) 79.9 (15.3) 80.9 (16.3)
Median (IQR) 85.7
(67.9–95.4)
83.7
(73.5–92.9)
85.7
(71.4–92.9)
85.7
(73.5–100)
78.6
(71.4–92.9)
80.1
(72.4–95.4)
Minimum, maximum 42.9, 100 57.1, 100 42.9, 100 35.7, 100 55.1, 100 35.7, 100
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TABLE 31 Child-reported QoL by domaina (continued )
Summary
Time point
6 months 12 months
CSII MDI Total CSII MDI Total
Children 8–12 years old (6- and 12-month follow-up)
n 59 54 113 57 55 112
Mean (SD) 87.9 (11.9) 83.7 (14.5) 85.9 (13.3) 89.6 (11.6) 84.8 (17.6) 87.2 (15)
Median (IQR) 92.9
(82.1–96.4)
85.7
(77.6–96.4)
89.3
(78.6–96.4)
92.9
(82.1–100)
92.9
(75–100)
92.9
(82.1–100)
Minimum, maximum 45.9, 100 39.3, 100 39.3, 100 53.1, 100 16.3, 100 16.3, 100
Children 13–16 years old (6- and 12-month follow-up)
n 29 31 60 38 33 71
Mean (SD) 90.1 (13.8) 87.2 (10.7) 88.6 (12.3) 84 (16.7) 85.3 (12.4) 84.6 (14.8)
Median (IQR) 96.4
(87.2–100)
85.7
(82.1–96.4)
92.9
(82.1–98)
91.3
(75–96.4)
85.7
(78.6–96.4)
89.3
(75–96.4)
Minimum, maximum 50, 100 60.7, 100 50, 100 42.9, 100 50, 100 42.9, 100
Child (worry)
Children 5–7 years old (6- and 12-month follow-up)
n 11 21 32 14 19 33
Mean (SD) 74.2 (26.2) 77.8 (24.9) 76.6 (25) 77.4 (31.1) 68.4 (28.8) 72.2 (29.7)
Median (IQR) 66.7
(66.7–100)
83.3
(66.7–100)
83.3
(66.7–100)
100
(50–100)
66.7
(50–100)
83.3
(50–100)
Minimum, maximum 16.7, 100 16.7, 100 16.7, 100 16.7, 100 0, 100 0, 100
Children 8–12 years old (6- and 12-month follow-up)
n 59 54 113 57 53 110
Mean (SD) 81.2 (16.8) 75.8 (20.7) 78.6 (18.9) 82.5 (17.7) 78 (23.4) 80.3 (20.6)
Median (IQR) 83.3
(75–91.7)
79.2
(58.3–91.7)
83.3
(66.7–91.7)
83.3
(75–100)
83.3
(66.7–100)
83.3
(66.7–100)
Minimum, maximum 33.3, 100 25, 100 25, 100 16.7, 100 8.3, 100 8.3, 100
Children 13–16 years old (6- and 12-month follow-up)
n 29 31 60 38 33 71
Mean (SD) 80.5 (22.1) 77.2 (17.9) 78.8 (19.9) 73 (23.2) 74.5 (23.3) 73.7 (23.1)
Median (IQR) 83.3
(66.7–100)
83.3
(66.7–91.7)
83.3
(66.7–91.7)
75
(50–100)
75
(58.3–100)
75
(50–100)
Minimum, maximum 25, 100 33.3, 100 25, 100 33.3, 100 25, 100 25, 100
Child (communication)
Children 5–7 years old (6- and 12-month follow-up)
n 11 22 33 14 18 32
Mean (SD) 56.1 (38.2) 77.3 (23.9) 70.2 (30.5) 57.1 (33.1) 80.6 (25.7) 70.3 (31)
Median (IQR) 50
(16.7–100)
83.3
(66.7–100)
66.7
(50–100)
58.3
(33.3–83.3)
83.3
(66.7–100)
75
(50–100)
Minimum, maximum 0, 100 33.3, 100 0, 100 0, 100 0, 100 0, 100
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TABLE 31 Child-reported QoL by domaina (continued )
Summary
Time point
6 months 12 months
CSII MDI Total CSII MDI Total
Children 8–12 years old (6- and 12-month follow-up)
n 58 55 113 54 54 108
Mean (SD) 82.2 (18.3) 72 (25.3) 77.2 (22.5) 79.7 (23.7) 75.6 (26.6) 77.6 (25.2)
Median (IQR) 83.3
(75–100)
75
(58.3–91.7)
83.3
(66.7–100)
91.7
(66.7–100)
83.3
(58.3–100)
83.3
(58.3–100)
Minimum, maximum 16.7, 100 0, 100 0, 100 8.3, 100 0, 100 0, 100
Children 13–16 years old (6- and 12-month follow-up)
n 29 29 58 38 33 71
Mean (SD) 86.2 (15.5) 81.6 (19.7) 83.9 (17.7) 81.6 (18.1) 76.8 (26.4) 79.3 (22.3)
Median (IQR) 91.7
(75–100)
83.3
(75–100)
87.5
(75–100)
83.3
(66.7–100)
83.3
(66.7–100)
83.3
(66.7–100)
Minimum, maximum 50, 100 16.7, 100 16.7, 100 33.3, 100 0, 100 0, 100
a Not prespecified in the statistical analysis plan to present data at 6 months.
TABLE 32 Parent-reported QoL by domaina
Questionnaire age group
Time point
6 months 12 months
CSII MDI Total CSII MDI Total
Parent (diabetes)
Parents/carers: children aged 2–4 years old (6- and 12-month follow-up)
n 25 18 43 22 18 40
Mean (SD) 62 (16) 58.1 (11.1) 60.4 (14.1) 62.7 (17.1) 56.2 (16.2) 59.8 (16.8)
Median (IQR) 62
(54.5–65.9)
58.1
(47.7–65.9)
61.4
(47.7–65.9)
59.1
(47.7–75)
56.8
(43.2–68.2)
56.8
(46.6–72.7)
Minimum, maximum 27.3, 97.7 38.6, 75 27.3, 97.7 33.1, 97.7 27.3, 81.8 27.3, 97.7
Parents/carers: children aged 5–7 years old (6- and 12-month follow-up)
n 14 23 37 17 18 35
Mean (SD) 66.2 (12) 61.4 (13.9) 63.2 (13.2) 68.3 (15.4) 60.8 (15.7) 64.5 (15.8)
Median (IQR) 65.9
(59.1–77.3)
59.1
(50–72.7)
61.4
(54.5–72.7)
65.9
(56.8–77.3)
61.4
(53.7–72.7)
65.9
(53.7–75)
Minimum, maximum 43.2, 84.1 38.6, 90.9 38.6, 90.9 45.5, 95.5 13.6, 81.8 13.6, 95.5
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TABLE 32 Parent-reported QoL by domaina (continued )
Questionnaire age group
Time point
6 months 12 months
CSII MDI Total CSII MDI Total
Parents/carers: children aged 8–12 years old (6- and 12-month follow-up)
n 58 58 116 55 55 110
Mean (SD) 62.9 (14.9) 62.7 (15.3) 62.8 (15) 66.2 (14.6) 60.8 (16.2) 63.5 (15.6)
Median (IQR) 63.6
(52.3–75)
61.4
(52.3–72.7)
61.4
(52.3–72.7)
65.9
(52.3–75.2)
61.4
(47.7–74.4)
63.6
(52.3–75)
Minimum, maximum 25, 93.2 36.4, 95.5 25, 95.5 43.2, 100 29.5, 97.7 29.5, 100
Parents/carers: children aged 13–16 years old (6- and 12-month follow-up)
n 30 29 59 38 34 72
Mean (SD) 63.9 (17.4) 60.3 (18.1) 62.1 (17.7) 60.3 (17.7) 61.5 (14) 60.9 (15.9)
Median (IQR) 58
(52.3–81.8)
61.4
(50–72.7)
59.1
(52.1–75)
59.1
(47.7–68.2)
61.4
(54.5–70.5)
61.4
(50–70.5)
Minimum, maximum 36.4, 97.7 24.8, 100 24.8, 100 27.3, 100 22.7, 90.9 22.7, 100
Parent (treatment I)
Parents/carers: children aged 2–4 years old (6- and 12-month follow-up)
n 25 18 43 21 18 39
Mean (SD) 79.8 (20.5) 69.8 (20.7) 75.6 (20.9) 80.7 (18.9) 73.6 (20.8) 77.4 (19.9)
Median (IQR) 87.5
(62.5–100)
68.8
(56.3–93.8)
75
(56.3–100)
87.5
(68.8–93.8)
81.3
(68.8–87.5)
81.3
(68.8–87.5)
Minimum, maximum 37.5, 100 31.3, 100 31.3, 100 31.3, 100 18.8, 100 18.8, 100
Parents/carers: children aged 5–7 years old (6- and 12-month follow-up)
n 14 23 37 17 18 35
Mean (SD) 63.8 (28.4) 69.3 (19.2) 67.2 (22.9) 72.8 (21.5) 69.8 (21.1) 71.3 (21.1)
Median (IQR) 62.5
(50–87.5)
68.8
(56.3–81.3)
68.8
(56.3–81.3)
81.3
(56.3–87.5)
71.9
(56.3–87.5)
75
(56.3–87.5)
Minimum, maximum 0, 100 31.3, 100 0, 100 37.5, 100 25, 100 25, 100
Parents/carers: children aged 8–12 years old (6- and 12-month follow-up)
n 58 57 115 55 55 110
Mean (SD) 71.3 (20.3) 67.9 (20.8) 69.6 (20.5) 69.1 (18.7) 66.9 (19.6) 68 (19.1)
Median (IQR) 75
(56.3–87.5)
68.8
(56.3–87.5)
68.8
(56.3–87.5)
68.8
(56.3–81.3)
62.5
(56.3–81.3)
68.8
(56.3–81.3)
Minimum, maximum 25, 100 12.5, 100 12.5, 100 25, 100 25, 100 25, 100
Parents/carers: children aged 13–16 years old (6- and 12-month follow-up)
n 30 29 59 38 34 72
Mean (SD) 65.2 (22.3) 61.3 (18.1) 63.3 (20.3) 67.3 (22.1) 62.3 (21.9) 64.9 (22)
Median (IQR) 68.8
(43.8–81.3)
62.5
(50–75)
62.5
(50–81.3)
68.8
(50–81.3)
62.5
(43.8–81.3)
68.8
(50–81.3)
Minimum, maximum 25, 100 31.3, 100 25, 100 25, 100 12.5, 100 12.5, 100
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TABLE 32 Parent-reported QoL by domaina (continued )
Questionnaire age group
Time point
6 months 12 months
CSII MDI Total CSII MDI Total
Parent (treatment II)
Parents/carers: children aged 2–4 years old (6- and 12-month follow-up)
n 25 18 43 22 18 40
Mean (SD) 85.4 (13.6) 74.2 (16.6) 80.8 (15.7) 88.6 (10.9) 82.7 (14.8) 85.9 (13)
Median (IQR) 91.8
(82.1–96.4)
73.2
(61.2–85.7)
82.1
(69.4–96.4)
92.3
(85.7–92.9)
87.8
(75–93.9)
90.8
(80.4–93.4)
Minimum, maximum 49, 100 40.8, 100 40.8, 100 59.7, 100 45.9, 100 45.9, 100
Parents/carers: children aged 5–7 years old (6- and 12-month follow-up)
n 14 23 37 16 18 34
Mean (SD) 84.2 (14.4) 82.8 (9.8) 83.3 (11.6) 84.8 (14.3) 77.6 (15.3) 81 (15.1)
Median (IQR) 91.3
(75–96.4)
82.1
(75–92.9)
85.7
(75–93.9)
85.7
(70.2–100)
76.8
(64.3–92.9)
82.1
(65.3–96.4)
Minimum, maximum 57.1, 98 64.3, 100 57.1, 100 64.3, 100 50, 98 50, 100
Parents/carers: children aged 8–12 years old (6- and 12-month follow-up)
n 58 58 116 55 55 110
Mean (SD) 86.4 (12.7) 80.9 (15.3) 83.7 (14.3) 86.8 (13.5) 81.1 (16.6) 83.9 (15.3)
Median (IQR) 87.2
(77.6–98)
82.1
(71.4–92.9)
85.7
(73.5–96.4)
89.3
(81.6–100)
85.7
(67.9–92.9)
89.3
(75–96.4)
Minimum, maximum 50, 100 39.3, 100 39.3, 100 44.9, 100 16.3, 100 16.3, 100
Parents/carers: children aged 13–16 years old (6- and 12-month follow-up)
n 29 29 58 38 34 72
Mean (SD) 84.6 (15.1) 79.4 (15) 82 (15.1) 80.7 (16.4) 77.7 (19.6) 79.3 (17.9)
Median (IQR) 85.7
(77.6–98)
82.1
(64.3–92.9)
85.7
(73.5–93.9)
81.9
(64.3–96.4)
78.6
(67.9–92.9)
81.6
(67.9–96.4)
Minimum, maximum 42.9, 100 55.1, 100 42.9, 100 39.3, 100 32.1, 100 32.1, 100
Parent (worry)
Parents/carers: children aged 2–4 years old (6- and 12-month follow-up)
n 25 18 43 21 18 39
Mean (SD) 63 (29.5) 45.4 (28.6) 55.6 (30.1) 47.9 (28.1) 48.6 (31.9) 48.2 (29.5)
Median (IQR) 58.3
(33.3–91.7)
41.7
(25–58.3)
50
(33.3–83.3)
41.7
(33.3–75)
54.2
(25–66.7)
50
(25–75)
Minimum, maximum 8.3, 100 0, 100 0, 100 0, 100 0, 100 0, 100
Parents/carers: children aged 5–7 years old (6- and 12-month follow-up)
n 14 23 37 17 18 35
Mean (SD) 61.3 (26.7) 75.4 (22) 70 (24.5) 61.3 (29.3) 67.1 (25.2) 64.3 (27)
Median (IQR) 58.3
(33.3–83.3)
83.3
(58.3–91.7)
75
(50–91.7)
66.7
(33.3–83.3)
75
(50–83.3)
75
(41.7–83.3)
Minimum, maximum 25, 100 25, 100 25, 100 16.7, 100 0, 100 0, 100
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TABLE 32 Parent-reported QoL by domaina (continued )
Questionnaire age group
Time point
6 months 12 months
CSII MDI Total CSII MDI Total
Parents/carers: children aged 8–12 years old (6- and 12-month follow-up)
n 58 58 116 55 55 110
Mean (SD) 72.1 (20.1) 64.4 (21.3) 68.2 (21) 68.2 (24.3) 67.7 (25.3) 68 (24.7)
Median (IQR) 75
(58.3–83.3)
66.7
(50–83.3)
66.7
(50–83.3)
75
(50–91.7)
66.7
(50–91.7)
70.8
(50–91.7)
Minimum, maximum 25, 100 25, 100 25, 100 8.3, 100 0, 100 0, 100
Parents/carers: children aged 13–16 years old (6- and 12-month follow-up)
n 30 29 59 38 34 72
Mean (SD) 69.2 (24.4) 65.2 (23.5) 67.2 (23.8) 71.9 (21) 66.9 (23.6) 69.6 (22.3)
Median (IQR) 75
(50–91.7)
66.7
(50–83.3)
66.7
(50–83.3)
75
(50–83.3)
75
(50–83.3)
75
(50–83.3)
Minimum, maximum 8.3, 100 16.7, 100 8.3, 100 33.3, 100 8.3, 100 8.3, 100
Parent (communication)
Parents/carers: children aged 2–4 years old (6- and 12-month follow-up)
n 24 19 43 21 17 38
Mean (SD) 83.7 (25.2) 74.1 (28.7) 79.5 (26.9) 81.3 (25.7) 70.6 (34) 76.5 (29.8)
Median (IQR) 100
(75–100)
75
(58.3–100)
91.7
(66.7–100)
91.7
(75–100)
83.3
(50–100)
91.7
(50–100)
Minimum, maximum 0, 100 0, 100 0, 100 25, 100 0, 100 0, 100
Parents/carers: children aged 5–7 years old (6- and 12-month follow-up)
n 13 23 36 17 17 34
Mean (SD) 82.7 (22.4) 84.1 (22.5) 83.6 (22.1) 72.5 (32.1) 80.9 (18.8) 76.7 (26.3)
Median (IQR) 100
(66.7–100)
91.7
(75–100)
95.8
(75–100)
83.3
(50–100)
83.3
(66.7–100)
83.3
(66.7–100)
Minimum, maximum 41.7, 100 16.7, 100 16.7, 100 0, 100 41.7, 100 0, 100
Parents/carers: children aged 8–12 years old (6- and 12-month follow-up)
n 58 57 115 54 55 109
Mean (SD) 78.7 (22.4) 75.7 (26.2) 77.2 (24.3) 80.1 (22.8) 67.2 (26.3) 73.6 (25.4)
Median (IQR) 83.3
(66.7–100)
83.3
(58.3–100)
83.3
(58.3–100)
87.5
(75–100)
75
(50–91.7)
75
(58.3–100)
Minimum, maximum 16.7, 100 0, 100 0, 100 0, 100 0, 100 0, 100
Parents/carers: children aged 13–16 years old (6- and 12-month follow-up)
n 29 28 57 38 34 72
Mean (SD) 77 (28.9) 67.3 (24.1) 72.2 (26.9) 73.2 (26.1) 72.8 (30.7) 73 (28.2)
Median (IQR) 83.3
(75–100)
66.7
(50–91.7)
83.3
(50–100)
75
(50–100)
79.2
(58.3–100)
75
(58.3–100)
Minimum, maximum 0, 100 25, 100 0, 100 0, 100 0, 100 0, 100
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TABLE 32 Parent-reported QoL by domaina (continued )
Questionnaire age group
Time point
6 months 12 months
CSII MDI Total CSII MDI Total
Parent (overall)
Parents/carers: children aged 2–4 years old (6- and 12-month follow-up)
n 24 18 42 20 17 37
Mean (SD) 72.5 (13) 64 (11.5) 68.9 (12.9) 73 (12.7) 67 (15.7) 70.2 (14.3)
Median (IQR) 72.8
(62.9–77.2)
61.8
(55.5–74.1)
68.8
(57–76.8)
75
(62.1–82.1)
70.5
(54.7–79.5)
73.2
(60.7–80.4)
Minimum, maximum 54.5, 98.6 46.7, 81.6 46.7, 98.6 52.4, 99.1 40.2, 90.2 40.2, 99.1
a Not prespecified in the statistical analysis plan to present data at 6 months.
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Appendix 3 Health economics analysis plan
This health economic analysis plan provides a detailed and comprehensive description of the pre-plannedeconomic analyses for the SCIPI study. The planned economic analysis described within this document
is compliant with those specified in brief within the SCIPI study protocol version 6.0 (16 February 2016).
This health economic analysis plan comprehensively describes the planned final analysis.
These planned analyses will be performed by health economists at the Centre for Health Economics and
Medicines Evaluation, Bangor University, Bangor, UK.
All analyses will be performed using Stata version 13 and reported according to CHEERS.
Overview
Within the SCIPI study, the cost-effectiveness of CSII compared with insulin administered subcutaneously by
MDI will be assessed from a UK NHS perspective. The cost-effectiveness will be based on the incremental cost
per QALY gained. The economic analysis will have two parts: (1) a trial-based evaluation of the first 12 months
from diagnosis and, if one intervention is clinically superior, (2) a lifetime extrapolation of costs and outcomes,
based on an economic model of diabetes.
Data sources
Resource use
Data on health-care resource use are based on:
l PLICS data and/or PAS data of participating hospitals.
l The trial CRFs, which will record health-care resource items (outpatient visits, primary care and hospital
stays) for the 3 months prior to randomisation at baseline and then at 3, 6, 9 and 12 months following
randomisation. All hospital stays will be measured irrespective of whether or not they are related
to diabetes.
l Prescription records, patient diaries and electronic downloads from pumps, to estimate the number of
units of insulin used by patients.
Unit costs
All resource use will be valued in monetary terms using UK unit costs current at the time of analysis. HRGs
will be used as the main currency of the economic analysis for inpatient stays with cost codes allocated
based on the latest available national tariff. Obsolete national tariff and schedule codes will be uplifted
using the hospital price index according to the current version of the compendium of Unit Costs of Health
and Social Care.123 This resource will also be the source of unit costs that will be applied to primary
health-care and outpatient contacts.
Bundled national tariff costs will be based on the hospital spell and incorporated excess ward days, market
forces factor and whether the case was elective or emergency. Tariff codes will be obtained primarily from
PLICS and PAS data but if unavailable they will be assigned by reference to CRFs and an appropriate HRG
code will be assigned based on condition and comorbidities. Similarly, appropriate HRGs will be applied to
unassignable national tariff HRG codes appearing in the PLICS and PAS data.
Unbundled costs such as intensive care unit stays are not expected to be common; however, if they do
arise they will be identified from reference to (1) lists of AEs, (2) CRF code 4 critical care, (3) PLICS data or
DOI: 10.3310/hta22420 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 42
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Blair et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
107
(4) PAS data. Appropriate HRG codes for unbundled costs will be assigned from the National Schedule of
reference costs.122
Insulin and concomitant medication costs will be based on those detailed in the British National Formulary.124
Utilities
Within-trial health utilities will be estimated from patients’ (aged ≥ 12 years) and their parents’ or
guardians’ responses to the HUI questionnaire and the application of UK tariff scores.
Data analysis
Costs
Within-trial total costs for each patient will be calculated from the sum of ward, outpatient, A&E, primary
care, disposable devices, insulin and concomitant medication usage. An annualised cost will be assigned
for the insulin pump and accoutrements.
Costs at baseline, relating to the 3 months preceding randomisation, will be calculated from CRF data with
reference to PAS and PLICS data when available. This will relate to all primary and secondary care activity.
If a hospitalisation is observed for the period subsequent to randomisation, an adjustment may be
necessary to apportion costs, given that ward costs relate to episodes of care that could start prior to
randomisation. Patients admitted to hospital n days before randomisation and spending N days in hospital
after randomisation will have their total costs calculated as:
Total cost = (N/n + N) × (ward cost derived from HRG). (6)
Patients’ use of health-care resources and total costs will be calculated for the ITT population, with
summary statistics generated by intervention group. Differences between intervention groups in mean
lengths of stay and costs will be compared with reference to bias-corrected and accelerated bootstrapped
95% CIs, based on 10,000 replicates.
Imbalances in baseline covariates, should any be present in spite of randomisation, may result in biased
estimates of cost-effectiveness. If there are imbalances in important clinical or demographic variables,
we will implement suitable regression techniques.
Outcomes
A QALY profile over the 12-month trial period will be estimated from HUI2/HUI3 derived utilities based on
the area under the curve, assuming the trapezoidal rule.
Incremental analysis
The trial-based cost-effectiveness analysis of CSII will be evaluated by its ICER, which will be calculated
according to:
ICER = ΔCosts/ΔQALY. (7)
where ΔCosts is the difference in total costs between interventions (cost CSII – cost MDI), and ΔQALY is
the difference in utility between interventions (QALY CSII – QALY MDI).
Uncertainty analysis
The joint uncertainty in costs and outcomes at 12 months will be considered by non-parametric bootstrapping
resampling (10,000) of patient costs and QALYs. Uncertainty will be represented using a cost-effectiveness
acceptability curve to present the probability of CSII being cost-effective for given ceiling thresholds for costs
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per QALY gained. Estimates of ICERs will be compared with the £20,000–30,000-per-QALY threshold of
cost-effectiveness set by NICE.
Sensitivity analyses
A range of sensitivity analyses will be considered, including different calculations for estimating the costs of
pumps, use of alternative (Canadian) tariff scores for the HUI3 algorithm and application of MICE for
imputing missing cost and utility data, when necessary.
Exploratory analyses
The contribution of baseline variables to total costs and QALYs will be examined using regression models.
Given the expected skewed nature of outcomes, we will specify generalised linear models using (1) total
cost per patient and (2) total QALYs per patient, as the dependent variable, and explanatory variables for
accounting for baseline cost, baseline HbA1c concentration, age, centre and other covariates, as specified in
the statistical analysis plan, as well as the intervention group. The Modified Park test will be used to
identify the preferred distributional family based on the lowest chi-squared test value. For each prediction
model, the link function will be identified using the Pearson correlation test, the Pregibon link test and the
modified Hosmer–Lemeshow test. When all three tests yield non-significant p-values, the link function is
said to fit well.
If there are significant differences in HbA1c concentrations between intervention groups at 12 months, we
will conduct an exploratory analysis in which trial results will be extrapolated to estimate lifetime costs and
benefits and to capture long-term microvascular and macrovascular complications, using the CDM. We
acknowledge that the CDM has not been validated for populations comparable with those in the SCIPI
study; however, this exploratory analysis will aim to assess potential lifetime benefits and incremental cost
per QALY of tighter glycaemic control in early diagnosed paediatric patients with T1D.
The CDM will be initialised with a cohort profile consistent with each intervention group of the SCIPI study,
in terms of demographic and clinical characteristics. A conservative estimate of treatment effect having
been reached at 12 months from randomisation will be assumed to calculate the risk factor trajectories
over time for blood pressure, lipids and HbA1c concentration using the default setting of the UK
Prospective Diabetes Study (UKPDS) panel equations. Costs inbuilt to the CDM will be used to estimate
lifetime total cost per patient. Costs and QALYs in the extrapolated phase will be discounted at 3.5%
per annum.
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Appendix 4 Patient and public involvement
We have aimed to describe patient and public involvement throughout this report. A summary isprovided below.
We have worked with young people and parent contributors from study design to delivery.
The MCRN group of children and young people, ‘Stand Up, Speak UP!’, advised us on the contents and
presentation of patient information leaflets and consent forms.
Three parent contributors were recruited to the TMG, which met by teleconference every month, and
one parent contributor joined the TSC. Our parent contributors were particularly valuable during the
recruitment period of the study. They advised us of the impact of the diagnosis of T1D and how and when
to approach patients and their families in a sensitive manner, and helped us to anticipate barriers
to recruitment.
When it became evident that recruitment rates were significantly influenced by patient preference for MDI,
we approached completed participants from both arms of the study to participate in the study video.
Participants and their parents shared their experiences of the diagnosis of T1D and of living with their
randomised treatment and their reasons for participating in clinical research. This video was very well
received by health-care professionals, families and patients.
Once recruitment rates had been optimised, we entered a phase of the study in which the TMG
discussions focused on issues relating to governance and internal study management. During this period, it
was more difficult to engage our parent contributors and to ensure that the discussions were relevant and
interesting to them.
As results became available, we invited our parent contributors to help us to interpret them and set them in
the context of living with childhood T1D. These discussions have been very helpful and have motivated us
to learn more about our study cohort, in particular how the experiences of those treated with MDI and CSII
may have differed in ways that were not identified through the study questionnaires. The importance of
extending the observation period was also discussed. We will apply for further funding to undertake this
research in the near future, and we hope to continue to work with our parent contributors to develop and
deliver new study protocols.
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